RPS GENE FAMILY, PRIMERS, PROBES, AND DETECTION METHODS

Abstract: Disclosed is substantially pure DNA encoding an Arabidopsis thaliana Rps2 polypeptide; substantially pure Rps2 polypeptide; and methods of using such DNA to express the Rps2 polypeptide in plant cells and whole plants to provide, in transgenic plants, disease resistance to pathogens. Also disclosed are conserved regions characteristic of the RPS family and primers and probes for the identification and isolation of additional RPS disease-resistance genes.

Description: RPS GENE FAMILY. PRIMERS. PROBES. AND DETECTION METHODS Statement as to Federally Sponsored Research This invention was made in part with Government funding and the Government therefore has certain rights in the invention. Background of the Invention The invention, relates to recombinant plant nucleic acids and polypeptides and uses thereof to confer disease resistance to pathogens in transgenic plants. Plants employ a variety of defensive strategies to combat pathogens. One defense response, the so-called hypersensitive response (HR) , involves rapid localized necrosis of infected tissue. In several host-pathogen interactions, genetic analysis has revealed a gene-for- gene correspondence between a particular avirulence (avr) gene in an avirulent pathogen that elicits an HR in a host possessing a particular resistance gene. Summary of the Invention In general, the invention features substantially pure DNA (for example, genomic DNA, cDNA, or synthetic DNA) encoding an Rps .polypeptide as defined below. In related aspects, the invention also features a vector, a cell (e.g., a plant cell), and a transgenic plant or seed thereof which includes such a substantially pure DNA encoding an Rps polypeptide. In preferred embodiments, an RPS gene is the RPS2 gene of a plant of the genus Arabidopsis . In various preferred embodiments, the cell is a transformed plant cell derived from a cell of a transgenic plant. In related aspects, the invention features a transgenic plant containing a transgene which encodes an Rps polypeptide that is expressed in plant tissue susceptible to infection by pathogens expressing the avrRpt2 avirulence gene or pathogens expressing an avirulence signal similarly recognized by an Rps polypeptide. In a second aspect, the invention features a substantially pure DNA which includes a promoter capable of expressing the RPS2 gene in plant tissue susceptible to infection by bacterial pathogens expressing the avrRpt2 avirulence gene. In preferred embodiments, the promoter is the promoter native to an RPS gene. Additionally, transcriptional and translational regulatory regions are preferably native to an RPS gene. The transgenic plants of the invention are preferably plants which are susceptible to infection by a pathogen expressing an avirulence gene, preferably the avrRpt2 avirulence gene. In preferred embodiments the transgenic plant is from the group of plants consisting of but not limited to Arabidopsis , tomato, soybean, bean, maize, wheat and rice. In another aspect, the invention features a method of providing resistance in a plant to a pathogen which involves: (a) producing a transgenic plant cell having a transgene encoding an Rps2 polypeptide wherein the transgene is integrated into the genome of the transgenic plant and is positioned for expression in the plant cell; and (b) growing a transgenic plant from the transgenic plant cell wherein the RPS2 transgene is expressed in the transgenic plant. In another aspect, the invention features a method of detecting a resistance gene in a plant cell involving: (a) contacting the RPS2 gene or a portion thereof greater than 9 nucleic acids, preferably greater than 18 nucleic acids in length with a preparation of genomic DNA from the plant cell under hybridization conditions providing detection of DNA sequences having about 50% or greater sequence identity to the DNA sequence of Fig. 2 encoding the Rps2 polypeptide. In another aspect, the invention features a method of producing an Rps2 -polypeptide which involves: (a) providing a cell transformed with DNA encoding an Rps2 polypeptide positioned for expression in the cell; (b) culturing the transformed cell under conditions for expressing the DNA; and (c) isolating the Rps2 polypeptide. In another aspect, the invention features substantially pure Rps2 polypeptide. Preferably, the polypeptide includes a greater than 50 amino acid sequence substantially identical to a greater than 50 amino acid sequence shown in Fig. 2, open reading frame "a". Most preferably, the polypeptide is the Arabidopsis thaliana Rps2 polypeptide. In another aspect, the invention features a method of providing resistance in a transgenic plant to infection by pathogens which do not carry the avrRpt2 avirulence gene wherein the method includes: (a) producing a transgenic plant cell having transgenes encoding an Rps2 polypeptide as well as a transgene encoding the avrRpt2 gene product wherein the transgenes are integrated into the genome of the transgenic plant; are positioned for expression in the plant cell; and the avrRpt2 transgene and, if desired, the RPS2 gene, are under the control of regulatory sequences suitable for controlled expression of the gene(s); and (b) growing a transgenic plant from the transgenic plant cell wherein the RPS2 and avrRpt2 transgenes are expressed in the transgenic plant. In another aspect, the invention features a method of providing resistance in a transgenic plant to infection by pathogens in the absence of avirulence gene expression in the pathogen wherein the method involves: (a) producing a transgenic plant cell having integrated in the genome a transgene containing the RPS2 gene under the control of a promoter providing constitutive expression of the RPS2 gene; and (b) growing a transgenic plant from the transgenic plant cell wherein the RPS2 transgene is expressed constitutively in the transgenic plant. In another aspect, the invention features a method of providing controllable resistance in a transgenic plant to infection by pathogens in the absence of avirulence gene expression in the pathogen wherein the method involves: (a) producing a transgenic plant cell having integrated in the genome a transgene containing the RPS2 gene under the control of a promoter providing controllable expression of the RPS2 gene; and (b) growing a transgenic plant from the transgenic plant cell wherein the RPS2 transgene is controllably expressed in the transgenic plant. In preferred embodiments, the RPS2 gene is expressed using a tissue-specific or cell type- specific promoter, or by a promoter that is activated by the introduction of an external signal or agent, such as a chemical signal or agent. In other aspects, the invention features a substantially pure oligonucleotide including one or a combination of the sequences: 5' GGNATGGGNGGNNTNGGNAARACNAC 3', [SEQ ID NO: 158] wherein N is A, T, G, or C; and R is A or G; 5' NARNGGNARNCC 3', [SEQ ID NO: 169] wherein N is A, T, G or C; and R is A or G; 5'NCGNGWNGTNAKDAWNCGNGA 3', [SEQ ID NO: 159] wherein N is A, T, G or C; is A or T; D is A, G, or T; and K is G or T; 5' GGWNTBGG AARACHAC 3', [SEQ ID NO: 160] wherein N is A, T, G or C; R is G or A; B is C, G, or T; H " is A, C, or T; and W is A or T; 5' TYGAYGAYRTBKRBRA 3', [SEQ ID NO: 163] wherein R is G or A; B is C, G, or T; D is A, G, or T; Y is T or C; and K is G or T; 5' TYCCAVAYRTCRTCNA 3', [SEQ ID NO: 164] wherein N is A, T, G or C; R is G or A; V is G or C or A; and Y is T or C; 5' GG YTBCC YTBGCHYT 3', [SEQ ID NO: 170] wherein B is C, G, or T; H is A, C, or T; W is A or T; and Y is T or C; 5' ARDGCVARWGGVARNCC 3', [SEQ ID NO: 171] wherein N is A, T, G or C; R is G or A; W is A or T; D is A, G, or T; and V is G, C, or A; and 5' ARRTTRTCRTADSWRAWYTT 3', [SEQ ID NO: 174] wherein R is G or A; W is A or T; D is A, G, or T; S is G or C; and Y is C or T. In other aspects, the invention features a recombinant plant gene including one or a combination of the DNA sequences: 5' GGNATGGGNGGNNTNGGNAARACNAC 3', [SEQ ID NO: 162] wherein N is A, T, G or C; and R is A or G; 5' NARNGGNARNCC 3 ' , [SEQ ID NO: 169] wherein N is A, T, G or C; and R is A or G; 5' NCGNG NGTNAKDA NCGNGA 3 ' , [SEQ ID NO: 167] wherein N is A, T, G or C; W is A or T; D is A, G or T; and K is G or T. In another aspect, the invention feaures a substantially pure plant polypeptide including one or a combiantion of the amino acid sequences: Gly Xaa- !^ Xaa 2 Gly Xaa 3 Gly Lys Thr Thr Xaa 4 Xaa 5 , [SEQ ID NO: 191] wherein Xaa χ is Met or Pro; Xaa 2 is Gly or Pro; Xaa 3 is lie, Leu, or Val; Xaa 4 is lie, Leu, or Thr; and Xaa 5 is Ala or Met; aa- L Xaa 2 Xaa 3 Leu Xaa Xaa 5 Xaa 6 Asp Asp Xaa 7 Xaa 8 , [SEQ ID NO; 192] wherein Xaa x is Phe or Lys; Xaa 2 is Arg or Lys; Xaa 3 is lie, Val, or Phe; Xaa 4 is lie, Leu, or Val; Xaa 5 is lie or Leu; Xaa 6 is lie or Val; Xaa 7 is lie. Leu, or Val; and Xaa 8 is Asp or Trp; Xaa- L Xaa 2 Xaa 3 Xaa 4 Xaa 5 Thr Xaa 6 Arg, [SEQ ID NO: 193] wherein Xaa x is Ser or Cys; Xaa 2 is Arg or Lys; Xaa 3 is Phe, lie, or Val; Xaa 4 is lie, or Met; Xaa 5 is lie, Leu, or Phe; Xaa 6 is Ser, Cys, or Thr; Gly Leu Pro Leu Xaa x Xaa 2 Xaa 3 Xaa 4 , [SEQ ID NO.: 194] wherein Xaa x is Thr, Ala, or Ser; Xaa 2 is Leu or Val; Xaa 3 is lie, Val, or Lys; and Xaa 4 is Val or Thr; and Xaa χ Xaa 2 Ser Tyr Xaa 3 Xaa 4 Leu, [SEQ ID NO: 195] wherein Xaa α is Lys or Gly; Xaa 2 is lie or Phe; Xaa 3 is Asp or Lys; and Xaa 4 is Ala, Gly, or Asn. In another aspect, the invention features a method of isolating a disease-resistance gene or fragment thereof from a plant cell, involving: (a) providing a sample of plant cell DNA; (b) providing a pair of oligonucleotides having sequence homology to a conserved region of an RPS disease-resistance gene; (c) combining the pair of oligonucleotides with the plant cell DNA sample under conditions suitable for polymerase chain reaction-mediated DNA amplification; and (d) isolating the amplified disease-resistance gene or fragment thereof. In preferred embodiments, the amplification is carried out using a reverse-transcription polymerase chain reaction, for example, the RACE method In another aspect, the invention features a method of identifying a plant disease-resistance gene in a plant cell, involving: (a) providing a preparation of plant cell DNA (for example, from the plant genome) ; (b) providing a detectably-labelled DNA sequence (for example, prepared by the methods of the invention) having homology to a conserved region of an RPS gene; (c) contacting the preparation of plant cell DNA with the detectablly-labelled DNA sequence under hybridization conditions providing detection of genes having 50% or greater sequence identity; and (d) identifying a disease- resistance gene by its association with the detectable label. In another aspect, the invention features a method of isolating a disease-resistance gene from a recombinant plant cell library, involving: (a) providing a recombinant plant cell library; (b) contacting the recombinant plant cell library with a detectably-labelled gene fragment produced according to the PCR method of the invention under hybridization conditions providing detection of genes having 50% or greater sequence identity; and (c) isolating a member of a disease- resistance gene by its association with the detectable label. In anotehr aspect, the invention features a method of isolating a disease-resistance gene from a recombinant plant cell library, involving: (a) providing a recombinant plant cell library; (b) contacting the recombinant plant cell library with a detectably-labelled RPS oligonucleotide of the invention under hybridization conditions providing detection of genes having 50% or greater sequence identity; and (c) isolating a disease- resistance gene by its association with the detectable label. In another aspect, the invention features a recombinant plant polypeptide capable of conferring disease-resistance wherein the plant polypeptide includes a P-loop domain or nucleotide binding site domain. Preferably, the polypeptide further includes a leucine- rich repeating domain. In another aspect, the invention features a recombinant plant polypeptide capable of conferring disease-resistance wherein the plant polypeptide contains a leucine-rich repeating domain. In anotehr aspect, the invention features a plant disease-resistance gene isolated according to the method involving: (a) providing a sample of plant cell DNA; (b) providing a pair of oligonucleotides having sequence homology to a conserved region of an RPS disease- resistance gene; (c) combining the pair of oligonucleotides with the plant cell DNA sample under conditions suitable for polymerase chain reaction- mediated DNA amplification; and (d) isolating the amplified disease-resistance gene or fragment thereof. In another aspect, the invention features a plant disease-resistance gene isolated according to the method involving: (a) providing a preparation of plant cell DNA; (b) providing a detectably-labelled DNA sequence having homology to a conserved region of an RPS gene; (c) contacting the preparation of plant cell DNA with the detectably-labelled DNA sequence under hybridization conditions providing detection of genes having 50% or greater sequence identity; and (d) identifying a disease- resistance gene by its association with the detectable label. In another aspect, the invention features a plant disease-resistance gene according to the method involving: (a) providing a recombinant plant cell library; (b) contacting the recombinant plant cell " library with a detectably-labelled RPS gene fragment produced according to the method of the invention under hybridization conditions providing detection of genes having 50% or greater sequence identity; and (c) isolating a disease-resistance gene by its association with the detectable label. In another aspect, the invention features a method of identifying a plant disease-resistance gene involving: (a) providing a plant tissue sample; (b) introducing by biolistic transformation into the plant tissue sample a candidate plant disease-resistance gene; (c) expressing the candidate plant disease-resistance gene within the plant tissue sample; and (d) determining whether the plant tissue sample exhibits a disease-resistance response, whereby a response identifies a plant disease- resistance gene. Preferably, the plant tissue sample is either leaf, root, flower, fruit, or stem tissue; the candidate plant disease-resistance gene is obtained from a cDNA expression library; and the disease-resistance response is the hypersensitive response. In another aspect, the invention features a plant disease-resistance gene isolated according to the method involving: (a) providing a plant tissue sample; (b) introducing by biolistic transformation into the plant tissue sample a candidate plant disease-resistance gene; (c) expressing the candidate plant disease-resistance gene within the plant tissue sample; and (d) determining whether the plant tissue sample exhibits a disease- resistance response, whereby a response identifies a plant disease-resistance gene. In another aspect, the invention features a purified antibody which binds specifically to an rps family protein. Such an antibody may be used in any standard immunodetection method for the identification of an RPS polypeptide. In another aspect, the invention features a DNA sequence substantially identical to the DNA sequence shown in Figure 12. In another aspect, the invention features a substantially pure polypeptide having a sequence substantially identical to a Prf amino acid sequence shown in Figure 5 (A or B) . By "disease resistance gene" is meant a gene encoding a polypeptide capable of triggering the plant defense response in a plant cell or plant tissue. An RPS gene is a disease resistance gene having about 50% or greater sequence identity to the RPS2 sequence of Fig. 2 or a portion thereof. The gene, RPS2, is a disease resistance gene encoding the Rps2 disease resistance polypeptide from Arabidopsis thaliana . By "polypeptide" is meant any chain of amino acids, regardless of length or post-translational modification (e.g., glycosylation or phosphorylation) . By "substantially identical" is meant a polypeptide or nucleic acid exhibiting at least 50%, preferably 85%, more preferably 90%, and most preferably 95% homology to a reference amino acid or nucleic acid sequence. For polypeptides, the length of comparison sequences will generally be at least 16 amino acids, preferably at least 20 amino acids, more preferably at least 25 amino acids, and most preferably 35 amino acids. For nucleic acids, the length of comparison sequences will generally be at least 50 nucleotides, preferably at least 60 nucleotides, more preferably at least 75 nucleotides, and most preferably 110 nucleotides. Sequence identity is typically measured using sequence analysis software (e.g., Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 • University Avenue, Madison, WI 53705) . Such software matches similar sequences by assigning degrees of homology to various substitutions, deletions, substitutions, and other modifications. Conservative substitutions typically include substitutions within the following groups: glycine alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid, asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine. By a "substantially pure polypeptide" is meant an Rps2 polypeptide which has been separated from components which naturally accompany it. Typically, the polypeptide is substantially pure when it is at least 60%, by weight, free from the proteins and naturally-occurring organic molecules with which it is naturally associated. Preferably, the preparation is at least 75%, more preferably at least 90%, and most preferably at least 99%, by weight, Rps2 polypeptide. A substantially pure Rps2 polypeptide may be obtained, for example, by extraction from a natural source (e.g., a plant cell); by expression of a recombinant nucleic acid encoding an Rps2 polypeptide; or by chemically synthesizing the protein. Purity can be measured by any appropriate method, e.g., those described in column chromatography, polyacrylamide gel electrophoresis, or by HPLC analysis. A protein is substantially free of naturally associated components when it is separated from those contaminants which accompany it in its natural state. Thus, a protein which is chemically synthesized or produced in a cellular system different from the cell from which it naturally originates will be substantially free from its naturally associated components. Accordingly, substantially pure polypeptides include those derived from eukaryotic organisms but synthesized in E. coli or other prokaryotes. By "substantially pure DNA" is meant DNA that is free of the genes which, in the naturally-occurring genome of the organism from which the DNA of the invention is derived, flank the gene. The term therefore includes, for example, a recombinant DNA which is incorporated into a vector; into an autonomously replicating plasmid or virus; or into the genomic DNA of a prokaryote or eukaryote; or which exists as a separate molecule (e.g., a cDNA or a genomic or cDNA fragment produced by PCR or restriction endonuclease digestion) independent of other sequences. It also includes a recombinant DNA which is part of a hybrid gene encoding additional polypeptide sequence. By "transformed cell" is meant a cell into which (or into an ancestor of which) has been introduced, by means of recombinant DNA techniques, a DNA molecule encoding (as used herein) an Rps2 polypeptide. By "positioned for expression" is meant that the DNA molecule is positioned adjacent to a DNA sequence which directs transcription and translation of the sequence (i.e., facilitates the production of, e.g., an Rps2 polypeptide, a recombinant protein or a RNA molecule) . By "reporter gene" is meant a gene whose expression may be assayed; such genes include, without limitation, ,9-glucuronidase (GUS) , luciferase, chloramphenicol transacetylase (CAT) , and β- galactosidase. By "promoter" is meant minimal sequence sufficient to direct transcription. Also included in the invention are those promoter elements which are sufficient to render promoter-dependent gene expression controllable for cell-type specific, tissue-specific or inducible by external signals or agents; such elements may be located in the 5' or 3' regions of the native gene. By "operably linked" is meant that a gene and a regulatory sequence(s) are connected in such a way as to permit gene expression when the appropriate molecules (e.g., transcriptional activator proteins) are bound to the regulatory sequence(s). By "plant cell" is meant any self-propagating cell bounded by a semi-permeable membrane and containing a plastid. Such a cell also requires a cell wall if further propagation is desired. Plant cell, as used herein includes, without limitation, algae, cyanobacteria, seeds suspension cultures, embryos, meristematic regions, callus tissue, leaves, roots, shoots, gametophytes, sporophytes, pollen, and microspores. By "transgene". is meant any piece of DNA which is inserted by artifice into a cell, and becomes part of the genome of the organism which develops from that cell. Such a transgene may include a gene which is partly or entirely heterologous (i.e., foreign) to the transgenic organism, or may represent a gene homologous to an endogenous gene of the organism. By "transgenic" is meant any cell which includes a DNA sequence which is inserted by artifice into a cell and becomes part of the genome of the organism which develops from that cell. As used herein, the transgenic organisms are generally transgenic plants and the DNA (transgene) is inserted by artifice into the nuclear or plastidic genome. By "pathogen" is meant an organism whose infection into the cells of viable plant tissue elicits a disease response in the plant tissue. By an "RPS disease-resistance gene" is meant any member of the family of plant genes characterized by their ability to trigger a plant defense response and having at least 20%, preferably 30%, and most preferably 50% amino acid sequence identity to one of the conserved regions of one of the RPS members described herein (i.e., either the RPS2, L6, N, or Prf genes). Representative members of the RPS gene family include, without limitation, the rps2 gene of Arabidopsis, the L6 gene of flax, the Prf gene of tomato, and the N gene of tobacco. By "conserved region" is meant any stretch of six or more contiguous amino acids exhibiting at least 30%, preferably 50%, and most preferably 70% amino acid sequence identity between two or more of the RPS family members, RPS2, L6, N, or Prf. Examples of preferred conserved regions are shown (as boxed or designated sequences) in Figures 5 A and B, 6, 7, and 8 and include, without limitation, nucleotide binding site domains, leucine-rich repeats, leucine zipper domains, and P-loop domains. By "detectably-labelled" is meant any means for marking and identifying the presence of a molecule, e.g., an oligonucleotide probe or primer, a gene or fragment thereof, or a cDNA molecule. Methods for detectably- labelling a molecule are well known in the art and include, without limitation, radioactive labelling (e.g., with an isotope such as 32 P or 35 S) and nonradioactive labelling (e.g., chemiluminescent labelling, e.g., fluorescein labelling) . By "biolistic transformation" is meant any method for introducing foreign molecules into a cell using velocity driven microprojectiles such as tungsten or gold particles. Such velocity-driven methods originate from pressure bursts which include, but are not limited to, helium-driven, air-driven, and gunpowder-driven techniques. Biolistic transformation may be applied to the transformation or transfection of a wide variety of cell types and intact tissues including, without limitation, intracellular organelles (e.g., chloroplasts and mitochondria) , bacteria, yeast, fungi, algae, pollen, animal tissue, plant .tissue (e.g., leaf, seedling, embryo, epidermis, flower, meristem, and root) , pollen, and cultured cells. By "purified antibody" is meant antibody which is at least 60%, by weight, free from proteins and naturally-occurring organic molecules with which it is naturally associated. Preferably, the preparation is at least 75%, more preferably 90%, and most preferably at least 99%, by weight, antibody, e.g., an rps2-specific antibody. A purified rps antibody may be obtained, for example, by affinity chromatography using recombinantly- produced rps protein or conserved motif peptides and standard techniques. By "specifically binds" is meant an antibody which recognizes and binds an rps protein but which does not substantially recognize and bind other molecules in a sample, e.g., a biological sample, which naturally includes rps protein. Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof, and from the claims. Detailed Description The drawings will first be described. Drawings Figs. IA - IF are a schematic summary of the physical and RFLP analysis that led to the cloning of the RPS2 locus. Fig. IA is a diagram showing the alignment of the genetic and the RFLP maps of the relevant portion of Arabidopsis thaliana 'chromosome IV adapted from the map published by Lister and Dean (1993) Plant J. 4:745-750. The RFLP marker L11F11 represents the left arm of the YUPllFll YAC clone. Fig. IB is a diagram showing the alignment of relevant YACs around the RPS2 locus. YAC constructs designated YUP16G5, YUP18G9 and YUPllFll were provided by J. Ecker, University of Pennsylvania. YAC constructs designated EW3H7, EW11D4, EW11E4, and EW9C3 were provided by E. Ward, Ciba-Geigy, Inc. Fig. IC is a diagram showing the alignment of cosmid clones around the RPS2 locus. Cosmid clones with the designation H are derivatives of the EW3H7 YAC clone whereas those with the designation E are derivatives of the EW11E4 YAC clone. Vertical arrows indicate the relative positions of RFLP markers between the ecotypes La-er and the rps2-101N plant. The RFLP markers were identified by screening a Southern blot containing more than 50 different restriction enzyme digests using either the entire part or pieces of the corresponding cosmid clones as probes. The cosmid clones described in Fig. IC were provided by J. Giraudat, C.N.R.S., Gif-sur-Yvette, France. Figs. ID and IE are maps of EcoRI restriction endonuclease sites irt the cosmids E4-4 and E4-6, respectively. The recombination break points surrounding the RPS2 locus are located within the 4.5 and 7.5 kb EcoRI restriction endonuclease fragments. Fig. IF is a diagram showing the approximate location of genes which encode the RNA transcripts which have been identified by polyA + RNA blot analysis. The sizes of the transcripts are given in kilobase pairs below each transcript. Fig. 2 [SEQ ID NOS; 1-104, 196-201] is the complete nucleotide sequence of cDNA-4 comprising the RPS2 gene locus. The three reading frames are shown below the nucleotide sequence. The deduced amino acid sequence of reading frame "a" is provided and contains 909 amino acids. The methionine encoded by the ATG start codon is circled in open reading frame "a" of Fig. 2. The A of the ATG start codon is nucleotide 31 of Fig. 2. Fig. 3 [SEQ ID NOS: 105-106] is the nucleotide sequence of the avrRpt2 gene and its deduced amino acid sequence. A potential ribosome binding site is underlined. An inverted repeat is indicated by horizontal arrows at the 3' end of the open reading frame. The deduced amino acid sequence is provided below the nucleotide sequence of the open reading frame. Fig. 4 is a schematic summary of the complementation analysis that allowed functional confirmation that the DNA carried on p4104 and p4115 (encoding cDNA-4) confers RPS2 disease resistance activity to Arabidopsis thaliana plants previously lacking RPS2 disease resistance activity. Small vertical marks along the "genome" line represent restriction enzyme EcoRI recognition sites, and the numbers above this line represent the size, in kilobase pairs (kb) , of the resulting DNA fragments (see also Fig. IE) . Opposite "cDNAs" are the approximate locations of the coding sequences for RNA transcripts (See also Fig. IF) ; arrowheads indicate the direction of transcription for cDNAs 4, 5, and 6. For functional complementation experiments, rps2-201C/rps2-201C plants were genetically transformed with the Arabidopsis thaliana genomic DNA sequences indicated; these sequences were carried on the named plasmids (derivatives of the binary cosmid vector pSLJ4541) and delivered to the plant via Agrobacterium- mediated transformation methods. The disease resistance phenotype of the resulting transformants following inoculation with P. syringae expressing avrRpt2 is given as "Sus." (susceptible, no resistance response) or "Res." (disease resistant) . Fig. 5A [SEQ ID NOS: 107-136;, AND 142] shows regions of sequence similarity between the L-6 protein of flax, N protein of tobacco, Prf protein of tomato, and rps2 protein of Arabidopsis . Fig. 5B [SEQ ID NOS: 107, 108, 137-140] shows sequence similarity between the N and L-6 proteins. Fig. 6 [SEQ ID NOS: 141 and 142] shows a sequence analysis of RPS2 polypeptide showing polypeptide regions corresponding to an N-terminal hydrophobic region, a leucine zipper, NBSs (kinase-la, kinase-2, and kinase-3 motifs) , and a predicted membrane integrated region. Fig. 7 [SEQ ID NOS: 143-146 shows the amino acid sequence of the RPS2 LRR (amino acids 505-867) . The top line indicates the consensus sequences for the RPS2 LRR. An "X" stands for an arbitrary amino acid sequence and an "a" stands for an aliphatic amino acid residue. The consensus sequence for the RPS2 LRR is closely related to the consensus for the yeast adenylate cyclase CYR1 LRR (PX Xa XXL XXL XXLXL XXNXaXXa) . The amino acid residues that match the consensus sequence are shown in bold. Although this figure shows 14 LRRs, the C-terminal boundary of the LRR is not very clear because the LRR closer to the C-terminus does not fit the consensus sequence very well. Fig. 8 [SEQ ID NO: 3] shows a sequence analysis of RPS2, indicating regions with similarity to leucine zipper, P-loop, membrane-spanning, and leucine-rich repeat motifs. Regions with similarity to defined functional domains are indicated with a line over the relevant amino acids. Potential N-glycosylation sequences are marked with a dot, and the location of the rps2-201 Thr to Pro mutation at animo acid 668 is marked with an asterisk. Fig. 9 is a schematic representation of the transient assay method. The top panel shows the essential principles of the assay. The bottom panel shows a schematic representation of the actual transient assay procedure. Psp NP53121 is used because it is a weak Arabidopsis pathogen, but potent in causing the HR when carrying an avirulence gene. In the absence of an HR, the damage to plant cells infected with NP53121 is minimal, enhancing the difference of GUS accumulation in cells that undergo the HR in comparison to those that do not. Prior to bombardment, one half of an Arabidopsis leaf is infiltrated with P. syringae (stippled side of leaf) ; the other half of the leaf serves as a noninfected control, an "internal" reference for the infected side, and as a measure of transformation efficiency. Fig. 10, panels A-B, are photographs showing the complementation of the rps2 mutant phenotype using the biolistic transient expression assay. The left sides of rps2-101C mutant leaves were infiltrated with Psp 3121/avrRpt2. Infiltrated leaves were cobombarded with either 35S-uidA plus ΔGUS (Panel A) or 35S-uidA plus 35S- RPS2 (cDNA-2 clone 4) (Panel B) . Note that in Panel B the infected side of the leaf shows less GUS activity than the uninfected side, indicating that the transformed cells on the infected side underwent an HR and that 35S- RPS2 complemented the mutant phenotype (see Fig. 9) . Fig. 11 is a schematic representation of pKEx4tr showing the structure of this cDNA expression vector. For convenience, the multiple cloning site contains the 8bp recognition sequences for Pmel and NotI and is flanked by T7 and T3 promoters. The region spanning the modified 35S promoter to the nopaline synthase 3' sequences (nos 3') was cloned into the Hind III-EcoRI site of pUC18, resulting in the loss of the EcoRI site. Fig. 12 shows a nucleic acid sequence of the tomato Prf gene. The Genetic Basis for Resistance to Pathogens An overview of the interaction between a plant host and a microbial pathogen is presented. The invasion of a plant by a potential pathogen can have a range of outcomes delineated by the following outcomes: either the pathogen successfully proliferates in the host, causing associated disease symptoms, or its growth is halted by the host defenses. In some plant-pathogen interactions, the visible hallmark of an active defense response is the so-called hypersensitive response or "HR". The HR involves rapid necrosis of cells near the site of the infection and may include the formation of a visible dry brown lesion. Pathogens which elicit an HR on a given host are said to be avirulent on that host, the host is said to be resistant, and the plant-pathogen interaction is said to be incompatible. Strains which proliferate and cause disease on a particular host are said to be virulent; in this case the host is said to be susceptible, and the plan -pathogen interaction is said to be compatible "Classical" genetic analysis has been used successfully to help elucidate the genetic basis of plant-pathogen recognition for those cases in which a series of strains (races) of a particular fungal or bacterial pathogen are either virulent or avirulent on a series of cultivars (or different wild accessions) of a particular host species. In many such cases, genetic analysis of both the host and the pathogen revealed that many avirulent fungal and bacterial strains differ from virulent ones by the possession of one or more avirulence (avr) genes that have corresponding "resistance" genes in the host. This avirulence gene-resistance gene correspondence is termed the "gene-for-gene" model (Crute, et al., (1985) pp 197-309 in: Mechanisms of Resistance to Plant Disease . R.S.S. Fraser, ed.; Ellingboe, (1981) Annu. Rev. Phytopathol. 19:125-143; Flor, (1971) Annu. Rev. Phytopathol. 9:275-296; Keen and Staskawicz, (1988) supra; and Keen et al. in: Application of Biotechnology to Plant Pathogen Control . I. Chet, ed. , John Wiley & Sons, 1993, pp. 65-88) . According to a simple formulation of this model, plant resistance genes encode specific receptors for molecular signals generated by avr genes. Signal transduction pathway(s) then carry the signal to a set of target genes that initiate the HR and other host defenses (Gabriel and Rolfe, (1990) Annu. Rev. Phytopathol. 28:365-391). Despite this simple predictive model, the molecular basis of the avr- resistance gene interaction is still unknown. One basic prediction of the gene-for-gene hypothesis has been convincingly confirmed at the molecular level by the cloning of a variety of bacterial avr genes (Innes, et.al., (1993) J. Bacteriol. 175:4859- 4869; Dong, et al., (1991) Plant Cell 3:61-72; Whelan et al., (1991) Plant Cell 3:49-59; Staskawicz et al., (1987) J. Bacteriol. 169:5789-5794; Gabriel et al., (1986) P.N.A.S., USA 83:6415-6419; Keen and Staskawicz, (1988) Annu. Rev. Microbiol. 42:421-440; Kobayashi et al., (1990) Mol. Plant-Microbe Interact. 3:94-102 and (1990) Mol. Plant-Microbe Interact. 3:103-111). Many of these cloned avirulence genes have been shown to correspond to individual resistance genes in the cognate host plants and have been shown to confer an avirulent phenotype when transferred to an otherwise virulent strain. The avrRpt2 locus was isolated from Pseudomonas syringae pv. tomato and sequenced by Innes et al. (Innes, R. et al. (1993) J. Bacteriol. 175:4859-4869). Fig. 3 is the nucleotide sequence and deduced -amino acid sequence of the avrRpt2 gene. Examples of known signals to which plants respond when infected by pathogens include harpins from Erwinia (Wei et al. (1992) Science 257:85-88) and Pseudomonas (He et al. (1993) Cell 73:1255-1266); avr4 (Joosten efal. (1994) Nature 367:384-386) and avr9 peptides (van den Ackerveken et al (1992) Plant J. 2:359-366) from Cladosporium; PopAl from Pseudomonas (Arlat et al. (1994) EMBO J. 13:543-553); avrD-generated lipopolysaccharide (Midland et al. (1993) J. Org. Chem. 58:2940-2945); and iVJPl from Rhynchosporium (Hahn et al. (1993) Mol. Plant- Microbe Interact. 6:745-754). Compared to avr genes, considerably less is known about plant resistance genes that correspond to specific avr-generated signals. The plant resistance gene, RPS2 (rps for resistance to Pseudomonas syringae) , the first gene of a new, previously unidentified class of plant disease resistance genes corresponds to a specific avr gene (avrRpt2) . Some of the work leading up to the cloning of RPS2 is described in Yu, et al., (1993), Molecular Plant-Microbe Interactions 6:434-443 and in Kunkel, et al., (1993) Plant Cell 5:865-875. An apparently unrelated avirulence gene which corresponds specifically to plant disease resistance gene, Pto, has been isolated from tomato (Lycopersicon eεculentum) (Martin et al., (1993) Science 262:1432-1436). Tomato plants expressing the Pto gene are resistant to infection by strains of Pseudomonas syringae pv. tomato that express the avrPto avirulence gene. The amino acid sequence inferred from the Pto gene DNA sequence displays strong similarity to serine-threonine protein kinases, implicating Pto in signal transduction. No similarity to the tomato Pto locus or any known protein kinases was observed for RPS2, suggesting that RPS2 is representative of a new class of plant disease resistance genes. The isolation of a race-specific resistance gene from Zea mays (corn) known as Hml has been reported (Johal and Briggs (1992) Science 258:985-987). Hml confers resistance against specific races of the fungal pathogen Cochliobolus carbonum by controlling degradation of a fungal toxin, a strategy that is mechanistically distinct from the avirulence-gene specific resistance of the RPS2-avrRpt2 resistance mechanism. The cloned RPS2 gene of the invention can be used to facilitate the construction of plants that are resistant to specific pathogens and to overcome the inability to transfer disease resistance genes between species using classical breeding techniques (Keen et al., (1993) , supra) . There now follows a description of the cloning and characterization of an Arabidopsis thaliana RPS2 genetic locus, the RPS2 genomic DNA, and the RPS2 cDNA. The avrRptΣ gene and the RPS2 gene, as well as mutants rps2-101C, rps2-102C, and rps2-201C (also designated rps2-201 ) , are described in Dong, et al., (1991) Plant Cell 3:61-72; Yu, et al., (1993) supra: Kunkel et al., (1993) supra: Whalen et al., (1991), supra; and Innes et al., (1993), supra) . A mutant designated rps2-101N has also been isolated. The identification and cloning of the RPS2 gene is described below. RPS2 Overcomes Sensitivity to Pathogens Carrying the ayrRpt2 Gene To demonstrate the genetic relationship between an avirulence gene in the pathogen and a resistance gene in the host, it was necessary first to isolate an avirulence gene. By screening Pseudomonas strains that are known pathogens of crop plants related to Arabidopsis , highly virulent strains, P. syringae pv. maculicola (Psm) ES4326, P. syringae pv. tomato (Pst) DC3000, and an avirulent strain, Pst MM1065 were identified and analyzed as to their respective abilities to grow in wild type Arabidopsis thaliana plants (Dong et al . , (1991) Plant Cell, 3:61-72; Whalen et al. , (1991) Plant Cell 3:49-59; MM1065 is designated "JL1065 in Whalen et al.). Ps ES4326 or Pst DC3000 can multiply 10 4 fold in Arabidopsis thaliana leaves and cause water-soaked lesions that appear over the course of two days. Pst MM1065 multiplies a maximum of 10 fold in Arabidopsis thaliana leaves and causes the appearance of a mildly chlorotic dry lesion after 48 hours. Thus, disease resistance is associated with severely inhibited growth of the pathogen. An avirulence gene (avr) of the Pst MM1065 strain was cloned using standard techniques as described in Dong et al . (1991), Plant Cell 3:61-72; Whalen et al., (1991) supra; and Innes et al., (1993), supra. The isolated avirulence gene from this strain was designated avrRptΣ. Normally, the virulent strain Psm ES4326 or Pst DC3000 causes the appearance of disease symptoms after 48 hours as described above. In contrast, Psm ES4326/avrJ?pt2 or Pst DC3000 /avrRpt 2 elicits the appearance of a visible necrotic hypersensitivity response (HR) within 16 hours and multiplies 50 fold less than Psm ES4326 or Pst DC3000 in wild type Arabidopsis thaliana leaves (Dong et al . , (1991), supra; and Whalen et al., (1991), supra) . Thus, disease resistance in a wild type Arabidopsis plant requires, in part, an avirulence gene in the pathogen or a signal generated by the avirulence gene. The isolation of four Arabidopsis thaliana disease resistance mutants has been described using the cloned avrRpt2 gene to search for the host gene required for disease resistance to pathogens carrying the avrRpt2 gene (Yu et al., (1993), supra; Kunkel et al., (1993), supra) . The four Arabidopsis thaliana mutants failed to develop an HR when infiltrated with Psm ES4326/avrRpt2 or Pst OC3000/ avrRpt 2 as expected for plants having lost their disease resistance capacity. In the case of one of these mutants, approximately 3000 five to six week old M 2 ecotype Columbia (Col-0 plants) plants generated by ethyl methanesulfonic acid (EMS) mutagenesis were hand- inoculated with Psm ES4326/avr-Rpt2 and a single mutant, rps2-101C was identified (resistance to Pseudomonas syringae) (Yu et al . , (1993), supra) . The second mutant was isolated using a procedure that specifically enriches for mutants unable to mount an HR (Yu et al . , (1993), supra) . When 10-day old Arabidopsis thaliana seedlings growing on petri plates are infiltrated with Pseudomonas syringae pv. phaseolicola (Psp) NPS3121 versus Psp NPS312 l/avrRpt2 , about 90% of the plants infiltrated with Psp NPS3121 survive, whereas about 90%-95% of the plants infiltrated with Psp NPS312 l/avrRpt2 die. Apparently, vacuum infiltration of an entire small Arabidopsis thaliana seedling with Psp NPS312 l/avrRpt2 elicits a systemic HR which usually kills the seedling. In contrast, seedlings infiltrated with Psp NPS3121 survive because Psp NPS3121 is a weak pathogen on Arabidopsis thaliana . The second disease resistance mutant was isolated by infiltrating 4000 EMS-mutagenized Columbia M 2 seedlings with Psp NPS3121 I avrRpt2. Two hundred survivors were obtained. These were transplanted to soil and re-screened by hand inoculation when the plants reached maturity. Of these 200 survivors, one plant failed to give an HR when hand- infiltrated with Psm ES4326/avrJ?pt2. This mutant was designated rps2-102C (Yu et al . , (1993), supra) . A third mutant, rps2-201C, was isolated in a screen of approximately 7500 M 2 plants derived from seed of Arabidopsis thaliana ecotype Col-0 that had been mutagenized with diepoxybutane (Kunkel et al., (1993), supra) . Plants were inoculated by dipping entire leaf rosettes into a solution containing Pst DC3000/avrRpt2 bacteria and the surfactant Silwet L-77 (Whalen et al.. (1991) , supra) , incubating plants in a controlled environment growth chamber for three to four days, -and then visually observing disease symptom development. This screen revealed four mutant lines (carrying the rps2-201C, rps2-202C, rps2-203C, and rps2-204C alleles) , and plants homozygous for rps2-201C were a primary subject for further study (Kunkel et al., (1993), supra and the instant application) . Isolation of the fourth rps2 mutant, rps2-101N, has not yet been published. This fourth isolate is either a mutant or a susceptible Arabidopsis ecotype. Seeds of the Arabidopsis Nossen ecotype were gamma- irradiated and then sown densely in flats and allowed to germinate and grow through a nylon mesh. When the plants were five to six weeks old, the flats were inverted, the plants were partially submerged in a tray containing a culture of Psm ES4326/avrRpt2 , and the plants were vacuum infiltrated in a vacuum desiccator. Plants inoculated this way develop an HR within 24 hours. Using this procedure, approximately 40,000 plants were screened and one susceptible plant was identified. Subsequent RFLP analysis of this plant suggested that it may not be a Nossen mutant but rather a different Arabidopsis ecotype that is susceptible to PSJΠ ES4326/avrRpt2. This plant is referred to as rps2-101N. The isolated mutants rps2- 101C, rps2-102C, rps2-201C , and rps2-101N are referred to collectively as the "rps2 mutants". The rps2 Mutants Fail to Specifically Respond to the Cloned Avirulence Gene, ayrRpt2 The RPS2 gene product is specifically required for resistance to pathogens carrying the avirulence gene, avrRpt2. A mutation in Rps2 polypeptide that eliminates or reduces its function would be observable as the absence of a hypersensitive response upon infiltration of the pathogen. The rps2 mutants displayed disease symptoms or a null response when infiltrated with Psm ES4326 I avrRptΣ, Pst DC3000 /avrRpt 2 or Psp NPS3121/a vrRpt2 , respectively. Specifically, no HR response was elicited, indicating that the plants were susceptible and had lost resistance to the pathogen despite the presence of the avrRpt2 gene in the pathogen. Pathogen growth in rps2 mutant plant leaves was similar in the presence and absence of the avrRpt2 gene. Psm ES4326 and Psm ES4326 /avrRpt 2 growth in rps2 mutants was compared and found to multiply equally well in the rps2 mutants, at the same rate that Psm Es4326 multiplied in wild-type Arabidopsis leaves. Similar results were observed for Pst DC3000 and Pst DC3000 /avrRpt 2 growth in rps2 mutants. The rps2 mutants displayed a HR when infiltrated with Pseudomonas pathogens carrying other avr genes, Psm ES4326/avr£, Pst DC3000/avrB, Psm ES4326 / avrRpml , Pst DC3000 I avrRpml . The ability to mount an HR to an avr gene other than avrRptΣ indicates that the rps2 mutants isolated by selection with avrRpt2 are specific to avrRpt2 . Mapping and Cloning of the RPS2 Gene Genetic analysis of rps2 mutants rpε2-101C, rps2- 102C, rps-201C and rps-lOlN showed that they all corresponded to genes that segregated as expected for a single Mendelian locus and that all four were most likely allelic. The four rps2 mutants were mapped to the bottom of chromosome IV using standard RFLP mapping procedures including polymerase -chain reaction (PCR)-based markers (Yu et al . , (1993), supra; Kunkel et al . , (1993), supra; and Mindrinos, M. , unpublished). Segregation analysis showed that rps2-101C and rps2-102C are tightly linked to the PCR marker, PG11, while the RFLP marker M600 was used to define the chromosome location of the rpε2-201C mutation (Fig. IA) (Yu et al . , (1993), supra; Kunkel et al . , (1993), supra) . RPS2 has subsequently been mapped to the centromeric side of PG11. Heterozygous RPS2/rps2 plants display a defense response that is intermediate between those displayed by the wild-type and homozygous rps2/rps2 mutant plants (Yu, et al., (1993), supra; and Kunkel et al., (1993), supra) . The heterozygous plants mounted an HR in response to Psm ES4326/avrRpt2 or Pst DC3000 /avrRptΣ infiltration; however, the HR appeared later than in wild type plants and required a higher minimum inoculum (Yu, et al., (1993), supra; and Kunkel et al., (1993), supra) . High Resolution Mapping of the RPS2 Gene and RPS2 cDNA Isolation To carry out map-based cloning of the RPS2 gene, rps2-101N/rps2-101N was crossed with Landsberg erecta RPS2/RPS2. Plants of the F χ generation were allowed to self pollinate (to "self") and 165 F 2 plants were selfed to generate F 3 families. Standard RFLP mapping procedures showed that rps2-101N maps close to and on the centromeric side of the RFLP marker, PG11. To obtain a more detailed map position, rps2-101N/rps-101N was crossed with a doubly marked Landsberg erecta strain containing the recessive mutations, cer2 and ap2 . The genetic distance between cer2 and ap2 is approximately 15 cM, and the rps2 locus is located within this interval. F 2 plants that displayed either a CER2 ap2 or a cer2 AP2 genotype were collected, selfed, and scored for RPS2 by inoculating at least 20 F 3 plants for each F 2 with Psm ES4326/avrRpt2 . DNA was also prepared from a pool of approximately 20 F 3 plants for each F 2 line. The CER2 ap2 and cer2 AP2 recombinants were used to carry out a chromosome walk that is illustrated in Figure 1. As shown in Figure 1, RPS2 was mapped to a 28-35 kb region spanned by cosmid clones E4-4 and E4-6. This region contains at least six genes that produce detectable transcripts. There were no significant differences in the sizes of the transcripts or their level of expression in the rps2 mutants as determined by RNA blot analysis. cDNA clones of each of these transcripts were isolated and five of these were sequenced. As is described below, one of these transcripts, cDNA-4, was shown to correspond to the RPS2 locus. From this study, three independent cDNA clones (cDNA-4-4, cDNA-4-5, and cDNA-4-11) were obtained corresponding to RPS2 from Columbia ecotype wild type plants. The apparent sizes of RPS2 transcripts were 3.8 and 3.1 kb as determined by RNA blot analysis. A fourth independent cDNA-4 clone (cDNA-4-2453) was obtained using map-based isolation of RPS2 in a separate study. Yeast artificial chromosome (YAC) clones were identified that arry contiguous, overlapping inserts of Arabidopsis thaliana ecotype Col-0 genomic DNA from the M600 region spanning approximately 900 kb in the RPS2 region. Arabidopsis YAC libraries were obtained from J. Ecker and E. Ward, supra and from E. Grill (Grill and Somerville (1991) Mol. Gen. Genet. 226:484-490). Cosmids designated "H" and "E" were derived from the YAC inserts and were used in the isolation of RPS2 (Fig. 1) . The genetic and physical location of RPS2 was more precisely defined using physically mapped RFLP, RAPD (random amplified polymorphic DNA) and CAPS (cleaved amplified polymorphic sequence) markers. Segregating populations from crosses between plants of genotype RPS2/RPS2 (No-0 wild type) and rps2-201/rps2-201 (Col-0 background) were used for genetic mapping. The RPS2 locus was mapped using markers 17B7LE, PG11, M600 and other markers. For high-resolution genetic mapping, a set of tightly linked RFLP markers was generated using insert end fragments from YAC and cosmid clones (Fig. 1) (Kunkel et al. (1993), supra; Konieczny and Ausubel (1993) Plant J. 4:403-410; and Chang et al. (1988) PNAS USA 85:6856-6860). Cosmid clones E4-4 and E4-6 were then used to identify expressed transcripts (designated cDNA- 4, -5, -6, -7, -8 of Fig IF) from this region, including the cDNA-4-2453 clone. RPS2 DNA Sequence Analysis DNA sequence analysis of cDNA-4 from wild-type Col-0 plants and from mutants rps2-101C, rps2-102C, rps2- 201C and rps2-101N showed that cDNA-4 corresponds to RPS2 . DNA sequence analysis of rps2-101C, rps2-102C and rps2-201C revealed changes from the wild-type sequence as shown in Table 1. The numbering system in Table 1 starts at the ATG start codon encoding the first methionine where A is nucleotide 1. DNA sequence analysis of cDNA-4 corresponding to mutant rps2-102C showed that it differed from the wild type sequence at amino acid residue 476. Moreover, DNA sequence analysis of the cDNA corresponding to cDNA-4 from rpε2-101N showed that it contained a 10 bp insertion at amino acid residue 581, a site within the leucine-rich repeat region which causes a shift in the RPS2 reading frame. Mutant rps2-101C contains a mutation that leads to the formation of a chain termination codon. The DNA sequence of mutant allele rps2-201C revealed a mutation altering a single amino acid within a segment of the LRR region that also has similarity to the helix- loop-helix motif, further supporting the designation of this locus as the RPS2 gene. The DNA and amino acid sequences are shown in Figure 2. Table 1 Mutant Wild type position of Change mutation rps2-101C 703 TGA 705 704 TAA Stop Codon rps2-101N 1741 GTG 1743 1741 GTGGAGTTGTATG Insertion rps2-102C 1426 AGA 1428 1427 AAA Amino acid 476 arg lys rps2-201C 2002 ACC 2004 2002 CCC Amino acid thr pro DNA sequence analysis of cDNA-4 corresponding to RPS2 from wild-type Col-0 plants revealed an open reading frame (between two stop codons) spanning 2,751 bp. There are 2,727 bp between the first methionine codon of this reading frame and the 3'-stop codon, which corresponds to a deduced 909 amino acid polypeptide (See open reading frame "a" of Fig. 2) . The amino acid sequence has a relative molecular weight of 104,460 and a pi of 6.51. As discussed below, RPS2 belongs to a new class of disease resistance genes; the structure of the Rps2 polypeptide does not resemble the protein structure of the product of the previously cloned and publicized avirulence gene-specific plant disease resistance gene, Pto, which has a putative protein kinase domain. From the above analysis of the deduced amino acid sequence, RPS2 contains several distinct protein domains conserved in other proteins from both eukaryotes and prokaryotes. These domains include, but are not limited, to Leucine Rich Repeats (LRR) (Kobe and Deisenhofer, (1994) Nature 366:751-756); nucleotide binding site, e.g. the kinase la motif (P-loop) (Saraste et al. (1990) Trends in Biological Sciences TIBS 15:430-434; Helix-Loop-Helix (Murre et al. (1989) ' Cell 56:777-783; and Leucine Zipper (Rodrigues and Park (1993) Mol. Cell Biol. 13:6711-6722). The amino acid sequence of Rps2 contains a LRR motif (LRR motif from amino acid residue 505 to amino acid residue 867) , which is present in many known proteins and which is thought to be involved in protein-protein interactions and may thus allow interaction with other proteins that are involved in plant disease resistance. The N-terminal portion of the Rps2 polypeptide LRR is, for example, related to the LRR of yeast (Saccharomyces cerevisiae) adenylate cyclase, CYR1. A region predicted to be a transmembrane spanning domain (Klein et al. (1985) Biochim. , Biophys. Acta 815:468-476) is located from amino acid residue 350 to amino acid residue 365, N- terminal to the LRR. An ATP/GTP binding site motif (P- loop) is predicted to be located between amino acid residue 177 and amino acid residue 194, inclusive. The motifs are discussed in more detail below. From the above analysis of the deduced amino acid sequence, the Rps2 polypeptide may have a membrane- receptor structure which consists of an N-terminal extracellular region and a C-terminal cytoplasmic region. Alternatively, the topology of the Rps2 may be the opposite: an N-terminal cytoplasmic region and a C- terminal extracellular region. LRR motifs are extracellular in many cases and the Rps2 LRR contains five potential N-glycosylation sites. Identification of RPS2 by Functional Complementation Complementation of rps2-201 homozygotes with genomic DNA corresponding to Arabidopsis thaliana functionally confirmed that the genomic region encoding cDNA-4 carries RPS2 activity. Cosmids were constructed that contained overlapping contiguous sequences of wild type Arabidopsis thaliana DNA from the RPS2 region contained in YACs EW11D4, EW9C3, and YUP11F1 of Fig. 1 and Fig. 4. The cosmid vectors were constructed from pSLJ4541 (obtained from J. Jones, Sainsbury Institute, Norwich, England) which contains sequences that allow the inserted sequence to be integrated into the plant genome via AgroJacterium-mediated transformation (designated "binary cosmid") . "H" and "E" cosmids (Fig. l) were used to identify clones carrying DNA from the AraJbidopsis thaliana genomic RPS2 region. More than forty binary cosmids containing inserted RPS2 region DNA were used to transform rps2-201 homozygous mutants utilizing Agrojbacteriujn-mediated transformation (Chang et al. ((1990) p. 28, Abstracts of the Fourth International Conference on Arabidopsis Research, Vienna, Austria) . Transfor ants which remained susceptible (determined by methods including the observed absence of an HR following infection to P. syringae pv. phaseolicola strain 3121 carrying avrRpt2 and Psp 3121 without avrRpt2) indicated that the inserted DNA did not contain functional RPS2. These cosmids conferred the "Sus." or susceptible phenotype indicated in Fig. 4. Transformants which had acquired avrRpt2-specific disease resistance (determined by methods including the display of a strong hypersensitive response (HR) when inoculated with Psp 3121 with avrRpt2, but not following inoculation with Psp 3121 without avrRpt2 ) suggested that the inserted DNA contained a functional -PS2 gene capable of conferring the "Res." or resistant phenotype indicated in Fig. 4. Transformants obtained using the pD4 binary cosmid displayed a strong resistance phenotype as described above. The presence of the insert DNA in the transformants was confirmed by classical genetic analysis (the tight genetic linkage of the disease resistance phenotype and the kanamycin resistance phenotype conferred by the cotransformed selectable marker) and Southern analysis. These results indicated that RPS2 is encoded by a segment of the 18 kb Arabidopsis thaliana genomic region carried on cosmid pD4 (Fig. 4) . To further localize the RPS2 locus and confirm its ability to confer a resistance phenotype on the rps2-201 homozygous mutants, a set of six binary cosmids containing partially overlapping genomic DNA inserts were tested. The overlapping inserts pD2, pD4, pD14, pD15, pD27, and pD47 were chosen based on the location of the transcription corresponding to the five cDNA clones in the RPS2 region (Fig. 4) . These transformation experiments utilized a vacuum infiltration procedure (Bechtold et al. (1993) CR. Acad. Sci. Paris 316:1194- 1199) for AgrroJbacterium-mediated transformation. AgrroJbacteriujn-mediated transformations with cosmids pD2, pD14, pD15, pD39, and pD46 were performed using a root transformation/regeneration protocol (Valveekens et al. (1988), PNAS 85:5536-5540). The results of pathogen inoculation experiments assaying for RPS2 activity in these transformants is indicated in Fig. 4. These experiments were further confirmed using a modification of the vacuum filtration procedure. In particular, the procedure of Bechtold et al. (supra) was modified such that plants were grown in peat-based potting soil covered with a screen, primary inflorescences were removed, and plants with secondary inflorescences (approximately 3 to 15 cm in length) were inverted directly into infiltration medium, infiltrated, and then grown to seed harvest without removal from soil (detailed protocol available on the AAtDB computer database (43) . The presence of introduced sequences in the initial pD4 transformant was verified by DNA blot analysis with a pD4 vector and insert sequences (separately) as probes. The presence of the expected sequences in transformants obtained with the vacuum infiltration protocol was also confirmed by DNA blot analysis. Root transformation experiments (19) were performed with an easily regenerable rps2-201/rpε2-201 x No-0 mapping population. Transformants were obtained for pD4 with in plant transformation, for pD2, 14, 16, 39, and 49 with root transformation, and for pD2, 4, 14, 15, 27, and 47 with vacuum infiltration as modified. Additional transformation experiments utilized binary cosmids carrying the complete coding region and more than 1 kb of upstream genomic sequence for only cDNA-4 or cDNA-6. Using the vacuum infiltration transformation method, three independent transformants were obtained that carried the wild-type cDNA-6 genomic region in a rps2-201c homozygous background (pAD431 of Fig. 4) . None of these plants displayed avrRpt2- dependent disease resistance. Homozygous rps2-201c mutants were transformed with wild-type genomic cDNA-4 (p4104 and p4115, each carrying Col-0 genomic sequences corresponding to all of the cDNA-4 open reading frame, plus approximately 1.7 kb of 5' upstream sequence and approximately 0.3 kb of 3' sequence downstream of the stop codon) . These p4104 and p4115 transformants displayed a disease resistance phenotype similar to the wild-type RPS2 homozygotes from which the rps2 were derived. Additional mutants (rps2-101N and rps2-101C homozygotes) also displayed avrRpt2-dependent resistance when transformed with the cDNA-4 genomic region. .RPS2 Sequences Allow Detection of Other Resistance Genes DNA blot analysis of Arabidopsis thaliana genomic DNA using RPS2 cDNA as the probe showed that Arabidopsis contains several DNA sequences that hybridize to RPS2 or a portion thereof, suggesting that there are several related genes in the Arabidopsis genome. From the aforementioned description and the nucleic acid sequence shown in Fig. 2, it is possible to isolate other plant disease resistance genes having about 50% or greater sequence identity to the RPS2 gene. Detection and isolation can be carried out with an oligonucleotide probe containing the RPS2 gene or a portion thereof greater than 9 nucleic acids in length, and preferably greater than about 18 nucleic acids in length. Probes to sequences encoding specific structural features of the Rps2 polypeptide are preferred as they provide a means of isolating disease resistance genes having similar structural domains. Hybridization can be done using standard techniques such as are described in Ausubel et al.. Current Protocols in Molecular Biology, John Wiley & Sons, (1989) . For example, high stringency conditions for detecting the RPS2 gene include hybridization at about 42°C, and about 50% formamide; a first wash at about 65°C, about 2X SSC, and 1% SDS; followed by a second wash at about 65°C and about 0.1% x SSC. Lower stringency conditions for detecting RPS genes having about 50% sequence identity to the RPS2 gene are detected by, for example, hybridization at about 42°C in the absence of formamide; a first wash at about 42°C, about 6X SSC, and about 1% SDS; and a second wash at about 50°C, about 6X SSC, and about 1% SDS. An approximately 350 nucleotide DNA probe encoding the middle portion of the LRR region of Rps2 was used as a probe in the above example. Under lower stringency conditions, a minimum of 5 DNA bands were detected in BamHI digested Arabidopsis thaliana genomic DNA as sequences having sufficient sequence identity to hybridize to DNA encoding the middle portion of the LRR motif of Rps2. Similar results were obtained using a probe containing a 300 nucleotide portion of the RPS2 gene encoding the extreme N-terminus of Rps2 outside of the LRR motif. Isolation of other disease resistance genes is performed by PCR amplification techniques well known to those skilled in the art of molecular biology using oligonucleotide primers designed to amplify only sequences flanked by 'the oligonucleotides in genes having sequence identity to RPS2. The primers are optionally designed to allow cloning of the amplified product into a suitable vector. The RPS Disease-Resistance Gene Family As discussed above, we have discovered that the Arabidopsis RPS2 gene described herein is representative of a new class of plant resistance genes. Analysis of the derived amino acid sequence for RPS2 revealed several regions of similarity with known polypeptide motifs (see, e.g., Schneider et al., Genes Dev. 6:797 (1991)). Most prominent among these is a region of multiple, leucine- rich repeats (LRRs) . The LRR motif has been implicated in protein-protein interactions and ligand binding in a diverse array of proteins (see, e.g., Kornfield et al., Annu. Rev. Biochem. 64:631 (1985); Alber, Curr. Opin. Gen. Dev. 2:205 (1992); Lupas et al. , Science 252:116 2 (1991); Saraste et al.. Trend Biochem. Sci. 15:430 (1990)). In one example, LRRs form the hormone binding sites of mammalian gonadotropin hormone receptors (see, e.g, Lupas et al.. Science 252:1162 (1991)) and, in another example, a domain of yeast adenylate cyclase that interacts with the RAS2 protein (Kornfield et al., Annu. Rev. Biochem. 64:631 (1985)). In RPS2 , the LRR domain spans amino acids 503-867 and contains fourteen repeat units of length 22-26 amino acids. A portion of each repeat resembles the LRR consensus sequence (I/L/V)XXLXXLXX(I/L)XL. In Figure 7, the LRRs from RPS2 are shown, as well as an -RPS2 consensus sequence. Within the RPS2 LRR region, five (of six) sequences matching the N-glycosylation consensus sequence [NX(S/T)] were observed (Figure 8, marked with a dot) . In particular, N-glycosylation is predicted to occur at amino acids 158, 543, 666, 757, 778, 787. Interestingly, the single nucleotide difference between functional RPS2 and mutant allele rps2-201 is within the LRR coding region, and this mutation disrupts one of the potential glycosylation sites. Also observed in the deduced amino acid sequence for RPS2 is a second potential protein-protein interaction domain, a leucine zipper (see, e.g., von Heijne, J. Mol. Biol. 225:487 (1992)), at amino acids 30- 57. This region contains four contiguous heptad repeats that match the leucine zipper consensus sequence (I/R)XDLXXX. Leucine zippers facilitate the dimerization of transcription factors by formation of coiled-coil structures, but no sequences suggestive of an adjacent DNA binding domain (such as a strongly basic region or a potential zinc-finger) were detected in RPS2. Coiled- coil regions also promote specific interactions between proteins that are not transcription factors (see, e.g.. Ward et al.. Plant Mol. Biol. 14:561 (1990); Ecker, Methods 1:186 (1990); Grill et al., Mol. Gen. Genet. 226:484 (1991)), and computer database similarity searches with the region spanning amino acids 30-57 of RPS2 revealed highest similarity to the coiled-coil regions of numerous myosin and paramyosin proteins. A third RPS2 motif was found at the sequence GPGGVGKT at deduced amino acids 182-189. This portion of RPS2 precisely matches the generalized consensus for the phosphate-binding loop (P-loop) of numerous ATP- and GTP- binding proteins (see, e.g., Saraste et al., supra) ) . The postulated RPS2 P-loop is similar to those found in RAS proteins and ATP synthase 0-subunits (Saraste et al., supra) , but surprisingly is most similar to the published P-loop sequences for the nifH and chvD genes, respectively. The presence of this P-loop sequence strongly suggests nucleotide triphosphate binding as one aspect of RPS2 function. This domain is also referred to as a kinase-la motif (or a nucleotide binding site, or NBS) . Other conserved NBSs are present in the RPS2 sequence; these NBSs include a kinase-2 motif at amino acids 258-262 and a kinase-3a motif at amino acids 330- 335. Finally, inspection of the RPS2 sequence reveals a fourth RPS2 motif, a potential membrane-spanning domain located at amino acids 340-360. Within this region, a conserved GLPLAL motif is found at amino acids 347-352. The presence of the membrane-spanning domain raises the possibility that the RPS2 protein is membrane localized, with the N-terminal leucine zipper and P-loop domains residing together on the opposite side of the membrane from the LRR region. An orientation in which the C- terminal LRR domain is extracellular is suggested by the fact that five of the six potential N-linked glycosylation sites occur C-terminal to the proposed membrane-spanning domain, as well as by the overall more positive charge of the N-terminal amino acid residues (see, e.g., Kornfield et al., supra: von Heijne, supra) . A number of proteins that contain LRRs are postulated or known to be membrane-spanning receptors in which the LRRs are displayed extracellularly as a ligand-binding domain (see, e.g., Lopez et al., Proc. Natl. Acad. Sci. 84:5615 (1987); Braun et al.,. EMBO J. 10:1885 (1991); Schneider et al., supra) . The plant kingdom contains hundreds of resistance genes that are necessarily divergent since they control different resistance specificities. However, plant defense responses such as production of activated oxygen species, PR-protein gene expression, and the hypersensitive response are common to diverse plant- pathogen interactions. This implies that there are points of convergence in the defense signal transduction pathways downstream of initial pathogen recognition, and also suggests that similar functional motifs may exist among diverse resistance gene products. Indeed, RPS2 is dissimilar from previously described disease resistance genes such as Hml or Pto (see , e . g. , Johal et al., supra; Martin et al. , supra) , and thus represents a new class of genes having disease resistance capabilities. Isolation of Other Members of the RPS Disease-Resistance Gene Family Using Conserved Motif Probes and Primers We have discovered that the RPS2 motifs described above are conserved in other disease-resistance genes, including, without limitation, the N protein, the L6 protein, and the Prf protein. As shown in Fig. 5(A and B) , we have determined that the L6 polypeptide of flax, the N polypepti.de of tobacco, and the Prf polypeptide of tomato each share unique regions of similarity (including, but not limited to, the leucine- rich repeats, the membrane-spanning domain, the leucine zipper, and the P-loop and other NBS domains) . On the basis of this discovery, the isolation of virtually any member of the RPS gene family is made possible using standard techniques. In particular, using all or a portion of the amino acid sequence of a conserved RPS motif (for example, the amino acid sequences defining any RPS P-loop, NBS, leucine-rich repeat, leucine zipper, or membrane-spanning region) , one may readily design RPS oligonucleotide probes, including RPS degenerate oligonucleotide probes (i.e., a mixture of all possible coding sequences for a given amino acid sequence) . These oligonucleotides may be based upon the sequence of either strand of the DNA comprising the motif. General methods for designing and preparing such probes are provided, for example, in Ausubel et al l , supra and Guide to Molecular Cloning Techniques , 1987, S. L. Berger and A. R. Kimmel, eds., Academic Press, New York. These oligonucleotides are useful for RPS gene isolation, either through their use as probes capable of hybridizing to RPS complementary sequences or as primers for various polymerase chain reaction (PCR) cloning strategies. Hybridization techniques and procedures are well known to those skilled in the art and are described, for example, in Ausubel et al., supra and Guide to Molecular Cloning Techniques , 1987, S. L. Berger and A. R. Kimmel, eds., Academic Press, New York. If desired, a combination of different oligonucleotide probes may be used for the screening of the recombinant DNA library. The oligonucleotides are labelled with 32 P using methods known in the art, and the detectably-labelled oligonucleotides are used to probe filter replicas from a recombinant plant DNA library. Recombinant DNA libraries may be prepared according to methods well known in the art, for example, as described in Ausubel et al., supra. Positive clones may, if desired, be rescreened with additional oligonucleotide probes based upon other RPS conserved regions. For example, an RPS clone identified based on hybridization with a P-loop-derived probe may be confirmed by re-screening with a leucine-rich repeat- derived oligonucleotide. As discussed above, RPS oligonucleotides may also be used as primers in PCR cloning strategies. Such PCR methods are well known in the art and described, for example, in PCR Technology, H.A. Erlich, ed. , Stockton Press, London, 1989; PCR Protocols: A Guide to Methods and Applications, M.A. Innis, D.H. Gelfand, J.J. Sninsky, and T.J. White, eds., Academic Press, Inc., New York, 1990; and Ausubel et al., supra. If desired, members of the RPS disease-resistance gene family may be isolated using the PCR "RACE" technique, or Rapid Amplification of cDNA Ends (see, e.g., Innis et al., supra) . By this method, oligonucleotide primers based on an RPS conserved domain are oriented in the 3' and 5' directions and are used to generate overlapping PCR fragments. These overlapping 3'- and 5'-end RACE products are combined to produce an intact full-length cDNA. This method is described in Innis et al., supra: and Frohman et al., Proc. Natl. Acad. Sci. 85:8998, 1988. Any number of probes and primers according to the invention may be designed based on the conserved RPS motifs described herein. Preferred motifs are boxed in the sequences shown in Fig. 5(A or B) . In particular, oligonucleotides according to the invention may be based on the conserved P-loop domain, the amino acids of which are shown below: MOTIF 1 L6 G MGGIGKTTTA [SEQ ID NO: 110] N G MGGVGKTTIA [SEQ ID NO: 111] PrfP G MPGLGKTTLA [SEQ ID NO: 112] RPS2 G PGGVGKTTLM [SEQ ID NO: 113] From these sequences, appropriate oligonucleotides are designed and prepared using standard methods. Particular examples of RPS oligonucleotides based on the P-loop domain are as follows (N is A, C, T, or G) . Based on MOTIF 1: 5' GGNATGGGNGGNNTNGGNAA(A or G)ACNAC 3' [SEQ ID NO: 158] 5' NCGNG(A/T)NGTNA(T/G) (G/A/T)A(T/A)NCGNA 3' [SEQ ID NO: 159] GG(T or A)NT(T or G or C)GG(T or A)AA(G or A)AC(T or C or A)AC 3' [SEQ ID NO: 160] 5' GGNATGGGNGGNNTNGGNAA(A or G)ACNAC 3 ' [SEQ ID NO: 158] 5' N(G or A) (C or T)N(A or G) (A or G or T)NGTNGT(C or T)TTNCCNANNCCN(G or L) (G or C)N(G or * A) (T or G)NCC 3 ' [SEQ ID NO: 161] 5' GGN(C or A) (T or C)N(G or C) (G or CJNGGNNTNGGNAA (A or G)ACNAC 3' [SEQ ID NO: 162] Other conserved RPS motifs useful for oligonucleotide design are shown below. These motifs are also depicted in the sequence of Fig. 5(A or B) . MOTIF 2 L6 FKILW LDDVD [SEQ ID NO: 114] N KKVLIV LDDID [SEQ ID NO: 115] PrfP KRFLIL IDDVW [SEQ ID NO: 116] RPS2 KRFLLL LDDVW [SEQ ID NO: 117] MOTIF 3 L6 SRFIIT SR [SEQ ID NO: 118] N SRIIIT TR [SEQ ID NO: 119] PrfP SRIILT TR [SEQ ID NO: 120] RPS2 CKVMFT TR [SEQ ID NO: 121] MOTIF 4 L6 GLPLTLK V [SEQ ID NO: 122] N GLPLALK V [SEQ ID NO: 123] PrfP GLPLSW L [SEQ ID NO: 124] RPS2 GLPLALI T [SEQ ID NO: 125] MOTIF 5 L6 KISYDAL [SEQ ID NO: 126] N KISYDGL [SEQ ID NO: 127] PrfP GFSYKNL [SEQ ID NO: 128] RPS2 KFSYDNL [SEQ ID NO: 129] From the above motifs and the sequence motifs designated in Figure 5A and B, appropriate oligonucleotides are designed and prepared. Particular examples of such RPS oligonucleotides are as follows (N is A, T, C, or G) . Based on MOTIF 2: 5' T(T or C)GA(T or C)GA(T or C) (A or G)T(T or G or C) (T or G) (A or G) (T or G or C) (G or A)A 3' [SEQ ID NO: 163] 5' T(T or C)CCA(G or C or A)A(T or C) (G or A)TC(A or G)TCNA 3 ' [SEQ ID NO: 164] 5' (C or G or A) (T or C) (C or A)NA(T or C) (G or A)TC(G or A)TCNA(G or A or T)NA(G or A or C)NANNA(G or A)NA 3' [SEQ ID NO: 165] 5' (T or A) (T or A)N(A or C) (A or G) (A or G) (T or G or A)TN(T or C)TNNTN(G or T or C)TN(A or T or C)TNGA(T or C)GA 3 , [SEQ ID NO: 166] Based on MOTIF 3: 5' NCGNG(A or T)NGTNA(T or G) (G or A or T)A(T or A)NCGNGA 3' [SEQ ID NO: 167] 5' NCGNG(A or T)NGTNA(T or G) (G or A or T)A(T or A)NCGNGA 3' [SEQ ID NO: 167] 5' NC(G or T)N(G or C) (A or T)NGTNA(A or G or T) (A or G or T)AT(A or G or T)AATNG 3 ' [SEQ ID NO: 168]. Based on MOTIF 4: 5' NA(G or A)NGGNA(G or A)NCC 3' [SEQ ID NO: 169] 5' GG(T or A) (T or C)T(T or G or C)CC(T or A) (T or C)T(T or G or C)GC(T or C or A) (T or C)T 3 ' [SEQ ID NO: 170] 5' A(A or G) (T or G or A)GC(G or C or A)A(G or A) (T or A)GG(G or C or A)A(G or A) (A or G or T or C)C C 3 ' [SEQ ID NO: 171] 5' NA(G or A)NGGNA(G or A)NCC 3' [SEQ ID NO: 169] 5' N(A or G)NN(T or A) (T or C)NA(G or C or A)N(C or G) (A or T or C)NA(G or A)NGGNA(G or A)NCC 3 ' [SEQ ID NO: 172] 5' GGN(T or C)TNCCN(T or C)TN(G or A or T) (C or G)N(T or G or C)T 3' [SEQ ID NO: 173] • Based on MOTIF 5: 5' A(A or G) (A or G)TT(A or G)TC(A or G)TA(G or A or T) (G or C) (T or A) (G or A)A(T or A) (C or T)TT 3' [SEQ ID NO: 174] 5' A(G or A)N(T or C) (T or C)NT(C or T) (A or G)TAN(G or C) (A or G)NANN(C or T) (C or T) 3' [SEQ ID NO: 175] 5' (G or A) (G or A)N(A or T)T(A or C or T) (T or A) (G or C)NTA(T or C) (G or A)AN(A or G) (A or C or G)N(T or C)T 3' [SEQ ID NO: 176] Based on MOTIF 6: 5' GTNTT(T or C) (T or C)TN(T or A) (G or C)NTT(T or C) (A or C)G(A or G)GG 3' [SEQ ID NO: 177] Based on MOTIF 7: 5' CCNAT(A or C or T)TT(T or C)TA(T or C) (G or A) (T or A) (G or T or C)GTNGA(T or C)CC 3 ' [SEQ ID NO: 178] Based on MOTIF 8: 5' GTNGGNAT(A or C or T)GA(T or C) (G or A) (A or C)NCA 3 ' [SEQ ID NO: 179] Based on MOTIF 9: 5' (G or A)AA(G or A)CANGC(A or G or T)AT(G or A)TCNA(G or A) (G or A)AA 3' [SEQ ID NO: 180] 5' TT(T or C) (T or C)TNGA(T or C)AT(A or C or T)GCNTG(T or C)TT 3' [SEQ ID NO: 181] Based on MOTIF 10: 5' CCCAT(G or A)TC(T or C) (T or C) (T or G)NA(T or G or A)N(T or A) (G or A) (G or A)TC(A or G)TGCAT 3' [SEQ ID NO: 182] 5' ATGCA(T or C)GA(T or C) (T or C) (T or A)N(A or C or T)TN(A or C) (A or G) (A or G)GA(T or C)ATGGG 3' [SEQ ID NO: 183] Based on MOTIF 11: 5 ' NA (G or A) N (G or C) (A or T) (T or C) T (T or C) NA (A or G) (C or T) TT 3 ' [ SEQ ID NO : -184 ] 5' (A or T) (G or C)NAA(A or G) (T or C)TN(A or G)A(A or 1 G) (A or T) (G or C)N(T or C)T 3' [SEQ ID NO: 185] Based on MOTIF 12: 5' (A or G or T) (A or T) (A or T) (C or T)TCNA(G or A)N(G or C) (A or T)N(T or C) (G or T)NA(G or A) NCC 3' [SEQ ID NO: 186] 5' GGN(T or C)TN(A or C) (G or A)N(A or T) (G or L)N(T or C)TNGA 3' [SEQ ID NO: 187] Once a clone encoding a candidate RPS family gene is identified, it is then determined whether such gene is capable of conferring disease-resistance to a plant host using the methods described herein or other methods well known in the art of molecular plant pathology. A Biolistic Transient Expression Assay For Identification of Plant Resistance Genes We have developed a functional transient expression system capable of providing a rapid and broadly applicable method for identifying and characterizing virtually any gene for its ability to confer disease-resistance to a plant cell. In brief, the assay system involves delivering by biolistic transformation a candidate plant disease-resistance gene to a plant tissue sample (e.g., a piece of tissue from a leaf) and then evaluating the expression of the gene within the tissue by appraising the presence or absence of a disease-resistance response (e.g., the hypersensitive response) . This assay provides a method for identifying disease-resistance genes from a wide variety of plant speqies, including ones that are not amenable to genetic or transgenic studies. The principle of the assay is depicted in the top portion of Figure 9. In general, plant cells carrying a mutation in the resistance gene of interest are utilized. Prior to biolistic transformation, the plant tissue is infiltrated with a phytopathogenic bacterium carrying the corresponding avirulence gene. In addition, a gene to be assayed for its resistance gene activity is co-introduced by biolistics with a reporter gene. The expression of the cobombarded reporter gene serves as an indicator for viability of the transformed cells. Both genes are expressed under the control of a strong and constitutive promoter. If the gene to be assayed does not complement the resistance gene function, the plant cells do not undergo a hypersensitive response (HR) and, therefore, survive (Fig. 9, top panel, right) . In this case, cells accumulate a large amount of the reporter gene product. If, on the other hand, a resistance gene is introduced, the plant cells recognize the signal from the avirulence- gene-carrying bacterium and undergo the HR because the expressed resistance gene product complements the function (Fig. 9, top panel, left). In this case, the plant cells do not have enough time to accumulate a large amount of reporter gene product before their death. Given the transformation efficiency estimated by a proper control (such as the uninfected half of the leaf) , measuring the accumulation of reporter gene product can thus indicate whether the gene to be assayed complements the resistance gene function. In one working example, we now demonstrate the effectiveness of the transient expression assay, using the bacterial avirulence gene avrRpt2 and the corresponding Arabidopsis thaliana resistance gene -PS2 (Fig. 9, bottom panel) . In brief, rps2 mutant leaves, preinfected with P. syringae carrying avrRpt2, were co- bombarded with two plasmids, one of which contained the RPS2 gene and the other the Escherichia coli uidA gene encoding / 8-glucuronidase (GUS; Jefferson et al., 19"86, supra) . Both the RPS2 and uidA genes are located downstream of the strong constitutive 35S promoter from cauliflower mosaic virus (Odell et al. , infra) . If the 35S-RPS2 construct complements the rps2 mutation, the transformed cells rapidly undergo programmed cell death in response to the P . syringae carrying avrRpt2, and relatively little GUS activity accumulates. If the rps2 mutation is not complemented, cell death does not occur and high levels of GUS activity accumulate. These differences in GUS activity are detected histochemically. Because the cDNA library used to identify JRPS2 was constructed in the expression vector pKEx4tr, the 35S- RPS2 cDNA construct in pKEx4tr could be used directly in the transient assay. As shown in Fig. 11, pKEx4tr is a cDNA expression vector designed for the unidirectional insertion of cDNA inserts. Inserted cDNA is expressed under the control of the 355 cauliflower mosaic virus promoter. Our results are shown in Fig. 9, lower panel. In this experiment, we infected one side of a leaf of an rps2 mutant plant with P. syringae pv. phaseloicola 3121 carrying avrRpt2 (Psp 312 l/avrRpt2 ) . Psp 3121 is a weak pathogen of A. thaliana and Psp 3121/avrRpt2 can elicit an HR in a plant carrying the resistance gene RPS2 (e. g. , a wild type plant) . Leaves of 5-week-old Arabidopsis plants were infiltrated with an appropriate bacterial suspension at a dose of 2 x 10 8 /ml by hand infiltration as described (Dong et al., supra) . After an ' incubation period (typically 2-4 hours) , the leaves were bombarded using a Bio-Rad PDS-1000/He apparatus (1100 psi) after 2- 4 hr of infection. Gold particles were prepared according to the instructions of the manufacturer. For each bombardment, 1.4 μg of pKEx4tr-G, 0.1 μg of a plasmid to be tested, and 0.5 mg of 1 μm gold particles were used. After the bombardment, the leaves were " incubated in a humidity chamber at 22°C for 1 day and then subjected to a histochemical GUS staining using 5- bromo-4-chloro-3-indiyl glucuronidase (X-Gluc) at 37°C for 12 hr (Jefferson, 1987, supra) . This staining method with X-gluc stains cells expressing GUS enzyme with a blue color. The uninfected side of the leaf serves as a control for transformation efficiency of the leaf because in a single leaf, transformation efficiency (i.e., density of transformed cells) is similar on both sides of the leaf. If transformed cells on the infected side are rapidly killed, staining of the cells on the infected side is weaker than staining on the uninfected side. When the resistance gene RPS2 was co-introduced, the transformed cells on the infected side of the leaf showed much weaker staining than ones on the uninfected side (Fig. 10) . In contrast, when an unrelated gene was co- introduced, the transformed cells on the infected side showed similar staining intensity to ones on the uninfected side (Fig. 10) . Thus, as summarized in the Table 2, 35S-RPS4 (cDNA 4) , but not cDNA-5 oif- cDNA-6, complemented the HR phenotype of rps2-101C. (See Figure 1) Table 2 Response Gene Tested (Decreased GUSActivitv) a ΔGUS (35S-uidA containing - internal uidA deletion) cDNA-5 (35S-AB11 ) CDNA-4 (35S-RPS2 ) + cDNA-6 (35S-CK1 ) a When decreased GUS activity was observed on the infiltrated side of the leaf, the response was scored as plus (Fig. 10) . Both RPS2 cDNA-4 clones 4 and 11, corresponding to the two RPS2 different transcript sizes, complemented the rps2 mutant phenotype, indicating that both transcripts encode a functional product. Moreover, 35S-RPS2 also complemented mutants rps2-102C, rps2-101N, and rps2-201C, further confirming that the rps2-101C, rps2-102C, rps2- 201C and rps2-101N mutations are all allelic. In short, the cloned RPS2 gene complemented the rps2 mutation in this transient expression assay, and complementation by RPS2 was observed in all four available rps2 mutant stains. Next we used the transient assay system to test the specificity of the cloned RPS2 gene for an avrRpt2- generated signal (i.e., the "gene-for-gene" specificity of a P. syringae avirulence gene and a corresponding A. thaliana resistance gene (avrRpml and RPM 1, respectively) ) . This experiment involved the use of an rps2-101 rpml double mutant that cannot mount an HR when challenged with P. syringae carrying avrRpt2 or the unrelated avirulence gene avr-pjι.2 (Debener et al., Plant Journal 1:289-302, 1991). As summarized in Table 3, complementation of the rps2 mutant phenotype by 35S-RPS2 was only observed in the presence of a signal generated by avrRpt2 , indicating that RPS2 does not simply sensitize the plant resistance response in a nonspecific manner. Table 3 Construct Cobombarded avr Gene with 35S-uidA Response None (vector only) ΔGUS b avrRPt2 ΔGUS avrRpml ΔGUS None (vector only) 35S-RPS2 avrRptΣ .35S-RPS2 avrRpml 35S-RPS2 a When decreased GUS activity was observed on the infiltrated side of the leaf, the response was scored as plus. (Figure 10, panel B) b ΔGUS is 35S-uidA containing an internal deletion in the uidA gene. Also as shown in Table 3, the RPS2 gene complemented the mutant phenotype when leaves were infected with Psp 312 l/avrRpt2 but not with Psp 3121 /avrRpml . Therefore, the RPS2 gene complemented only the rps2 mutation; it did not the rpml mutation. We have also discovered that overexpression of an rps gene family member, e.g. , rps2 but not other genes, in the transient assay leads to apparent cell death, obviating the need to .know the corresponding avirulence gene for a putative resistance gene that has been cloned. Using this assay, any plant disease-resistance gene may be identified from a cDNA expression library. In one particular example, a cDNA library is constructed in an expression vector and then introduced as described herein into a plant cultivar or its corresponding mutant plant lacking the resistance gene of interest. Preferably, the cDNA library is divided into small pools, and each pool co-introduced with a reporter gene. If a pool contains a resistance gene clone (i.e., the pool "complements" the resistance gene function) , the positive pool is divided into smaller pools and the same procedure is repeated until identification of a single positive clone is ultimately achieved. This approach facilitates the cloning of any resistance gene of interest without genetic crosses or the creation of transgenics. We now describe the cloning of another member of the RPS gene family, the Prf gene of tomato. The initial step for the cloning of the Prf gene came from classical genetic analysis which showed that Prf was tightly linked to the tomato Pto gene (Salmeron et al., The Plant Cell 6:511-520, 1994). This prompted construction of a cosmid contig of 200 kb in length which encompassed the Pto locus. DNA probes from this contig were used to screen a tomato cDNA library constructed using tomato leaf tissue that had been infected with Pst expressing the avrPto avirulence gene as source material. Two classes of cDNAs were identified based on cross- hybridization of clones to each other. While one class corresponded to members of the Pto gene family, the other class displayed no hybridization to Pto family members. Taking the assumption (based on the aforementioned genetic analysis) that Prf might reside extremely close to the Pto gene, cDNAs from the second class were analyzed further as candidate Prf clones. These clones were hybridized to filters containing DNAs from six independent prf mutant lines that had been isolated by diepoxybutane or fast neutron treatment. In one of the fast neutron mutants, the cDNA probe revealed a 1.1 kb deletion in the genomic DNA, suggesting that the cDNA clone might in fact represent Prf. Wild-type DNA corresponding to the deletion was cloned from Prf/Prf tomato. A 5 kb region was sequenced and found to potentially encode a protein containing P-loop and leucine-rich repeat motifs, supporting the hypothesis that this DNA encoded Prf. The corresponding DNA was cloned and sequenced from the fast neutron mutant plant. Sequencing this DNA confirmed the mutation to be a simple 1.1 kb deletion excising DNA between the potential P-loop and leucine-rich repeat coding regions. The gene is expressed based on RT-PCR analysis which has shown that an mRNA is transcribed from this region. The identity of the cloned DNA as the Prf gene is based on both the existence of the deletion mutation and the predicted protein sequence, which reveals patches of strong similarity to other cloned disease resistance gene products throughout the amino-terminal half (as described herein) . A partial sequence of the Prf gene is shown in Figure 12. RPS Expression in Transgenic Plant Cells and Plants The expression of the RPS2 genes in plants susceptible to pathogens carrying avrRpt2 is achieved by introducing into a plant a DNA sequence containing the RPS2 gene for expression of the Rps2 polypeptide. A number of vectors suitable for stable transfection of plant cells or for the establishment of transgenic plants are available to the public; such vectors are described in, e.g., Pouwels et al.. Cloning Vectors: A Laboratory Manual , 1985, Supp. 1987); Weissbach and Weissbach, Methods for Plant Molecular Biology, Academic Press, 1989; and Gelvin et al.. Plant Molecular Biology Manual , Kluwer Academic Publishers, 1990. Typically, plant expression vectors include (1) one or more cloned plant genes under the transcriptional control of 5' and 3' regulatory sequences and (2) a dominant selectable marker. Such plant expression vectors may also contain, if desired, a promoter regulatory region (e.g., a regulatory region controlling inducible or constitutive, environmentally- or developmentally-regulated, or cell- or tissue-specific expression) , a transcription initiation start site., a ribosome binding site, an ' RNA processing signal, a transcription termination site, and/or a polyadenylation signal. An example of a useful plant promoter which could be used to express a plant resistance gene according to the invention is a caulimovirus promoter, e.g., the cauliflower mosaic virus (CaMV) 35S promoter. These promoters confer high levels of expression in most plant tissues, and the activity of these promoters is not dependent on virtually encoded proteins. CaMV is a source for both the 35S and 19S promoters. In most tissues of transgenic plants, the CaMV 35S promoter is a strong promoter (see, e.g., Odel et al., Nature 313:810, (1985)). The CaMV promoter is also highly active in monocots (see, e.g., Dekeyser et al., Plant Cell 2:591, (1990); Terada and Shimamoto, Mol. Gen. Genet. 220:389, (1990)) . Other useful plant promoters include, without limitation, the nonpaline synthase promoter (An et al., Plant Physiol. 88:547, (1988)) and the octopine synthase promoter (Fromm et al., Plant Cell 1:977, (1989)). For certain applications, it may be desirable to produce the RPS2 gene product or the avrRpt2 gene product in an appropriate tissue, at an appropriate level, or at an appropriate developmental time. Thus, there are a variety of gene promoters, each with its own distinct characteristics embodied in its regulatory sequences, shown to be regulated in response to the environment, hormones, and/or developmental cues. These include gene promoters that are responsible for (1) heat-regulated gene expression (see,- e.g., Callis et al., Plant Physiol. 88: 965, (1988)), (2) light-regulated gene expression (e.g., the pea rbcS-3A described by Kuhlemeier et al. , Plant Cell 1: 471, (1989) ; the maize rbcS promoter described by Schaffner and Sheen, Plant Cell 3: 997, (1991) ; or the chlorophyll a/b-binding protein gene found in pea described by Simpson et al., EMBO J. 4: 2723, (1985)), (3) hormone-regulated gene expression (e.g., the abscisic acid responsive sequences from the Em gene of wheat described Marcotte et al., Plant Cell 1:969, (1989)), (4) wound-induced gene expression (e.g., of wunl described by Siebertz et al., Plant Cell 1: 961, (1989)), or (5) organ-specific gene expression (e.g., of the tuber-specific storage protein gene described by Roshal et al., EMBO J. 6:1155, (1987); the 23-kDa zein gene from maize described by Schernthaner et al., EMBO J. 7: 1249, (1988) ; or the French bean β-phaseolin gene described by Bustos et al., Plant Cell 1:839, (1989)). Plant expression vectors may also optionally include RNA processing signals, e.g, introns, which have been shown to be important for efficient RNA synthesis and accumulation (Callis et al., Genes and Dev. 1: 1183, (1987) ) . The location of the RNA splice sequences can influence the level of transgene expression in plants. In view of this fact, an intron may be positioned upstream or downstream of an Rps2 polypeptide-encoding sequence in the transgene to modulate levels of gene expression. In addition to the aforementioned 5' regulatory control sequences, the expression vectors may also include regulatory control regions which are generally present in the 3' regions of plant genes (Thornburg et al., Proc. Natl Acad. Sci USA 84: 744, (1987); An et al., Plant Cell 1: 115, (1989)). For example, the 3' terminator region may be included in the expression vector to increase stability of the mRNA. One such terminator region may be derived from the PI-II terminator region of potato. In addition, other commonly used terminators are derived from the octopine or nopaline synthase signals. The plant expression vector also typically contains a dominant selectable marker gene used to identify the cells that have become transformed. Useful selectable marker genes for plant systems include genes encoding antibiotic resistance genes, for example, those encoding resistance to hygromycin, kanamycin, bleomycin, G418, streptomycin or spectinomycin. Genes required for photosynthesis may also be used as selectable markers in photosynthetic-deficient strains. Finally, genes encoding herbicide resistance may be used as selectable markers; useful herbicide resistance genes include the Jbar gene encoding the enzyme phosphinothricin acetyltransferase, which confers resistance to the broad spectrum herbicide Basta® (Hoechst AG, Frankfurt, Germany) . Efficient use of selectable markers is facilitated by a determination of the susceptibility of a plant cell to a particular selectable agent and a determination of the concentration of this agent which effectively kills most, if not all, of the transformed cells. Some useful concentrations of antibiotics for tobacco transformation include, e.g., 75-100 /xg/ml (kanamycin), 20-50 μg/ml (hygromycin) , or 5-10 μg/ml (bleomycin) . A useful strategy for selection of transformants for herbicide resistance is described, e.g., in Vasil I.K., Cell Culture and Somatic Cell Genetics of Plants , Vol I, II, III Laboratory Procedures and Their Applications Academic Press, New York, 1984. It should be readily apparent to one skilled in the field of plant molecular biology that the level of gene expression is dependent not only on the combination of promoters, RNA processing signals and terminator elements, but also on how these elements are used to increase the levels of gene expression. The above exemplary techniques may be used for the expression of any gene in the RPS family. Plant Transformation Upon construction of the plant expression vector, several standard methods are known for introduction of the recombinant genetic material into the host plant for the generation of a transgenic plant. These methods include (1) Agrobacterium-mediated transformation (A. tumefaciens or A. rhizogenes) (see, e.g., Lichtenstein and Fuller In: Genetic Engineering, vol 6, PWJ Rigby, ed, London, Academic Press, 1987; and Lichtenstein, C.P., and Draper, J, . In: DNA Cloning, Vol II, D.M. Glover, ed, Oxford, IRI Press, 1985) , (2) the particle delivery system (see, e.g., Gordon-Kamm et al.. Plant Cell 2:603, (1990); or BioRad Technical Bulletin 1687, supra) , (3) microinjection protocols (see, e.g., Green et al., Plant Tissue and Cell Culture, Academic Press, New York, 1987) , (4) polyethylene glycol (PEG) procedures (see, e.g., Draper et al., Plant Cell Physiol 23:451, (1982); or e.g., Zhang and Wu, Theor. Appl. Genet. 76:835, (1988)), (5) liposome-mediated DNA uptake (see, e.g., Freeman et al., Plant Cell Physiol 25: 1353, (1984)), (6) electroporation protocols (see, e.g., Gelvin et al supra; Dekeyser et al. supra; or Fromm et al Nature 319: 791, (1986)), and (7) the vortexing method (see, e.g., Kindle, K., Proc. Natl. Acad. Sci., USA 87:1228, (1990)). The following is an example outlining an Agrrobacterium-mediated plant transformation. The general process for manipulating genes to be transferred into the genome of plant cells is carried out in two phases. First, all the cloning and DNA modification steps are done in E . coli , and the plasmid containing the gene construct of interest is transferred by conjugation into AσroJbaσteriujn. Second, the resulting Agrobacterium strain is used to transform plant cells. Thus, for the generalized plant expression vector, the plasmid contains an origin of replication that allows it to replicate in AgrroJacteriu-n and a high copy number origin of replication functional in E. coli . This permits facile production and testing of transgenes in E. coli prior to transfer to Agrobacterium for subsequent introduction into plants. Resistance genes can be carried on the vector, one for selection in bacteria, e.g., streptomycin, and the other that will express in plants, e.g., a gene encoding for kanamycin resistance or an herbicide resistance gene. Also present are restriction endonuclease sites for the addition of one or more transgenes operably linked to appropriate regulatory sequences and directional T-DNA border sequences which, when recognized by the transfer functions of Agrobacterium, delimit the region that will be transferred to the plant. In another example, plant cells may be transformed by shooting into the cell tungsten microprojectiles on which cloned DNA is precipitated. In the Biolistic Apparatus (Bio-Rad, Hercules, CA) used for the shooting, a gunpowder charge (22 caliber Power Piston Tool Charge) or an air-driven blast drives a plastic macroprojectile through a gun barrel. An aliquot of a suspension of tungsten particles on which DNA has been precipitated is placed on the front of the plastic macroprojectile. The latter is fired at an acrylic stopping plate that has a hole through it that is too small for the macroprojectile to go through. As a result, the plastic macroprojectile smashes against the stopping plate and the tungsten microprojectiles continue toward their target through the hole in the plate. For the instant invention the target can be any plant cell, tissue, seed, or embryo. The DNA introduced into the cell on the microprojectiles becomes integrated into either the nucleus or the chloroplast. Transfer and expression of transgenes in plant cells is now routine practice to those skilled in the art. It has become a major tool to carry out gene expression studies and to attempt to obtain improved plant varieties of agricultural or commercial interest. Transgenic Plant Regeneration Plant cells transformed with a plant expression vector can be regenerated, e.g., from single cells, callus tissue or leaf discs according to standard plant tissue culture techniques. It is well known in the art that various cells, tissues and organs from almost any plant can be successfully cultured to regenerate an entire plant; such technigues are described, e.g., in Vasil supra; Green et.al., supra: Weissbach and Weissbach, supra: and Gelvin et al., supra. In one possible example, a vector carrying a selectable marker gene (e.g., kanamycin resistance), a cloned RPS2 gene under the control of its own promoter and terminator or, if desired, under the control of exogenous regulatory sequences such as the 35S CaMV promoter and the nopaline synthase terminator is transformed into Agrobacterium . Transformation of leaf tissue with vector-containing Agrobacterium is carried out as described by Horsch et al. (Science 227: 1229, (1985)). Putative transformants are selected after a few weeks (e.g., 3 to 5 weeks) on plant tissue culture media containing kanamycin (e.g. 100 μg/ml) . Kanamycin- resistant shoots are then placed on plant tissue culture media without hormones for root initiation. Kanamycin- resistant plants are then selected for greenhouse growth. If desired, seeds from self-fertilized transgenic plants can then be sowed in a soil-less media and grown in a greenhouse. Kanamycin-resistant progeny are selected by sowing surfaced sterilized seeds on hormone-free kanamycin-containing media. Analysis for the integration of the transgene is accomplished by standard techniques (see, e.g., Ausubel et al. supra: Gelvin et al. supra) . Transgenic plants expressing the selectable marker are then screened for .transmission of the transgene DNA by standard immunoblot and DNA and RNA detection techniques. Each positive transgenic plant and its transgenic progeny are unique in comparison to other transgenic plants established with the same transgene. Integration of the transgene DNA into the plant genomic DNA is in most cases random and the site of integration can profoundly effect the levels, and the tissue and developmental patterns of transgene expression. Consequently, a number of transgenic lines are usually screened for each transgene to identify and select plants with the most appropriate expression profiles. Transgenic lines are evaluated for levels of transgene expression. Expression at the RNA level is determined initially to identify and quantitate expression-positive plants. Standard techniques for RNA analysis are employed and include PCR amplification assays using oligonucleotide primers designed to amplify only transgene RNA templates and solution hybridization assays using transgene-specific probes (see, e.g., Ausubel et al., supra) . The RNA-positive plants are then analyzed for protein expression by Western immunoblot analysis using Rps2 polypeptide-specific antibodies (see, e.g., Ausubel et al., supra) . In addition, in situ hybridization and immunocytochemistry according to standard protocols can be done using transgene-specific nucleotide probes and antibodies, respectively, to localize sites of expression within transgenic tissue. Once the Rps2 polypeptide has been expressed in any cell or in a transgenic plant (e.g., as described above) , it can be isolated using any standard technique, e.g., affinity chromatography. In one example, an anti- Rps2 antibody (e.g., produced as described in Ausubel et al., supra. or by any standard technique) may be attached to a column and used to isolate the polypeptide. Lysis and fractionation of Rps2-producing cells prior to affinity chromatography may be performed by standard methods (see, e.g., Ausubel et al., supra) . Once isolated, the recombinant polypeptide can, if desired, be further purified, e.g.-, by high performance liquid chromatography (see, e.g.. Fisher, Laboratory Techniques In Biochemistry And Molecular Biology, Work and Burdon, eds., Elsevier, 1980). These general techniques of polypeptide expression and purification can also be used to produce and isolate useful Rps2 fragments or analogs. Antibody Production Using a polypeptide described above (e.g., the recombinant protein or a chemically synthesized RPS peptide based on its deduced amino acid sequence) , polyclonal antibodies which bind specifically to an RPS polypeptide may be produced by standard techniques (see, e.g., Ausubel et al., supra) and isolated, e.g., following peptide antigen affinity chromatography. Monoclonal antibodies can also be prepared using standard hybridoma technology (see, e.g., Kohler et al., Nature 256: 495, 1975; Kohler et al., Eur. J. Immunol . 6: 292, 1976; Hammerling et al., in Monoclonal Antibodies and T Cell Hybridomas , Elsevier, N.Y., 1981; and Ausubel et al. , supra) . Once produced, polyclonal or monoclonal antibodies are tested for specific RSP polypeptide recognition by Western blot or immunoprecipitation analysis (by methods described in Ausubel et al., supra) . Antibodies which specifically recognize a RPS polypeptide are considered to be useful in the invention; such antibodies may be used, e.g., for screening recombinant expression libraries as described in Ausubel et al., supra. Exemplary peptides (derived from Rps2) for antibody production include: LKFSYDNLESDLL- [SEQ ID NO: 188] GVYGPGGVGKTTLMQS [SEQ ID NO: 189] GGLPLALITLGGAM [SEQ ID NO: 190] Use Introduction of RPS2 into a transformed plant cell provides for resistance to bacterial pathogens carrying the avrRpt2 avirulence gene. For example, transgenic plants of the instant invention expressing RPS2 might be used to alter, simply and inexpensively, the disease resistance of plants normally susceptible to plant pathogens carrying the avirulence gene, avrRpt2. The invention also provides for broad-spectrum pathogen resistance by mimicking the natural mechanism of host resistance. First, the RPS2 transgene is expressed in plant cells at a sufficiently high level to initiate the plant defense response constitutively in the absence of signals from the pathogen. The level of expression associated with plant defense response initiation is determined by measuring the levels of defense response gene expression as described in Dong et al., supra. Second, the RPS2 transgene is expressed by a controllable promoter such as a tissue-specific promoter, cell-type specific promoter or by a promoter that is induced by an external signal or agent thus limiting the temporal and tissue expression of 'a defense response. Finally, the RPS2 gene product is co-expressed with the avrRpt2 gene product. The RPS2 gene is expressed by its natural promoter, by a constitutively expressed promoter such as the CaMV 35S promoter, by a tissue-specific or cell-type specific promoter, or by a promoter that is activated by an external signal or agent. Co-expression of RPS2 and avrRpt2 will mimic the production of gene products associated with the initiation of the plant defense response and provide resistance to pathogens in the absence of specific resistance gene-avirulence gene corresponding pairs in the host plant and pathogen. The invention also provides for expression in plant cells of a nucleic acid having the sequence of Fig. 2 or the expression of a degenerate variant thereof encoding the amino acid sequence of open reading frame "a" of Fig. 2. The invention further provides for the isolation of nucleic acid sequences having about 50% or greater sequence identity to RPS2 by using the RPS2 sequence of Fig. 2 or a portion thereof greater than 9 nucleic acids in length, and preferably greater than about 18 nucleic acids in length as a probe. Appropriate reduced hybridization stringency conditions are utilized to isolate DNA sequences having about 50% or greater sequence identity to the RPS2 sequence of Fig. 2. Also provided by the invention are short conserved regions characteristic of RPS disease resistance genes. These conserved regions provide oligonucleotide sequences useful for the production of hybridization probes and PCR primers for the isolation of other plant disease- resistance genes. Both the RPS2 gene and related RPS family genes provide disease resistance to plants, especially crop plants, most especially important crop plants such as tomato, pepper, maize, wheat, rice and legumes such as soybean and bean, or any plant which is susceptible to pathogens carrying an avirulence gene, e.g., the avrRpt2 avirulence gene. Such pathogens include, but are not limited to, Pseudomonas syringae strains. The invention also includes any biologically active fragment or analog of an Rps2 polypeptide. By "biologically active" is meant possessing any in vivo activity which is characteristic of the Rps2 polypeptide shown in Fig. 2. A useful Rps2 fragment or Rps2 analog is one which exhibits a biological activity in any biological assay for disease resistance gene product activity, for example, those assays described by Dong et al. (1991), supra; Yu et al. (1993) supra; Kunkel et al. (1993) supra; and Whalen et al. (1991) . In particular, a biologically active Rps2 polypeptide fragment or analog is capable of providing substantial resistance to plant pathogens carrying the avrRpt2 avirulence gene. By substantial resistance is meant at least partial reduction in susceptibility to plant pathogens carrying the avrRpt2 gene. Preferred analogs include Rps2 polypeptides (or biologically active fragments thereof) whose sequences differ from the wild-type sequence only by conservative amino acid substitutions, for example, substitution of one amino acid for another with similar characteristics (e.g., valine for glycine, arginine for lysine, etc.) or by one or more non-conservative amino acid substitutions, deletions, or insertions which do not abolish the polypeptide's biological activity. Analogs can differ from naturally occurring Rps2 polypeptide in amino acid sequence or can be modified in ways that do not involve sequence, or both. Analogs of the invention will generally exhibit at least 70%, preferably 80%, more preferably 90%, and most preferably 95% or even 99%, homology with a segment of 20 amino acid residues, preferably 40 amino acid residues, or more preferably the entire sequence of a naturally occurring Rps2 polypeptide sequence. Alterations in primary sequence include genetic variants, both natural and induced. Also included are analogs that include residues other than naturally occurring L-amino acids, e.g., D-amino acids or non- naturally occurring or synthetic amino acids, e.g., β or γ amino acids. Also included in the invention are Rps2 polypeptides modified by in vivo chemical derivatization of polypeptides, including acetylation, methyla ion, phosphorylation, carboxylation, or glycosylation. In addition to substantially full-length polypeptides, the invention also includes biologically active fragments of the polypeptides. As used herein, the term "fragment", as applied to a polypeptide, will ordinarily be at least 20 residues, more typically at least 40 residues, and preferably at least 60 residues in length. Fragments of Rps2 polypeptide can be generated by methods known to those skilled in the art. The ability of a candidate fragment to exhibit a biological activity of Rps2 can be assessed by those methods described herein. Also included in the invention are Rps2 polypeptides containing residues that are not required for biological activity of the peptide, e.g., those added by alternative mRNA splicing or alternative protein processing events. Other embodiments are within the following claims. SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: Ausubel, Frederick M. Staskawicz, Brian J. Brent, Andrew F. Dahlbeck, Douglas Katagiri, Fumiaki Kunkel, Barbara N. Mindrinos, Michael N. Yu, Guo- iang (ii) TITLE OF INVENTION: RPS2 GENE AND USES THEREOF (iii) NUMBER OF SEQUENCES: 201 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Fish & Richardson (B) STREET: 225 Franklin Street Suite 3100 (C) CITY: Boston (D) STATE: MA (E) COUNTRY: USA (F) ZIP: 02110-2904 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: PatentIn Release #1.0, Version #1.30B (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: US 08/227,360 (B) FILING DATE: 13-APR-1994 (C) CLASSIFICATION: (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: Clark, Paul T. (B) REGISTRATION NUMBER: 30,162 (C) REFERENCE/DOCKET NUMBER: 00786/230001 (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: (617) 542-5070 (B) TELEFAX: (617) 542-8906 (C) TELEX: 100254 (2) INFORMATION FOR SEQ ID NO:l: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2903 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:l: AAGTAAAAGA AAGAGCGAGA AATCATCGAA ATGGATTTCA TCTCATCTCT TATCGTTGGC 60 TGTGCTCAGG TGTTGTGTGA ATCTATGAAT ATGGCGGAGA GAAGAGGACA TAAGACTGAT 120 CTTAGACAAG CCATCACTGA TCTTGAAACA GCCATCGGTG ACTTGAAGGC CATACGTGAT 180 GACCTGACTT TACGGATCCA ACAAGACGGT CTAGAGGGAC GAAGCTGCTC AAATCGTGCC' 240 AGAGAGTGGC TTAGTGCGGT GCAAGTAACG GAGACTAAAA CAGCCCTACT TTTAGTGAGG 300 TTTAGGCGTC GGGAACAGAG GACGCGAATG AGGAGGAGAT ACCTCAGTTG TTTCGGTTGT 360 GCCGACTACA AACTGTGCAA GAAGGTTTCT GCCATATTGA AGAGCATTGG TGAGCTGAGA 420 GAACGCTCTG AAGCTATCAA AACAGATGGC GGGTCAATTC AAGTAACTTG TAGAGAGATA 480 CCCATCAAGT CCGTTGTCGG AAATACCACG ATGATGGAAC AGGTTTTGGA ATTTCTCAGT 540 GAAGAAGAAG AAAGAGGAAT CATTGGTGTT TATGGACCTG GTGGGGTTGG GAAGACAACG 600 TTAATGCAGA GCATTAACAA CGAGCTGATC ACAAAAGGAC ATCAGTATGA TGTACTGATT 660 TGGGTTCAAA TGTCCAGAGA ATTCGGCGAG TGTACAATTC AGCAAGCCGT TGGAGCACGG 720 TTGGGTTTAT CTTGGGACGA GAAGGAGACC GGCGAAAACA GAGCTTTGAA GATATACAGA 780 GCTTTGAGAC AGAAACGTTT CTTGTTGTTG CTAGATGATG TCTGGGAAGA GATAGACTTG 840 GAGAAAACTG GAGTTCCTCG ACCTGACAGG GAAAACAAAT GCAAGGTGAT GTTCACGACA 900 CGGTCTATAG CATTATGCAA CAATATGGGT GCGGAATACA AGTTGAGAGT GGAGTTTCTG 960 GAGAAGAAAC ACGCGTGGGA GCTGTTCTGT AGTAAGGTAT GGAGAAAAGA TCTTTTAGAG 1020 TCATCATCAA TTCGCCGGCT CGCGGAGATT ATAGTGAGTA AATGTGGAGG ATTGCCACTA 1080 GCGTTGATCA CTTTAGGAGG AGCCATGGCT CATAGAGAGA CAGAAGAAGA GTGGATCCAT 1140 GCTAGTGAAG TTCTGACTAG ATTTCCAGCA GAGATGAAGG GTATGAACTA TGTATTTGCC 1200 CTTTTGAAAT TCAGCTACGA CAACCTCGAG AGTGATCTGC TTCGGTCTTG TTTCTTGTAC 1260 TGCGCTTTAT TCCCAGAAGA ACATTCTATA GAGATCGAGC AGCTTGTTGA GTACTGGGTC 1320 GGCGAAGGGT TTCTCACCAG CTCCCATGGC GTTAACACCA TTTACAAGGG ATATTTTCTC 1380 ATTGGGGATC TGAAAGCGGC ATGTTTGTTG GAAACCGGAG ATGAGAAAAC ACAGGTGAAG 1440 ATGCATAATG TGGTCAGAAG CTTTGCATTG TGGATGGCAT CTGAACAGGG GACTTATAAG 1500 GAGCTGATCC TAGTTGAGCC TAGCATGGGA CATACTGAAG CTCCTAAAGC AGAAAACTGG 1560 CGACAAGCGT TGGTGATCTC ATTGTTAGAT AACAGAATCC AGACCTTGCC TGAAAAACTC 1620 ATATGCCCGA AACTGACAAC ACTGATGCTC CAACAGAACA GCTCTTTGAA GAAGATTCCA 1680 ACAGGGTTTT TCATGCATAT GCCTGTTCTC AGAGTCTTGG ACTTGTCGTT CACAAGTATC 1740 ACTGAGATTC CGTTGTCTAT CAAGTATTTG GTGGAGTTGT ATCATCTGTC TATGTCAGGA 1800 ACAAAGATAA GTGTATTGCC ACAGGAGCTT GGGAATCTTA GAAAACTGAA GCATCTGGAC 1860 CTACAAAGAA CTCAGTTTCT TCAGACGATC CCACGAGATG CCATATGTTG GCTGAGCAAG 1920 CTCGAGGTTC TGAACTTGTA CTACAGTTAC GCCGGTTGGG AACTGCAGAG CTTTGGAGAA 1980 GATGAAGCAG AAGAACTCGG ATTCGCTGAC TTGGAATACT TGGAAAACCT AACCACACTC 2040 GGTATCACTG TTCTCTCATT GGAGACCCTA AAAACTCTCT TCGAGTTCGG TGCTTTGCAT 2100 AAACATATAC AGCATCTCCA CGTTGAAGAG TGCAATGAAC TCCTCTACTT CAATCTCCCA ' 2160 TCACTCACTA ACCATGGCAG GAACCTGAGA AGACTTAGCA TTAAAAGTTG CCATGACTTG 2220 GAGTACCTGG TCACACCCGC AGATTTTGAA AATGATTGGC TTCCGAGTCT AGAGGTTCTG 2280 ACGTTACACA GCCTTCACAA CTTAACCAGA GTGTGGGGAA ATTCTGTAAG CCAAGATTGT 2340 CTGCGGAATA TCCGTTGCAT AAACATTTCA CACTGCAACA AGCTGAAGAA TGTCTCATGG 2400 GTTCAGAAAC TCCCAAAGCT AGAGGTGATT GAACTGTTCG ACTGCAGAGA GATAGAGGAA 2460 TTGATAAGCG AACACGAGAG TCCATCCGTC GAAGATCCAA CATTGTTCCC AAGCCTGAAG 2520 ACCTTGAGAA CTAGGGATCT GCCAGAACTA AACAGCATCC TCCCATCTCG ATTTTCATTC 2580 CAAAAAGTTG AAACATTAGT CATCACAAAT TGCCCCAGAG TTAAGAAACT GCCGTTTCAG 2640 GAGAGGAGGA CCCAGATGAA CTTGCCAACA GTTTATTGTG AGGAGAAATG GTGGAAAGCA 2700 CTGGAAAAAG ATCAACCAAA CGAAGAGCTT TGTTATTTAC CGCGCTTTGT TCCAAATTGA 2760 TATAAGAGCT AAGAGCACTC TGTACAAATA TGTCCATTCA TAAGTAGCAG GAAGCCAGGA 2820 AGGTTGTTCC AGTGAAGTCA TCAACTTTCC ACATAGCCAC AAAACTAGAG ATTATGTAAT 2880 CATAAAAACC AAACTATCCG CGA 2903 (2) INFORMATION FOR SEQ ID NO:2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 885 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: 1inear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: Lys Lys Glu Arg Glu lie lie Glu Met Asp Phe lie Ser Ser Leu lie 1 5 10 15 Val Gly Cys Ala Gin Val Leu Cys Glu Ser Met Asn Met Ala Glu Arg 20 25 30 Arg Gly His Lys Thr Asp Leu Arg Gin Ala lie Thr Asp Leu Arg lie 35 40 45 Gin Gin Asp Gly Leu Glu Gly Arg Ser Cys Ser Asn Arg Ala Arg Glu 50 55 60 Trp Leu Ser Ala Val Gin Val Thr Glu Thr Lys Thr Ala Leu Leu Leu 65 70 75 80 Val Arg Phe Arg Arg Arg Glu Gin Arg Thr Arg Met Arg Arg Arg Tyr 85 90 95 Leu Ser Cys Phe Gly Cys Ala Asp Tyr Lys Leu Cys Lys Lys Val Ser 100 105 110 Ala lie Leu Lys Ser lie Gly Glu Leu Arg Glu Arg Ser Glu Ala lie 115 120 125 Lys Thr Asp Gly Gly Ser lie Gin Val Thr Cys Arg Glu lie Pro lie 130 135 140 Lys Ser Val Val Gly Asn Thr Thr Met Met Glu Gin Val Leu Glu Phe 145 150 155 160 Leu Ser Glu Glu Glu Glu Arg Gly lie lie Gly Val Tyr Gly Pro Gly 165 170 175 Gly Val Gly Lys Thr Thr Leu Met Gin Ser lie Asn Asn Glu Leu lie 180 185 190 Thr Lys Gly His Gin Tyr Asp Val Leu lie Trp Val Gin Met Ser Arg 195 200 205 Glu Phe Gly Glu Cys Thr lie Gin Gin Ala Val Gly Ala Arg Leu Gly 210 215 220 Leu Ser Trp Asp Glu Lys Glu Thr Gly Glu Asn Arg Ala Leu Lys lie 225 230 235 240 Tyr Arg Ala Leu Arg Gin Lys Arg Phe Leu Leu Leu Leu Asp Asp Val 245 . 250 255 Trp Glu Glu lie Asp Leu Glu Lys Thr Gly Val Pro Arg Pro Asp Arg 260 265 270 Glu Asn Lys Cys Lys Val Met Phe Thr Thr Arg Ser lie Ala Leu Cys 275 280 285 Asn Asn Met Gly Ala Glu Tyr Lys Leu Arg Val Glu Phe Leu Glu Lys 290 295 300 Lys His Ala Trp Glu Leu Phe Cys Ser Lys Val Trp Arg Lys Asp Leu 305 310 315 320 Leu Glu Ser Ser Ser lie Arg Arg Leu Ala Glu lie lie Val Ser Lys 325 330 335 Cys Gly Gly Leu Pro Leu Ala Leu lie Thr Leu Gly Gly Ala Met Ala 340 345 350 His Arg Glu Thr Glu Glu Glu Trp lie His Ala Ser Glu Val Leu Thr 355 360 365 Arg Phe Pro Ala Glu Met Lys Gly Met Asn Tyr Val Phe Ala Leu Leu 370 375 380 Lys Phe Ser Tyr Asp Asn Leu Glu Ser Asp Leu Leu Arg Ser Cys Phe 385 390 395 400 Leu Tyr Cys Ala Leu Phe Pro Glu Glu His Ser lie Glu lie Glu Gin 405 410 415 Leu Val Glu Tyr Trp Val Gly Glu Gly Phe Leu Thr Ser Ser His Gly 420 425 430 Val Asn Thr lie Tyr Lys Gly Tyr Phe Leu lie Gly Asp Leu Lys Ala 435 440 445 Ala Cys Leu Leu Glu Thr Gly Asp Glu Lys Thr Gin Val Lys Met His 450 455 460 Asn Val Val Arg Ser Phe Ala Leu Trp Met Ala Ser Glu Gin Gly Thr 465 470 475 480 Tyr Lys Glu Leu lie Leu Val Glu Pro Ser Met Gly His Thr Glu Ala 485 490 495 Pro Lys Ala Glu Asn Trp Arg Gin Ala Leu Val lie Ser Leu Leu Asp 500 505 510 Asn Arg lie Gin Thr Leu Pro Glu Lys Leu lie Cys Pro Lys Leu Thr 515 520 525 Thr Leu Met Leu Gin Gin Asn Ser Ser Leu Lys Lys lie Pro Thr Gly 530 535 540 Phe Phe Met His Met Pro Val Leu Arg Val Leu Asp Leu Ser Phe Thr 545 550 555 560 Ser lie Thr Glu lie Pro Leu Ser lie Lys Tyr Leu Val Glu Leu Tyr 565 570 575 His Leu Ser Met Ser Gly Thr Lys lie Ser Val Leu Pro Gin Glu Leu 580 585 590 Gly Asn Leu Arg Lys Leu Lys His Leu Asp Leu Gin Arg Thr Gin Phe 595 600 605 Leu Gin Thr lie Pro Arg Asp Ala lie Cys Trp Leu Ser Lys Leu Glu 610 615 620 Val Leu Asn Leu Tyr Tyr Ser Tyr Ala Gly Trp Glu Leu Gin Ser Phe 625 630 635 640 Gly Glu Asp Glu Ala Glu Glu Leu Gly Phe Ala Asp Leu Glu Tyr Leu 645 650 655 Glu Asn Leu Thr Thr Leu Gly lie Thr Val Leu Ser Leu Glu Thr Leu 660 665 670 Lys Thr Leu Phe Glu Phe Gly Ala Leu His Lys His lie Gin His Leu 675 680 685 His Val Glu Glu Cys Asn Glu Leu Leu Tyr Phe Asn Leu Pro Ser Leu 690 695 700 Thr Asn His Gly Arg Asn Leu Arg Arg Leu Ser lie Lys Ser Cys His 705 710 715 720 Asp Leu Glu Tyr Leu Val Thr Pro Ala Asp Phe Glu Asn Asp Trp Leu 725 730 735 Pro Ser Leu Glu Val Leu Thr Leu His Ser Leu His Asn Leu Arg Cys 740 745 750 lie Asn lie Ser His Cys Asn Lys Leu Lys Asn Val Ser Trp Val Gin 755 760 765 Lys Leu Pro Lys Leu Glu Val lie Glu Leu Phe Asp Cys Arg Glu lie 770 775 780 Glu Glu Leu lie Ser Glu His Glu Ser Pro Ser Val Glu Asp Pro Thr 785 790 795 800 Leu Phe Pro Ser Leu Lys Thr Leu Arg Thr Arg Asp Leu Pro Glu Leu 805 810 815 Asn Ser lie Leu Pro Ser Arg Phe Ser Phe Gin Lys Val Glu Thr Leu 820 825 830 Val lie Thr Asn Cys Pro Arg Val Lys Lys Leu Pro Phe Gin Glu Arg 835 840 845 Arg Thr Gin Met Asn Leu Pro Thr Val Tyr Cys Glu Glu Lys Trp Trp 850 855 860 Lys Ala Leu Glu Lys Asp Gin Pro Asn Glu Glu Leu Cys Tyr Leu Pro 865 870 875 880 Arg Phe Val Pro Asn 885 (2) INFORMATION FOR SEQ ID NO:3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: Glu His Ser Val Gin lie Cys Pro Phe He Ser Ser Arg Lys Pro Gly 1 5 10 15 Arg Leu Phe Gin 20 (2) INFORMATION FOR SEQ ID NO:4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 6 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4: Ser His Gin Leu Ser Thr 1 5 (2) INFORMATION FOR SEQ ID NO:5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 11 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5: Arg Leu Cys Asn His Lys Asn Gin Thr He Arg 1 5 10 (2) INFORMATION FOR SEQ ID NO:6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 28 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6: Ser Lys Arg Lys Ser Glu Lys Ser Ser Lys Trp He Ser Ser His Leu 1 5 10 15 Leu Ser Leu Ala Val Leu Arg Cys Cys Val Asn Leu 20 25 (2) INFORMATION FOR SEQ ID NO:7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 25 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: 1inear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7: He Trp Arg Arg Glu Glu Asp He Arg Leu He Leu Asp Lys Pro Ser 1 5 10 15 Leu He Leu Lys Gin Pro Ser Val Thr 20 25 (2) INFORMATION FOR SEQ ID NO:8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 6 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8: Arg Pro Tyr Val Met Thr 1 5 (2) INFORMATION FOR SEQ ID NO:9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9: Leu Tyr Gly Ser Asn Lys Thr Val 1 5 (2) INFORMATION FOR SEQ ID NO:10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 17 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10: Arg Asp Glu Ala Ala Gin He Val Pro Glu Ser Gly Leu Val Arg Cys 1 5 10 15 Lys (2) INFORMATION FOR SEQ ID NO:11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:ll: Arg Arg Leu Lys Gin Pro Tyr Phe 1 5 (2) INFORMATION FOR SEQ ID NO:12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12: Gly Leu Gly Val Gly Asn Arg Gly Arg Glu 1 5 10 (2) INFORMATION FOR SEQ ID NO:13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13: Gly Gly Asp Thr Ser Val Val Ser Val Val Pro Thr Thr Asn Cys Ala 1 5 10 15 Arg Arg Phe Leu Pro Tyr 20 (2) ■ INFORMATION FOR SEQ ID NO:14: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14: Arg Ala Leu Val Ser (2) INFORMATION FOR SEQ ID NO:15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15: Glu Asn Ala Leu Lys Leu Ser Lys Gin Met Ala Gly Gin Phe Lys 1 5 10 15 (2) INFORMATION FOR SEQ ID NO:16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: 1inear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16: Leu Val Glu Arg Tyr Pro Ser Ser Pro Leu Ser Glu He Pro Arg 1 5 10 15 (2) INFORMATION FOR SEQ ID NO:17: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 29 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17: Trp Asn Arg Phe Trp Asn Phe Ser Val Lys Lys Lys Lys Glu Glu Ser 1 5 10 15 Leu Val Phe Met Asp Leu Val Gly Leu Gly Arg Gin Arg 20 25 (2) INFORMATION FOR SEQ ID NO:18: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18: Cys Arg Ala Leu Thr Thr Ser 1 5 (2) INFORMATION FOR SEQ ID NO:19: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 9 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19: Ser Gin Lys Asp He Ser Met Met Tyr 1 5 (2) INFORMATION FOR SEQ ID NO:20: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 36 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20: Phe Gly Phe Lys Cys Pro Glu Asn Ser Ala Ser Val Gin Phe Ser Lys 1 5 10 15 Pro Leu Glu His Gly Trp Val Tyr Leu Gly Thr Arg Arg Arg Pro Ala 20 25 30 Lys Thr Glu Leu 35 (2) INFORMATION FOR SEQ ID NO:21: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21: Arg Tyr Thr Glu Leu 1 5 (2) INFORMATION FOR SEQ ID NO:22: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22; Asp Arg Asn Val Ser Cys Cys Cys 1 5 (2) INFORMATION FOR SEQ ID NO:23: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 6 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23; Met Met Ser Gly Lys Arg 1 5 (2) INFORMATION FOR SEQ ID NO:24: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 17 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: 1inear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24: Thr Trp Arg Lys Leu Glu Phe Leu Asp Leu Thr Gly Lys Thr Asn Ala 1 5 10 15 Arg (2) INFORMATION FOR SEQ ID NO:25: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 6 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25: Cys Ser Arg His Gly Leu 1 5 (2) INFORMATION FOR SEQ ID NO:26: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 11 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26: His Tyr Ala Thr He Trp Val Arg Asn Thr Ser 1 5 10 (2) INFORMATION FOR SEQ ID NO:27: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear ' (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27: Glu Trp Ser Phe Trp Arg Arg Asn Thr Arg Gly Ser Cys Ser Val Val 1 5 10 15 Arg Tyr Gly Glu Lys He Phe 20 (2) INFORMATION FOR SEQ ID NO:28: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 11 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:28: Ser His His Gin Phe Ala Gly Ser Arg Arg Leu 1 5 10 (2) INFORMATION FOR SEQ ID NO:29: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:29: Val Asn Val Glu Asp Cys His 1 5 (2) INFORMATION FOR SEQ ID NO:30: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:30: Glu Glu Pro Trp Leu He Glu Arg Gin Lys Lys Ser Gly Ser Met Leu 1 5 10 15 Val Lys Phe (2) INFORMATION FOR SEQ ID NO:31: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 6 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:31: Leu Asp Phe Gin Gin Arg 1 5 (2) INFORMATION FOR SEQ ID NO:32: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 6 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:32: Thr Met Tyr Leu Pro Phe 1 5 (2) INFORMATION FOR SEQ ID NO:33: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:33: Asn Ser Ala Thr Thr Thr Ser Arg Val He Cys Phe Gly Leu Val Ser 1 5 10 15 Cys Thr Ala Leu Tyr Ser Gin Lys Asn He Leu 20 25 (2) INFORMATION FOR SEQ ID NO:34: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 33 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:34: Arg Ser Ser Ser Leu Leu Ser Thr Gly Ser Ala Lys Gly Phe Ser Pro - 81 - 1 5 10 15 Ala Pro Met Ala Leu Thr Pro Phe Thr Arg Asp He Phe Ser Leu Gly 20 25 30 He (2) INFORMATION FOR SEQ ID NO:35: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:35: Lys Arg His Val Cys Trp Lys Pro Glu Met Arg Lys His Arg 1 5 10 (2) INFORMATION FOR SEQ ID NO:36: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:36: Arg Cys He Met Trp Ser Glu Ala Leu His Cys Gly Trp His Leu Asn 1 5 10 15 Arg Gly Leu He Arg Ser 20 (2). INFORMATION FOR SEQ ID NO:37: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:37: Leu Ser Leu Ala Trp Asp He Leu Lys Leu Leu Lys Gin Lys Thr Gly 1 5 10 15 Asp Lys Arg Trp 20 (2) INFORMATION FOR SEQ ID NO:38: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:38: He Thr Glu Ser Arg Pro Cys Leu Lys Asn Ser Tyr Ala Arg Asn 1 5 10 15 (2) INFORMATION FOR SEQ ID NO:39: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:39: Cys Ser Asn Arg Thr Ala Leu 1 5 (2) INFORMATION FOR SEQ ID NO:40: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 46 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:40: Arg Arg Phe Gin Gin Gly Phe Ser Cys He Cys Leu Phe Ser Glu Ser 1 5 10 15 Trp Thr Cys Arg Ser Gin Val Ser Leu Arg Phe Arg Cys Leu Ser Ser 20 25 30 He Trp Trp Ser Cys He He Cys Leu Cys Gin Glu Gin Arg 35 40 45 (2) INFORMATION FOR SEQ ID NO:41: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 12 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:41: Val Tyr Cys His Arg Ser Leu Gly He Leu Glu Asn 1 5 10 (2) INFORMATION FOR SEQ ID NO:42: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:42: Ser He Trp Thr Tyr Lys Glu Leu Ser Phe Phe Arg Arg Ser His Glu 1 5 10 15 Met Pro Tyr Val Gly 20 (2) INFORMATION FOR SEQ ID NO:43: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear • (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:43: Ala Ser Ser Arg Phe 1 5 (2) INFORMATION FOR SEQ ID NO:44: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 32 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:44: Thr Cys Thr Thr Val Thr Pro Val Gly Asn Cys Arg Ala Leu Glu Lys 1 5 10 15 Met Lys Gin Lys Asn Ser Asp Ser Leu Thr Trp Asn Thr Trp Lys Thr 20 25 30 (2) INFORMATION FOR SEQ ID NO:45: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 12 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:45: Pro His Ser Val Ser Leu Phe Ser His Trp Arg Pro 1 5 10 (2) INFORMATION FOR SEQ ID NO:46: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 38 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein ■ (xi) SEQUENCE DESCRIPTION: SEQ ID NO:46: Lys Leu Ser Ser Ser Ser Val Leu Cys He Asn He Tyr Ser He Ser 1 5 10 15 Thr Leu Lys Ser Ala Met Asn Ser Ser Thr Ser He Ser His His Ser 20 25 30 Leu Thr Met Ala Gly Thr 35 (2) INFORMATION FOR SEQ ID NO:47: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:47: Glu Asp Leu Ala Leu Lys Val Ala Met Thr Trp Ser Thr Trp Ser His 1 5 10 15 Pro Gin He Leu Lys Met He Gly Phe Arg Val 20 25 (2) INFORMATION FOR SEQ ID NO:48: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:48: Arg Tyr Thr Ala Phe Thr Thr 1 5 (2) INFORMATION FOR SEQ ID NO:49: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:49; Pro Glu Cys Gly Glu He Leu 1 5 (2) INFORMATION FOR SEQ ID NO:50: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:50: Ala Lys He Val Cys Gly He Ser Val Ala 1 5 10 (2) INFORMATION FOR SEQ ID NO:51: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:51: Thr Phe His Thr Ala Thr Ser 1 5 (2) INFORMATION FOR SEQ ID NO:52: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 6 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein ( i) SEQUENCE DESCRIPTION: SEQ ID NO:52: Phe Arg Asn Ser Gin Ser 1 5 (2) INFORMATION FOR SEQ ID NO:53: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:53: Leu Asn Cys Ser Thr Ala Glu Arg 1 5 (2) INFORMATION FOR SEQ ID NO:54: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 16 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:54: Ala Asn Thr Arg Val His Pro Ser Lys He Gin His Cys Ser Gin Ala 1 5 10 15 (2) INFORMATION FOR SEQ ID NO:55: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:55: Glu Leu Gly He Cys Gin Asn 1 5 (2) INFORMATION FOR SEQ ID NO:56: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:56: Thr Ala Ser Ser His Leu Asp Phe His Ser Lys Lys Leu Lys His 1 5 10 15 (2) INFORMATION FOR SEQ ID NO:57: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: 1inear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:57: Ser Ser Gin He Ala Pro Glu Leu Arg Asn Cys Arg Phe Arg Arg Gly 1 5 10 15 Gly Pro Arg (2) INFORMATION FOR SEQ ID NO:58: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 47 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:58: Thr Cys Gin Gin Phe He Val Arg Arg Asn Gly Gly Lys His Trp Lys 1 5 10 15 Lys He Asn Gin Thr Lys Ser Phe Val He Tyr Arg Ala Leu Phe Gin 20 25 30 He Asp He Arg Ala Lys Ser Thr Leu Tyr Lys Tyr Val His Ser 35 40 45 (2) INFORMATION FOR SEQ ID NO:59: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 33 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:59: Val Ala Gly Ser Gin Glu Gly Cys Ser Ser Glu Val He Asn Phe Pro 1 5 10 15 His Ser His Lys Thr Arg Asp Tyr Val He He Lys Thr Lys Leu Ser 20 25 30 Ala (2) INFORMATION FOR SEQ ID NO:60: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 25 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:60: Val Lys Glu Arg Ala Arg Asn His Arg Asn Gly Phe His Leu He Ser 1 5 10 15 Tyr Arg Trp Leu Cys Ser Gly Val Val 20 25 (2) INFORMATION FOR SEQ ID NO:61: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:61: He Tyr Glu Tyr Gly Gly Glu Lys Arg Thr 1 5 10 (2) INFORMATION FOR SEQ ID NO:62: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein ■ (xi) SEQUENCE DESCRIPTION: SEQ ID NO:62: Leu Glu Gly His Thr 1 5 (2) INFORMATION FOR SEQ ID NO:63: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:63: Pro Asp Phe Thr Asp Pro Thr Arg Arg Ser Arg Gly Thr Lys Leu Leu 1 5 10 15 Lys Ser Cys Gin Arg Val Ala 20 (2) INFORMATION FOR SEQ ID NO:64: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:64: Cys Gly Ala Ser Asn Gly Asp 1 5 (2) INFORMATION FOR SEQ ID NO:65: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:65: Asn Ser Pro Thr Phe Ser Glu Val 1 5 (2) INFORMATION FOR SEQ ID NO:66: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 35 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:66: Ala Ser Gly Thr Glu Asp Ala Asn Glu Glu Glu He Pro Gin Leu Phe 1 5 10 15 Arg Leu Cys Arg Leu Gin Thr Val Gin Glu Gly Phe Cys His He Glu 20 25 30 Glu His Trp 35 (2) INFORMATION FOR SEQ ID NO:67: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:67: Ala Glu Arg Thr Leu 1 5 (2) INFORMATION FOR SEQ ID NO:68: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 13 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:68: Ser Tyr Gin Asn Arg Trp Arg Val Asn Ser Ser Asn Leu 1 5 10 (2) INFORMATION FOR SEQ ID NO:69: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:69: Arg Asp Thr His Gin Val Arg Cys Arg Lys Tyr His Asp Asp Gly Thr 1 5 10 15 Gly Phe Gly He Ser Gin 20 (2) INFORMATION FOR SEQ ID NO:70: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:70: Arg Arg Arg Lys Arg Asn His Trp Cys Leu Trp Thr Trp Trp Gly Trp 1 5 10 15 Glu Asp Asn Val Asn Ala Glu His 20 (2) INFORMATION FOR SEQ ID NO:71: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:71: Gin Arg Ala Asp His Lys Arg Thr Ser Val 1 5 10 (2) INFORMATION FOR SEQ ID NO:72: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 55 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear • (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:72: Cys Thr Asp Leu Gly Ser Asn Val Gin Arg He Arg Arg Val Tyr Asn 1 5 10 15 Ser Ala Ser Arg Trp Ser Thr Val Gly Phe He Leu Gly Arg Glu Gly 20 25 30 Asp Arg Arg Lys Gin Ser Phe Glu Asp He Gin Ser Phe Glu Thr Glu 35 40 45 Thr Phe Leu Val Val Ala Arg 50 55 (2) INFORMATION FOR SEQ ID NO:73: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:73: Cys Leu Gly Arg Asp Arg Leu Gly Glu Asn Trp Ser Ser Ser Thr 1 5 10 15 (2) INFORMATION FOR SEQ ID NO:74: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 9 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:74: Arg Asp Arg Arg Arg Val Asp Pro Cys 1 5 (2) INFORMATION FOR SEQ ID NO:75: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 41 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear ' (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:75: Gin Gly Lys Gin Met Gin Gly Asp Val His Asp Thr Val Tyr Ser He 1 5 10 15 Met Gin Gin Tyr Gly Cys Gly He Gin Val Glu Ser Gly Val Ser Gly 20 25 30 Glu Glu Thr Arg Val Gly Ala Val Leu 35 40 (2) INFORMATION FOR SEQ ID NO:76: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:76: Gly Met Glu Lys Arg Ser Phe Arg Val He He Asn Ser Pro Ala Arg 1 5 10 15 Gly Asp Tyr Ser Glu 20 (2) INFORMATION FOR SEQ ID NO:77: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 17 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:77: Met Trp Arg He Ala Thr Ser Val Asp His Phe Arg Arg Ser His Gly 1 5 10 15 Ser (2) INFORMATION FOR SEQ ID NO:78: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:78: He Ser Ser Arg Asp Glu Gly Tyr Glu Leu Cys He Cys Pro Phe Glu 1 5 10 15 He Gin Leu Arg Gin Pro Arg Glu 20 (2) INFORMATION FOR SEQ ID NO:79: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:79: Ser Ala Ser Val Leu Phe Leu Val Leu Arg Phe He Pro Arg Arg Thr 1 5 10 15 Phe Tyr Arg Asp Arg Ala Ala Cys 20 (2) INFORMATION FOR SEQ ID NO:80: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:80: Val Leu Gly Arg Arg Arg Val Ser His Gin Leu Pro Trp Arg 1 5 10 (2) INFORMATION FOR SEQ ID NO:81: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear ' (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:81: His His Leu Gin Gly He Phe Ser His Trp Gly Ser Glu Ser Gly Met 1 5 10 15 Phe Val Gly Asn Arg Arg 20 (2) INFORMATION FOR SEQ ID NO:82: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:82: Glu Asn Thr Gly Glu Asp Ala 1 5 (2) INFORMATION FOR SEQ ID NO:83: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 43 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:83: Lys Thr His Met Pro Glu Thr Asp Asn Thr Asp Ala Pro Thr Glu Gly 1 5 10 15 Leu Phe Glu Glu Asp Ser Asn Arg Val Phe His Ala Tyr Ala Cys Ser 20 25 30 Gin Ser Leu Gly Leu Val Val His Lys Tyr His 35 40 (2) INFORMATION FOR SEQ ID NO:84: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 11 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:84: Cys Gly Gin Lys Leu Cys He Val Asp Gly He 1 5 10 (2) INFORMATION FOR SEQ ID NO:85: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:85: Gly Ala Asp Pro Ser 1 5 (2) INFORMATION FOR SEQ ID NO:86: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:86: Ser Arg Lys Leu Ala Thr Ser Val Gly Asp Leu He Val Arg 1 5 10 (2) INFORMATION FOR SEQ ID NO:87: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 6 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:87: Gin Asn Pro Asp Leu Ala 1 5 (2) INFORMATION FOR SEQ ID NO:88: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 31 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:88: Asp Ser Val Val Tyr Gin Val Phe Gly Gly Val Val Ser Ser Val Tyr 1 5 10 15 Val Arg Asn Lys Asp Lys Cys He Ala Thr Gly Ala Trp Glu Ser 20 25 30 (2) INFORMATION FOR SEQ ID NO:89: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 47 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:89: Lys Thr Glu Ala Ser Gly Pro Thr Lys Asn Ser Val Ser Ser Asp Asp 1 5 10 15 Pro Thr Arg Cys His Met Leu Ala Glu Gin Ala Arg Gly Ser Glu Leu 20 25 30 Val Leu Gin Leu Arg Arg Leu Gly Thr Ala Glu Leu Trp Arg Arg 35 40 45 (2) INFORMATION FOR SEQ ID NO:90: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:90: Ser Arg Arg Thr Arg He Arg 1 5 (2) INFORMATION FOR SEQ ID NO:91: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:91: Leu Gly He Leu Gly Lys Pro Asn His Thr Arg Tyr His Cys Ser Leu 1 5 10 15 He Gly Asp Pro Lys Asn Ser Leu Arg Val Arg Cys Phe Ala 20 25 30 (2) INFORMATION FOR SEQ ID NO:92: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:92: Thr Tyr Thr Ala Ser Pro Arg 1 5 (2) INFORMATION FOR SEQ ID NO:93: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:93: Thr Pro Leu Leu Gin Ser Pro He Thr His 1 5 10 (2) INFORMATION FOR SEQ ID NO:94: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:94: Pro Trp Gin Glu Pro Glu Lys Thr 1 5 (2) INFORMATION FOR SEQ ID NO:95: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:95: Leu Gly Val Pro Gly His Thr Arg Arg Phe 1 5 10 (2) INFORMATION FOR SEQ ID NO:96: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 58 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:96: Leu Ala Ser Glu Ser Arg Gly Ser Asp Val Thr Gin Pro Ser Gin Leu 1 5 10 15 Asn Gin Ser Val Gly Lys Phe Cys Lys Pro Arg Leu Ser Ala Glu Tyr 20 25 30 Pro Leu His Lys His Phe Thr Leu Gin Gin Ala Glu Glu Cys Leu Met 35 40 45 Gly Ser Glu Thr Pro Lys Ala Arg Gly Asp 50 55 (2) INFORMATION FOR SEQ ID NO:97: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 33 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:97: Thr Val Arg Leu Gin Arg Asp Arg Gly He Asp Lys Arg Thr Arg Glu 1 5 10 15 Ser He Arg Arg Arg Ser Asn He Val Pro Lys Pro Glu Asp Leu Glu 20 25 30 Asn (2) INFORMATION FOR SEQ ID NO:98: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 18 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:98: Gly Ser Ala Arg Thr Lys Gin His Pro Pro He Ser He Phe He Pro 1 5 10 15 Lys Ser (2) INFORMATION FOR SEQ ID NO:99: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:99: Asn He Ser His His Lys Leu Pro Gin Ser 1 5 10 (2) INFORMATION FOR SEQ ID NO:100: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 18 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:100: Glu Thr Ala Val Ser Gly Glu Glu Asp Pro Asp Glu Leu Ala Asn Ser 1 5 10 15 Leu Leu (2) INFORMATION FOR SEQ ID NO:101: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:101: Thr Ser His His 1 (2) INFORMATION FOR SEQ ID NO:102: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 13 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:102: Glu Leu Arg Ala Leu Cys Thr Asn Met Ser He His Lys 1 5 10 (2) INFORMATION FOR SEQ ID NO:103: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:103: Gin Glu Ala Arg Lys Val Val Pro Val Lys Ser Ser Thr Phe His He 1 5 10 15 Ala Thr Lys Leu Glu He Met 20 (2) INFORMATION FOR SEQ ID NO:104: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 6 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:104: Lys Pro Asn Tyr Pro Arg 1 5 (2) INFORMATION FOR SEQ ID NO:105: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1491 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:105: ATCGATTGAT CTCTGGCTCA GTGCGAGTAG TCCATTTGAG AGCAGTCGTA GCCCCGCGTG 60 GCGCATCATG GAGCTATTTG GAATTTTCGC AGGGTTATCG ATTCGTAGTG GGAACCCATT 120 CATTGTTTGG AACCACCAAC GGACGACTTA ACAAGCTCCC CGAGGTGCAT GATGAAAATT 180 GCTCCAGTTG CCATAAATCA CAGCCCGCTC AGCAGGGAGG TCCCGTCACA CGCGGCACCC 240 ACTCAGGCAA AGCAAACCAA CCTTCAATCT GAAGCTGGCG ATTTAGATGC AAGAAAAAGT 300 AGCGCTTCAA GCCCGGAAAC CCGCGCATTA CTCGCTACTA AGACAGTACT CGGGAGACAC 360 AAGATAGAGG TTCCGGCCTT TGGAGGGTGG TTCAAAAAGA AATCATCTAA GCACGAGACG 420 GGCGGTTCAA GTGCCAACGC AGATAGTTCG AGCGTGGCTT CCGATTCCAC CGAAAAACCT 480 TTGTTCCGTC TCACGCACGT TCCTTACGTA TCCCAAGGTA ATGAGCGAAT GGGATGTTGG 540 TATGCCTGCG CAAGAATGGT TGGCCATTCT GTCGAAGCTG GGCCTCGCCT AGGGCTGCCG 600 GAGCTCTATG AGGGAAGGGA GGCGCCAGCT GGGCTACAAG ATTTTTCAGA TGTAGAAAGG 660 TTTATTCACA ATGAAGGATT AACTCGGGTA GACCTTCCAG ACAATGAGAG ATTTACACAC 720 GAAGAGTTGG GTGCACTGTT GTATAAGCAC GGGCCGATTA TATTTGGGTG GAAAACTCCG 780 AATGACAGCT GGCACATGTC GGTCCTCACT GGTGTCGATA AAGAGACGTC GTCCATTACT 840 TTTCACGATC CCCGACAGGG GCCGGACCTA GCAATGCCGC TCGATTACTT TAATCAGCGA 900 TTGGCATGGC AGGTTCCACA CGCAATGCTC TACCGCTAAG TAGCAGGGTA TCTTCACGTG 960 GCGGCATCAT GACAAGCCCA TGATGCCGCC AGCAGCTACC TGAATGCCGT CTGGCTTTTT 1020 GGTCCCTATT GTCGTATCCG GAAGATGACG TCAAAGAATC TCGGCAAGAG CTTTCTTGCT 1080 CGACTCCTCA GCTTCCGGAT CGATCAGGTC GCTTGCCAGA GCGCGCTTGT CCATGAGCAT 1140 CTGCCACAGC TGCTGGTCGA TGGTGTCCTC AGCTAAAGGG ATTTTGACGA CAACCATGCG ' 1200 CAACTGCCCG TTGCGATACG CTCGATCCTG AAGCCCCGGT GTCCATGGCA GCCCCAAGAA 1260 AAAGACATAG TTCGCCGCTG TGAGGTTGTA GCCTGTGCCG GCGGCCGACC TGGTCCCGAT 1320 AAACACCCTG CAGTCCGGAT CCTGCTGGAA AGCATCAATC GCCTTCTGCC GCTTCTTGGG 1380 CGAGTCACTG CCCACCAACG TCACGCACCC GACGCCAAGC TTGAGGCAGT GCTCCCGCAA 1440 CGTGGCCACG GATTCCTGAT ACTCGCAGAA GAGGATCACC TTGTCGTCGA C 1491 (2) INFORMATION FOR SEQ ID NO:106: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 255 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:106: Met Lys He Ala Pro Val Ala He Asn His Ser Pro Leu Ser Arg Glu 1 5 10 15 Val Pro Ser His Ala Ala Pro Thr Gin Ala Lys Gin Thr Asn Leu Gin 20 25 30 Ser Glu Ala Gly Asp Leu Asp Ala Arg Lys Ser Ser Ala Ser Ser Pro 35 40 45 Glu Thr Arg Ala Leu Leu Ala Thr Lys Thr Val Leu Gly Arg His Lys 50 55 60 He Glu Val Pro Ala Phe Gly Gly Trp Phe Lys Lys Lys Ser Ser Lys 65 70 75 80 His Glu Thr Gly Gly Ser Ser Ala Asn Ala Asp Ser Ser Ser Val Ala 85 90 95 Ser Asp Ser Thr Glu Lys Pro Leu Phe Arg Leu Thr His Val Pro Tyr 100 105 110 Val Ser Gin Gly Asn Glu Arg Met Gly Cys Trp Tyr Ala Cys Ala Arg 115 120 125 Met Val Gly His Ser Val Glu Ala Gly Pro Arg Leu Gly Leu Pro Glu 130 135 140 Leu Tyr Glu Gly Arg Glu Ala Pro Ala Gly Leu Gin Asp Phe Ser Asp 145 150 155 160 Val Glu Arg Phe He His Asn Glu Gly Leu Thr Arg Val Asp Leu Pro 165 170 175 Asp Asn Glu Arg Phe Thr His Glu Glu Leu Gly Ala Leu Leu Tyr Lys 180 185 190 His Gly Pro He He Phe Gly Trp Lys Thr Pro Asn Asp Ser Trp His 195 200 205 Met Ser Val Leu Thr Gly Val Asp Lys Glu Thr Ser Ser He Thr Phe 210 215 220 His Asp Pro Arg Gin Gly Pro Asp Leu Ala Met Pro Leu Asp Tyr Phe 225 230 235 240 Asn Gin Arg Leu Ala Trp Gin Val Pro His Ala Met Leu Tyr Arg 245 250 255 (2) INFORMATION FOR SEQ ID NO:107: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1209 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:107: Met Asn Pro Ser Gly Ser Phe Pro Ser Val Glu Tyr Glu Val Phe Leu 1 5 10 15 Ser Phe Arg Gly Pro Asp Thr Arg Glu Gin Phe Thr Asp Phe Leu Tyr 20 25 30 Gin Ser Leu Arg Arg Tyr Lys He His Thr Phe Arg Asp Asp Asp Glu 35 40 45 Leu Leu Lys Gly Lys Glu He Gly Pro Asn Leu Leu Arg Ala He Asp 50 55 60 Gin Ser Lys He Tyr Val Pro He He Ser Ser Gly Tyr Ala Asp Ser 65 70 75 80 Lys Trp Cys Leu Met Glu Leu Ala Glu He Val Arg Arg Gin Glu Glu 85 90 95 Asp Pro Arg Arg He He Leu Pro He Phe Tyr Met Val Asp Pro Ser 100 105 110 Asp Val Arg His Gin Thr Gly Cys Tyr Lys Lys Ala Phe Arg Lys His 115 120 125 Ala Asn Lys Phe Asp Gly Gin Thr He Gin Asn Trp Lys Asp Ala Leu 130 135 140 Lys Lys Val Gly Asp Leu Lys Gly Trp His He Gly Lys Asn Asp Lys 145 150 155 160 Gin Gly Ala He Ala Asp Lys Val Ser Ala Asp He Trp Ser His He 165 170 175 Ser Lys Glu Asn Leu He Leu Glu Thr Asp Glu Leu Val Gly He Asp 180 185 190 Asp His He Thr Ala Val Leu Glu Lys Leu Ser Leu Asp Ser Glu Asn 195 200 205 Val Thr Met Val Gly Leu Tyr Gly Met Gly Gly He Gly Lys Thr Thr 210 215 220 Thr Ala Lys Ala Val Tyr Asn Lys He Ser Ser Cys Phe Asp Cys Cys 225 230 235 240 Cys Phe He Asp Asn He Arg Glu Thr Gin Glu Lys Asp Gly Val Val 245 250 255 Val Leu Gin Lys Lys Leu Val Ser Glu He Leu Arg He Asp Ser Gly 260 265 270 Ser Val Gly Phe Asn Asn Asp Ser Gly Gly Arg Lys Thr He Lys Glu 275 280 285 Arg Val Ser Arg Phe Lys He Leu Val Val Leu Asp Asp Val Asp Glu 290 295 300 Lys Phe Lys Phe Glu Asp Met Leu Gly Ser Pro Lys Asp Phe He Ser 305 310 315 320 Gin Ser Arg Phe He He Thr Ser Arg Ser Met Arg Val Leu Gly Thr 325 330 335 Leu Asn Glu Asn Gin Cys Lys Leu Tyr Glu Val Gly Ser Met Ser Lys 340 345 350 Pro Arg Ser Leu Glu Leu Phe Ser Lys His Ala Phe Lys Lys Asn Thr 355 360 365 Pro Pro Ser Ser Tyr Tyr Glu Thr Leu Ala Asn Asp Val Val Asp Thr 370 375 380 Thr Ala Gly Leu Pro Leu Thr Leu Lys Val He Gly Ser Leu Leu Phe 385 390 395 400 Lys Gin Glu He Ala Val Trp Glu Asp Thr Leu Glu Gin Leu Arg Arg 405 410 415 Thr Leu Asn Leu Asp Glu Val Tyr Asp Arg Leu Lys He Ser Tyr Asp 420 425 430 Ala Leu Asn Pro Glu Ala Lys Glu He Phe Leu Asp He Ala Cys Phe 435 440 445 Phe He Gly Gin Asn Lys Glu Glu Pro Tyr Tyr Met Trp Thr Asp Cys 450 455 460 Asn Phe Tyr Pro Ala Ser Asn He He Phe Leu He Gin Arg Cys Met 465 470 475 480 He Gin Val Gly Asp Asp Asp Glu Phe Lys Met His Asp Gin Leu Arg 485 490 495 Asp Met Gly Arg Glu He Val Arg Arg Glu Asp Val Leu Pro Trp Lys 500 505 510 Ser Arg He Trp Ser Ala Glu Glu Gly He Asp Leu Leu Leu Asn Lys 515 520 525 Arg Lys Gly Ser Ser Lys Val Lys Ala He Ser He Pro Trp Gly Val 530 535 540 Lys Tyr Glu Phe Lys Ser Glu Cys Phe Leu Asn Leu Ser Glu Leu Arg 545 550 555 560 Tyr Leu His Ala Arg Glu Ala Met Leu Thr Gly Asp Phe Asn Asn Leu 565 570 575 Leu Pro Asn Leu Lys Trp Leu Glu Leu Pro Phe Tyr Lys His Gly Glu 580 585 590 Asp Asp Pro Pro Leu Thr Asn Tyr Thr Met Lys Asn Leu He He Val 595 600 605 He Leu Glu His Ser His He Thr Ala Asp Asp Trp Gly Gly Trp Arg 610 615 620 His Met Met Lys Met Ala Glu Arg Leu Lys Val Val Arg Leu Ala Ser 625 630 635 640 Asn Tyr Ser Leu Tyr Gly Arg Arg Val Arg Leu Ser Asp Cys Trp Arg 645 650 655 Phe Pro Lys Ser He Glu Val Leu Ser Met Thr Ala He Glu Met Asp 660 665 670 Glu Val Asp He Gly Glu Leu Lys Lys Leu Lys Thr Leu Val Leu Lys 675 680 685 Pro Cys Pro He Gin Lys He Ser Gly Gly Thr Phe Gly Met Leu Lys 690 695 700 Gly Leu Arg Glu Leu Cys Leu Glu Phe Asn Trp Gly Thr Asn Leu Arg 705 710 715 720 Glu Val Val Ala Asp He Gly Gin Leu Ser Ser Leu Lys Val Leu Lys 725 730 735 Thr Gly Ala Lys Glu Val Glu He Asn Glu Phe Pro Leu Gly Leu Lys 740 745 750 Thr Glu Leu Ser Thr Ser Ser Arg He Pro Asn Asn Leu Ser Gin Leu 755 760 765 Leu Asp Leu Glu Val Leu Lys Val Tyr Asp Cys Lys Asp Gly Phe Asp 770 775 780 Met Pro Pro Ala Ser Pro Ser Glu Asp Glu Ser Ser Val Trp Trp Lys 785 790 795 800 Val Ser Lys Leu Lys Ser Leu Gin Leu Glu Lys Thr Arg He Asn Val 805 810 815 Asn Val Val Asp Asp Ala Ser Ser Gly Gly His Leu Pro Arg Tyr Leu 820 825 830 Leu Pro Thr Ser Leu Thr Tyr Leu Lys He Tyr Gin Cys Thr Glu Pro 835 840 845 Thr Trp Leu Pro Gly He Glu Asn Leu Glu Asn Leu Thr Ser Leu Glu 850 855 860 Val Asn Asp He Phe Gin Thr Leu Gly Gly Asp Leu Asp Gly Leu Gin 865 870 875 880 Gly Leu Arg Ser Leu Glu He Leu Arg He Arg Lys Val Asn Gly Leu 885 890 895 Ala Arg He Lys Gly Leu Lys Asp Leu Leu Cys Ser Ser Thr Cys Lys 900 905 910 Leu Arg Lys Phe Tyr He Thr Glu Cys Pro Asp Leu He Glu Leu Leu 915 920 925 Pro Cys Glu Leu Gly Val Gin Thr Val Val Val Pro Ser Met Ala Glu 930 935 940 Leu Thr He Arg Asp Cys Pro Arg Leu Glu Val Gly Pro Met He Arg 945 950 955 960 Ser Leu Pro Lys Phe Pro Met Leu Lys Lys Leu Asp Leu Ala Val Ala 965 970 975 Asn He Thr Lys Glu Glu Asp Leu Asp Ala He Gly Ser Leu Glu Glu 980 985 990 Leu Val Ser Leu Glu Leu Glu Leu Asp Asp Thr Ser Ser Gly He Glu 995 1000 1005 Arg He Val Ser Ser Ser Lys Leu Gin Lys Leu Thr Thr Leu Val Val 1010 1015 1020 Lys Val Pro Ser Leu Arg Glu He Glu Gly Leu Glu Glu Leu Lys Ser 1025 1030 1035 1040 Leu Gin Asp Leu Tyr Leu Glu Gly Cys Thr Ser Leu Gly Arg Leu Pro 1045 1050 1055 Leu Glu Lys Leu Lys Glu Leu Asp He Gly Gly Cys Pro Asp Leu Thr 1060 1065 1070 Glu Leu Val Gin Thr Val Val Ala Val Pro Ser Leu Arg Gly Leu Thr 1075 1080 1085 He Arg Asp Cys Pro Arg Leu Glu Val Gly Pro Met He Gin Ser Leu 1090 1095 1100 Pro Lys Phe Pro Met Leu Asn Glu Leu Thr Leu Ser Met Val Asn He 1105 1110 1115 1120 Thr Lys Glu Asp Glu Leu Glu Val Leu Gly Ser Leu Glu Glu Leu Asp 1125 1130 1135 Ser Leu Glu Leu Thr Leu Asp Asp Thr Cys Ser Ser He Glu Arg He 1140 1145 1150 Ser Phe Leu Ser Lys Leu Gin Lys Leu Thr Thr Leu He Val Glu Val 1155 1160 1165 Pro Ser Leu Arg Glu He Glu Gly Leu Ala Glu Leu Lys Ser Leu Arg 1170 1175 1180 - 109 - He Leu Tyr Leu Glu Gly Cys Thr Ser Leu Glu Arg Leu Trp Pro Asp 1185 1190 1195 12Q0 Gin Gin Gin Leu Gly Ser Leu Lys Asn 1205 (2) INFORMATION FOR SEQ ID NO:108: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1143 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:108: Met Ala Ser Ser Ser Ser Ser Ser Arg Trp Ser Tyr Asp Val Phe Leu 1 5 10 15 Ser Phe Arg Gly Glu Asp Thr Arg Lys Thr Phe Thr Ser His Leu Tyr 20 25 30 Glu Val Leu Asn Asp Lys Gly He Lys Thr Phe Gin Asp Asp Lys Arg 35 40 45 Leu Glu Tyr Gly Ala Thr He Pro Gly Glu Leu Cys Lys Ala He Glu 50 55 60 Glu Ser Gin Phe Ala He Val Val Phe Ser Glu Asn Tyr Ala Thr Ser 65 70 75 80 Arg Trp Cys Leu Asn Glu Leu Val Lys He Met Glu Cys Lys Thr Arg 85 90 95 Phe Lys Gin Thr Val He Pro He Phe Tyr Asp Val Asp Pro Ser His 100 105 110 Val Arg Asn Gin Lys Glu Ser Phe Ala Lys Ala Phe Glu Glu His Glu 115 120 125 Thr Lys Tyr Lys Asp Asp Val Glu Gly He Gin Arg Trp Arg He Ala 130 135 140 Leu Asn Glu Ala Ala Asn Leu Lys Gly Ser Cys Asp Asn Arg Asp Lys 145 150 155 160 Thr Asp Ala Asp Cys He Arg Gin He Val Asp Gin He Ser Ser Lys 165 170 175 Leu Cys Lys He Ser Leu Ser Tyr Leu Gin Asn He Val Gly He Asp 180 185 190 Thr His Leu Glu Lys He Glu Ser Leu Leu Glu He Gly He Asn Gly 195 200 205 Val Arg He Met Gly He Trp Gly Met Gly Gly Val Gly Lys Thr Thr 210 215 220 He Ala Arg Ala He Phe Asp Thr Leu Leu Gly Arg Met Asp Ser Ser 225 230 235 240 Tyr Gin Phe Asp Gly Ala Cys Phe Leu Lys Asp He Lys Glu Asn Lys 245 250 255 Arg Gly Met His Ser Leu Gin Asn Ala Leu Leu Ser Glu Leu Leu Arg 260 265 270 Glu Lys Ala Asn Tyr Asn Asn Glu Glu Asp Gly Lys His Gin Met Ala 275 280 285 Ser Arg Leu Arg Ser Lys Lys Val Leu He Val Leu Asp Asp He Asp 290 295 300 Asn Lys Asp His Tyr Leu Glu Tyr Leu Ala Gly Asp Leu Asp Trp Phe 305 310 315 320 Gly Asn Gly Ser Arg He He He Thr Thr Arg Asp Lys His Leu He 325 330 335 Glu Lys Asn Asp He He Tyr Glu Val Thr Ala Leu Pro Asp His Glu 340 345 350 Ser He Gin Leu Phe Lys Gin His Ala Phe Gly Lys Glu Val Pro Asn 355 360 365 Glu Asn Phe Glu Lys Leu Ser Leu Glu Val Val Asn Tyr Ala Lys Gly 370 375 380 Leu Pro Leu Ala Leu Lys Val Trp Gly Ser Leu Leu His Asn Leu Arg 385 390 395 400 Leu Thr Glu Trp Lys Ser Ala He Glu His Met Lys Asn Asn Ser Tyr 405 410 415 Ser Gly He He Asp Lys Leu Lys He Ser Tyr Asp Gly Leu Glu Pro 420 425 430 Lys Gin Gin Glu Met Phe Leu Asp He Ala Cys Phe Leu Arg Gly Glu 435 440 445 Glu Lys Asp Tyr He Leu Gin He Leu Glu Ser Cys His He Gly Ala 450 455 460 Glu Tyr Gly Leu Arg He Leu He Asp Lys Ser Leu Val Phe He Ser 465 470 475 480 Glu Tyr Asn Gin Val Gin Met His Asp Leu He Gin Asp Met Gly Lys 485 490 495 Tyr He Val Asn Phe Gin Lys Asp Pro Gly Glu Arg Ser Arg Leu Trp 500 505 510 Leu Ala Lys Glu Val Glu Glu Val Met Ser Asn Asn Thr Gly Thr Met 515 520 525 Ala Met Glu Ala He Trp Val Ser Ser Tyr Ser Ser Thr Leu Arg Phe 530 535 540 Ser Asn Gin Ala Val Lys Asn Met Lys Arg Leu Arg Val Phe Asn Met 545 550 555 560 Gly Arg Ser Ser Thr His Tyr Ala He Asp Tyr Leu Pro Asn Asn Leu - Ill - 565 570 575 Arg Cys Phe Val Cys Thr Asn Tyr Pro Trp Glu Ser Phe Pro Ser Thr 580 585 590 Phe Glu Leu Lys Met Leu Val His Leu Gin Leu Arg His Asn Ser Leu 595 600 605 Arg His Leu Trp Thr Glu Thr Lys His Leu Pro Ser Leu Arg Arg He 610 615 620 Asp Leu Ser Trp Ser Lys Arg Leu Thr Arg Thr Pro Asp Phe Thr Gly 625 630 635 640 Met Pro Asn Leu Glu Tyr Val Asn Leu Tyr Gin Cys Ser Asn Leu Glu 645 650 655 Glu Val His His Ser Leu Gly Cys Cys Ser Lys Val He Gly Leu Tyr 660 665 670 Leu Asn Asp Cys Lys Ser Leu Lys Arg Phe Pro Cys Val Asn Val Glu 675 680 685 Ser Leu Glu Tyr Leu Gly Leu Arg Ser Cys Asp Ser Leu Glu Lys Leu 690 695 700 Pro Glu He Tyr Gly Arg Met Lys Pro Glu He Gin He His Met Gin 705 710 715 720 Gly Ser Gly He Arg Glu Leu Pro Ser Ser He Phe Gin Tyr Lys Thr 725 730 735 His Val Thr Lys Leu Leu Leu Trp Asn Met Lys Asn Leu Val Ala Leu 740 745 750 Pro Ser Ser He Cys Arg Leu Lys Ser Leu Val Ser Leu Ser Val Ser 755 760 765 Gly Cys Ser Lys Leu Glu Ser Leu Pro Glu Glu He Gly Asp Leu Asp 770 775 780 Asn Leu Arg Val Phe Asp Ala Ser Asp Thr Leu He Leu Arg Pro Pro 785 790 795 800 Ser Ser He He Arg Leu Asn Lys Leu He He Leu Met Phe Arg Gly 805 810 815 Phe Lys Asp Gly Val His Phe Glu Phe Pro Pro Val Ala Glu Gly Leu 820 825 830 His Ser Leu Glu Tyr Leu Asn Leu Ser Tyr Cys Asn Leu He Asp Gly 835 840 845 Gly Leu Pro Glu Glu He Gly Ser Leu Ser Ser Leu Lys Lys Leu Asp 850 855 860 Leu Ser Arg Asn Asn Phe Glu His Leu Pro Ser Ser He Ala Gin Leu 865 870 875 880 Gly Ala Leu Gin Ser Leu Asp Leu Lys Asp Cys Gin Arg Leu Thr Gin 885 890 895 Leu Pro Glu Leu Pro Pro Glu Leu Asn Glu Leu His Val Asp Cys His 900 905 910 Met Ala Leu Lys Phe He His Tyr Leu Val Thr Lys Arg Lys Lys Leu 915 920 925 His Arg Val Lys Leu Asp Asp Ala His Asn Asp Thr Met Tyr Asn Leu 930 935 940 Phe Ala Tyr Thr Met Phe Gin Asn He Ser Ser Met Arg His Asp He 945 950 955 960 Ser Ala Ser Asp Ser Leu Ser Leu Thr Val Phe Thr Gly Gin Pro Tyr 965 970 975 Pro Glu Lys He Pro Ser Trp Phe His His Gin Gly Trp Asp Ser Ser 980 985 990 Val Ser Val Asn Leu Pro Glu Asn Trp Tyr He Pro Asp Lys Phe Leu 995 1000 1005 Gly Phe Ala Val Cys Tyr Ser Arg Ser Leu He Asp Thr Thr Ala His 1010 1015 1020 Leu He Pro Val Cys Asp Asp Lys Met Ser Arg Met Thr Gin Lys Leu 1025 1030 1035 1040 Ala Leu Ser Glu Cys Asp Thr Glu Ser Ser Asn Tyr Ser Glu Trp Asp 1045 1050 1055 He His Phe Phe Phe Val Pro Phe Ala Gly Leu Trp Asp Thr Ser Lys 1060 1065 1070 Ala Asn Gly Lys Thr Pro Asn Asp Tyr Gly He He Arg Leu Ser Phe 1075 1080 1085 Ser Gly Glu Glu Lys Met Tyr Gly Arg Leu Arg Leu Tyr Lys Glu Gly 1090 1095 1100 Pro Glu Val Asn Ala Leu Leu Gin Met Arg Glu Asn Ser Asn Glu Pro 1105 1110 1115 1120 Thr Glu His Ser Thr Gly He Arg Arg Thr Gin Tyr Asn Asn Arg Thr 1125 1130 1135 Ser Phe Tyr Glu Leu He Asn 1140 (2) INFORMATION FOR SEQ ID NO:109: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 429 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:109: Leu Arg Ser Lys Leu Asp Leu He He Asp Leu Lys His Gin He Glu 1 5 10 15 Ser Val Lys Glu Gly Leu Leu Cys Leu Arg Ser Phe He Asp His Phe 20 25 30 Ser Glu Ser Tyr Val Glu His Asp Glu Ala Cys Gly Leu He Ala Arg 35 40 45 Val Ser Val Met Ala Tyr Lys Ala Glu Tyr Val He Asp Ser Cys Leu 50 55 60 Ala Tyr Ser His Pro Leu Trp Tyr Lys Val Leu Trp He Ser Glu Val 65 70 75 80 Leu Glu Asn He Lys Leu Val Asn Lys Val Val Gly Glu Thr Cys Glu 85 90 95 Arg Arg Asn Thr Glu Val Thr Val His Glu Val Ala Lys Thr Thr Thr 100 105 110 Asn Val Ala Pro Ser Phe Ser Ala Tyr Thr Gin Arg Ala Asn Glu Glu 115 120 125 Met Glu Gly Phe Gin Asp Thr He Asp Glu Leu Lys Asp Lys Leu Leu 130 135 140 Gly Gly Ser Pro Glu Leu Asp Val He Ser He Val Gly Met Pro Gly 145 150 155 160 Leu Gly Lys Thr Thr Leu Ala Lys Lys He Tyr Asn Asp Pro Glu Val 165 170 175 Thr Ser Arg Phe Asp Val His Ala Gin Cys Val Val Thr Gin Leu Tyr 180 185 190 Ser Trp Arg Glu Leu Leu Leu Thr He Leu Asn Asp Val Leu Glu Pro 195 200 205 Ser Asp Arg Asn Glu Lys Glu Asp Gly Glu He Ala Asp Glu Leu Arg 210 215 220 Arg Phe Leu Leu Thr Lys Arg Phe Leu He Leu He Asp Asp Val Trp 225 230 235 240 Asp Tyr Lys Val Trp Asp Asn Leu Cys Met Cys Phe Ser Asp Val Ser 245 250 255 Asn Arg Ser Arg He He Leu Thr Thr Arg Leu Asn Asp Val Ala Glu 260 265 270 Tyr Val Lys Cys Glu Ser Asp Pro His His Leu Arg Leu Phe Arg Asp 275 280 285 Asp Glu Ser Trp Thr Leu Leu Gin Lys Glu Val Phe Gin Gly Glu Ser 290 295 300 Cys Pro Pro Glu Leu Glu Asp Val Gly Phe Glu He Ser Lys Ser Cys 305 310 315 320 Arg Gly Leu Pro Leu Ser Val Val Leu Val Ala Gly Val Leu Lys Gin 325 330 335 Lys Lys Lys Thr Leu Asp Ser Trp Lys Val Val Glu Gin Ser Leu Ser 340 345 350 Ser Gin Arg He Gly Ser Leu Glu Glu Ser He Ser He He Gly Phe 355 360 365 Ser Tyr Lys Asn Leu Pro His Tyr Leu Lys Pro Cys Phe Leu Tyr Phe 370 375 380 Gly Gly Phe Leu Gin Gly Lys Asp He His Asp Ser Lys Met Thr Lys 385 390 395 400 Leu Trp Val Ala Glu Glu Phe Val Gin Ala Asn Asn Glu Lys Gly Gin 405 410 415 Glu Asp Thr Arg Thr Arg Phe Leu Gly Arg Ser Tyr Trp 420 425 (2) INFORMATION FOR SEQ ID NO:110: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 11 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:110: Gly Met Gly Gly He Gly Lys Thr Thr Thr Ala 1 5 10 (2) INFORMATION FOR SEQ ID NO:111: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 11 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NOtlll: Gly Met Gly Gly Val Gly Lys Thr Thr He Ala 1 5 10 (2) INFORMATION FOR SEQ ID NO:112: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 11 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:112: Gly Met Pro Gly Leu Gly Lys Thr Thr Leu Ala 1 5 10 -<2) INFORMATION FOR SEQ ID NO:113: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 11 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:113: Gly Pro Gly Gly Val Gly Lys Thr Thr Leu Met 1 5 10 (2) INFORMATION FOR SEQ ID NO:114: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 11 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:114: Phe Lys He Leu Val Val Leu Asp Asp Val Asp 1 5 10 (2) INFORMATION FOR SEQ ID NO:115: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 11 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:115: Lys Lys Val Leu He Val Leu Asp Asp He Asp 1 5 10 (2) INFORMATION FOR SEQ ID NO:116: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 11 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID N0:116: Lys Arg Phe Leu He Leu He Asp Asp Val Trp 1 5 10 (2) INFORMATION FOR SEQ ID NO:117: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 11 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:117: Lys Arg Phe Leu Leu Leu Leu Asp Asp Val Trp 1 5 10 (2) INFORMATION FOR SEQ ID NO:118: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:118: Ser Arg Phe He He Thr Ser Arg 1 5 (2) INFORMATION FOR SEQ ID NO:119: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (D) TOPOLOGY: 1inear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:119: Ser Arg He He He Thr Thr Arg 1 5 (2) INFORMATION FOR SEQ ID NO:120: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:120: Ser Arg He He Leu Thr Thr Arg 1 5 (2) INFORMATION FOR SEQ ID NO:121: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:121: Thr Thr Arg 1 (2) INFORMATION FOR SEQ ID NO:122: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:122: Gly Leu Pro Leu Thr Leu Lys Val 1 5 (2) INFORMATION FOR SEQ ID NO:123: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (D) TOPOLOGY: 1inear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:123: Gly Leu Pro Leu Ala Leu Lys Val 1 5 (2) INFORMATION FOR SEQ ID NO:124: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:124: Gly Leu Pro Leu Ser Val Val Leu 1 5 (2) INFORMATION FOR SEQ ID NO:125: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:125: Gly Leu Pro Leu Ala Leu He Thr 1 5 (2) INFORMATION FOR SEQ ID NO:126: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:126: Lys He Ser Tyr Asp Ala Leu 1 5 (2) INFORMATION FOR SEQ ID NO:127: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:127: Lys He Ser Tyr Asp Gly Leu 1 5 (2) INFORMATION FOR SEQ ID NO:128: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:128: Gly Phe Ser Tyr Lys Asn Leu 1 5 (2) INFORMATION FOR SEQ ID NO:129: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:129: Val Phe Leu Ser Phe Arg Gly 1 5 (2) INFORMATION FOR SEQ ID NO:130: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:130: Pro He Phe Tyr Met Val Asp Pro 1 5 (2) INFORMATION FOR SEQ ID NO:131: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:131: Pro He Phe Tyr Asp Val Asp Pro 1 5 (2) INFORMATION FOR SEQ ID NO:132: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 6 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:132: Val Gly He Asp Asp His 1 5 (2) INFORMATION FOR SEQ ID NO:133: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 6 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:133: Val Gly He Asp Thr His 1 5 (2) INFORMATION FOR SEQ ID NO:134: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:134: Phe Leu Asp He Ala Cys Phe 1 5 (2) INFORMATION FOR SEQ ID NO:135: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 9 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:135: Met His Asp Gin Leu Arg Asp Met Gly 1 5 (2) INFORMATION FOR SEQ ID NO:136: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 9 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:136: Met His Asp Leu He Gin Asp Met Gly 1 5 (2) INFORMATION FOR SEQ ID NO:137: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 9 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:137: Met His Asp Leu He Gin Asp Met Gly 1 5 (2) INFORMATION FOR SEQ ID NO:138: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 6 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:138: Ser Lys Leu Glu Ser Leu 1 5 (2) INFORMATION FOR SEQ ID NO:139: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:139: Gly Leu His Ser Leu Glu Tyr Leu 1 5 (2) INFORMATION FOR SEQ ID NO:140: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 base pairs (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:140: Gly Leu Arg Ser Leu Glu He Leu 1 5 (2) INFORMATION FOR SEQ ID NO:141: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3432 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:141: ACAAGTAAAA GAAAGAGCGA GAAATCATCG AAATGGATTT CATCTCATCT CTTATCGTTG 60 GCTGTGCTCA GGTGTTGTGT GAATCTATGA ATATGGCGGA GAGAAGAGGA CATAAGACTG 120 ATCTTAGACA AGCCATCACT GATCTTGAAA CAGCCATCGG TGACTTGAAG GCCATACGTG 180 ATGACCTGAC TTTACGGATC CAACAAGACG GTCTAGAGGG ACGAAGCTGC TCAAATCGTG 240 CCAGAGAGTG GCTTAGTGCG GTGCAAGTAA CGGAGACTAA AACAGCCCTA CTTTTAGTGA 300 GGTTTAGGCG TCGGGAACAG AGGACGCGAA TGAGGAGGAG ATACCTCAGT TGTTTCGGTT 360 GTGCCGACTA CAAACTGTGC AAGAAGGTTT CTGCCATATT GAAGAGCATT GGTGAGCTGA 420 GAGAACGCTC TGAAGCTATC AAAACAGATG GCGGGTCAAT TCAAGTAACT TGTAGAGAGA 480 TACCCATCAA GTCCGTTGTC GGAAATACCA CGATGATGGA ACAGGTTTTG GAATTTCTCA 540 GTGAAGAAGA AGAAAGAGGA ATCATTGGTG TTTATGGACC TGGTGGGGTT GGGAAGACAA 600 CGTTAATGCA GAGCATTAAC AACGAGCTGA TCACAAAAGG ACATCAGTAT GATGTACTGA " 660 TTTGGGTTCA AATGTCCAGA GAATTCGGCG AGTGTACAAT TCAGCAAGCC GTTGGAGCAC 720 GGTTGGGTTT ATCTTGGGAC GAGAAGGAGA CCGGCGAAAA CAGAGCTTTG AAGATATACA 780 GAGCTTTGAG ACAGAAACGT TTCTTGTTGT TGCTAGATGA GTCTGGGAAG AGATAGACTT 840 GGAGAAAACT GGAGTTCCTC GACCTTGACA GGGAAAACAA ATGCAAGGTG ATGTTCACGA 900 CACGGTCTAT AGCATTATGC AACAATATGG GTGCGGAATA CAAGTTGAGA GTGGAGTTTC 960 TGGAGAAGAA ACACGCGTGG GAGCTGTTCT GTAGTAAGGT ATGGAGAAAA GATCTTTTAG 1020 AGTCATCATC AATTCGCCGG CTCGCGGAGA TTATAGTGAG TAAATGTGGA GGATTGCCAC 1080 TAGCGTTGAT CACTTTAGGA GGAGCCATGG CTCATAGAGA GACAGAAGAA GAGTGGATCC 1140 ATGCTAGTGA AGTTCTGACT AGATTTCCAG CAGAGATGAA GGGTATGAAC TATGTATTTG 1200 CCCTTTTGAA ATTCAGCTAC GACAACCTCG AGAGTGATCT GCTTCGGTCT TGTTTCTTGT 1260 ACTGCGCTTT ATTCCCAGAA GAACATTGTA TAGAGATCGA GCAGCTTGTT CAGTACTGGG 1320 TCGGCGAAGG GTTTCTCACC AGCTCCCATG GCGTTAACAC CATTTACAAG GGATATTTTC 1380 TCATTGGGGA TCTGAAAGCG GCATGTTTGT TGGAAACCGG AGATGAGAAA ACACAGGTGA 1440 AGATGCATAA TGTGGTCAGA AGCTTTGCAT TGTGGATGGC ATCTGAACAG GGGACTTATA 1500 AGGAGCTGAT CCTAGTTGAG CCTAGCATGG GACATACTGA AGCTCCTAAA GCAGAAAACT 1560 GGCGACAAGC TTGGTGATCT CATTGTTAGA TAACAGAATC CAGACCTTGC CTGAAAAACT 1620 CATATGCCCG AAACTGACAA CACTGATGCT CCAACAGAAC AGCTCTTTGA AGAAGATTCC 1680 AACAGGGTTT TTCATGCATA TGCCTGTTCT CAGAGTCTTG GACTTGTCGT TCACAAGTAT 1740 CACTGAGATT CCGTTGTCTA TCAAGTATTT GGTGGAGTTG TATCATCTGT CTATGTCAGG 1800 AACAAAGATA AGTGTATTGC CACAGGAGCT TGGGAATCTT AGAAAACTGA AGCATCTGGA 1860 CCTACAAAGA ACTCAGTTTC TTCAGACGAT CCCACGAGAT GCCATATGTT GGCTGAGCAA 1920 GCTCGAGGTT CTGAACTTGT ACTACAGTTA CGCCGGTTGG GAACTGCAGA GCTTTGGAGA 1980 AGATGAAGCA GAAGAACTCG GATTCGCTGA CTTGGAATAC TTGGAAAACC TAACCACACT 2040 CGGTATCACT GTTCTCTCAT TGGAGACCCT AAAAACTCTC TTCGAGTTCG GTGCTTTGCA 2100 TAAACATATA CAGCATCTCC ACGTTGAAGA GTGCAATGAA CTCCTCTACT TCAATCTCCC 2160 ATCACTCACT AACCATGGCA GGAACCTGAG AAGACTTAGC ATTAAAAGTT GCCATGACTT 2220 GGAGTACCTG GTCACACCCG CAGATTTTGA AAATGATTGG CTTCCGAGTC TAGAGGTTCT 2280 GACGTTACAC AGCCTTCACA ACTTAACCAG AGTGTGGGGA AATTCTGTAA GCCAAGATTG 2340 TCTGCGGAAT ATCCGTTGCA TAAACATTTC ACACTGCAAC AAGCTGAAGA ATGTCTCATG 2400 GGTTCAGAAA CTCCCAAAGC TAGAGGTGAT TGAACTGTTC GACTGCAGAG AGATAGAGGA 2460 ATTGATAAGC GAACACGAGA GTCCATCCGT CGAAGATCCA ACATTGTTCC CAAGCCTGAA 2520 GACCTTGAGA ACTAGGGATC TGCCAGAACT AAACAGCATC CTCCCATCTC GATTTTCATT " 2580 CCAAAAAGTT GAAACATTAG TCATCACAAA TTGCCCCAGA GTTAAGAAAC TGCCGTTTCA 2640 GGAGAGGAGG ACCCAGATGA ACTTGCCAAC AGTTTATTGT GAGGAGAAAT GGTGGAAAGC 2700 ACTGGAAAAA GTTGAAACAT TAGTCATCAC AAATTGCCCC AGAGTTAAGA AACTGCCGTT 2760 TCAGGAGAGG AGGACCCAGA TGAACTTGCC AACAGTTTAT TGTGAGGAGA AATGGTGGAA 2820 AGCACTGGAA AAAGATCAAC CAAACGAAGA GCTTTGTTAT TTACCGCGCT TTGTTCCAAA 2880 TTGATATAAG AGCTAAGAGC ACTCTGTACA AATATGTCCA TTCATAAGTA GCAGGAAGCC 2940 AGGAAGGTTG TTCCAGTGAA GTCATCAACT TTCCACTAGA CCACAAAACT AGAGATTATG 3000 TAATCATAAA AACCAAACTA TCCGCGATCA AATAGATCTC ACGACTATGA GGACGAAGAC 3060 TCACCGAGTA TCGTCGATAT AGAAACTCCA AGCTCCAGTT CCGATCAGTG AAGACGAACA 3120 AGTTTATCAG ATCTCTGCAA CAATTCTGGG AATCGTCACC TCAGATTAGA CCTCCAGTAA 3180 GAAGTGAGAA AGCATGGACG ACGACTGTGA AGAATTGAGC TAATGAGCTG AACCGGATCC 3240 GGTGAAATTG CAGAACCGGA TCGGAGAAGA AGAATTTTGC ATTTGTGCAT CTTTATTTTT 3300 AATTGTTACG TTTGAGCCCC AATAATCATA GATATTGTAG TGAAGACCAA ATTTCATGGT 3360 GGATCAATCA AATTGTATTT TCAAATTTTC GTAGTGTAAT AACGGAAAAA GGAATAAAAA 3420 GGTCACTGAG TA 3432 (2) INFORMATION FOR SEQ ID NO:142: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 909 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:142: Met Asp Phe He Ser Ser Leu He Val Gly Cys Ala Gin Val Leu Cys 1 5 10 15 Glu Ser Met Asn Met Ala Glu Arg Arg Gly His Lys Thr Asp Leu Arg 20 25 30 Gin Ala He Thr Asp Leu Glu Thr Ala He Gly Asp Leu Lys Ala He 35 40 45 Arg Asp Asp Leu Thr Leu Arg He Gin Gin Asp Gly Leu Glu Gly Arg 50 55 60 Ser Cys Ser Asn Arg Ala Arg Glu Trp Leu Ser Ala Val Gin Val Thr 65 70 75 80 Glu Thr Lys Thr Ala Leu Leu Leu Val Arg Phe Arg Arg Arg Glu Gin 85 90 95 Arg Thr Arg Met Arg Arg Arg Tyr Leu. Ser Cys Phe Gly Cys Ala Asp " 100 105 110 Tyr Lys Leu Cys Lys Lys Val Ser Ala He Leu Lys Ser He Gly Glu 115 120 125 Leu Arg Glu Arg Ser Glu Ala He Lys Thr Asp Gly Gly Ser He Gin 130 135 140 Val Thr Cys Arg Glu He Pro He Lys Ser Val Val Gly Asn Thr Thr 145 150 155 160 Met Met Glu Gin Val Leu Glu Phe Leu Ser Glu Glu Glu Glu Arg Gly 165 170 175 He He Gly Val Tyr Gly Pro Gly Gly Val Gly Lys Thr Thr Leu Met 180 185 190 Gin Ser He Asn Asn Glu Leu He Thr Lys Gly His Gin Tyr Asp Val 195 200 205 Leu He Trp Val Gin Met Ser Arg Glu Phe Gly Glu Cys Thr He Gin 210 215 220 Gin Ala Val Gly Ala Arg Leu Gly Leu Ser Trp Asp Glu Lys Glu Thr 225 230 235 240 Gly Glu Asn Arg Ala Leu Lys He Tyr Arg Ala Leu Arg Gin Lys Arg 245 250 255 Phe Leu Leu Leu Leu Asp Asp Val Trp Glu Glu He Asp Leu Glu Lys 260 265 270 Thr Gly Val Pro Arg Pro Asp Arg Glu Asn Lys Cys Lys Val Met Phe 275 280 285 Thr Thr Arg Ser He Ala Leu Cys Asn Asn Met Gly Ala Glu Tyr Lys 290 295 300 Leu Arg Val Glu Phe Leu Glu Lys Lys His Ala Trp Glu Leu Phe Cys 305 310 315 320 Ser Lys Val Trp Arg Lys Asp Leu Leu Glu Ser Ser Ser He Arg Arg 325 330 335 Leu Ala Glu He He Val Ser Lys Cys Gly Gly Leu Pro Leu Ala Leu 340 345 350 He Thr Leu Gly Gly Ala Met Ala His Arg Glu Thr Glu Glu Glu Trp 355 360 365 He His Ala Ser Glu Val Leu Thr Arg Phe Pro Ala Glu Met Lys Gly 370 375 380 Met Asn Tyr Val Phe Ala Leu Leu Lys Phe Ser Tyr Asp Asn Leu Glu 385 390 395 400 Ser Asp Leu Leu Arg Ser Cys Phe Leu Tyr Cys Ala Leu Phe Pro Glu 405 410 415 Glu His Ser He Glu He Glu Gin Leu Val Glu Tyr Trp Val Gly Glu 420 425 430 Gly Phe Leu Thr Ser Ser His Gly Val Asn Thr He Tyr Lys Gly Tyr 435 440 445 Phe Leu He Gly Asp Leu Lys Ala Ala Cys Leu Leu Glu Thr Gly Asp 450 455 460 Glu Lys Thr Gin Val Lys Met His Asn Val Val Arg Ser Phe Ala Leu 465 470 475 480 Trp Met Ala Ser Glu Gin Gly Thr Tyr Lys Glu Leu He Leu Val Glu 485 490 495 Pro Ser Met Gly His Thr Glu Ala Pro Lys Ala Glu Asn Trp Arg Gin 500 505 510 Ala Leu Val He Ser Leu Leu Asp Asn Arg He Gin Thr Leu Pro Glu 515 520 525 Lys Leu He Cys Pro Lys Leu Thr Thr Leu Met Leu Gin Gin Asn Ser 530 535 540 Ser Leu Lys Lys He Pro Thr Gly Phe Phe Met His Met Pro Val Leu 545 550 555 560 Arg Val Leu Asp Leu Ser Phe Thr Ser He Thr Glu He Pro Leu Ser 565 570 575 He Lys Tyr Leu Val Glu Leu Tyr His Leu Ser Met Ser Gly Thr Lys 580 585 590 He Ser Val Leu Pro Gin Glu Leu Gly Asn Leu Arg Lys Leu Lys His 595 600 605 Leu Asp Leu Gin Arg Thr Gin Phe Leu Gin Thr He Pro Arg Asp Ala 610 615 620 He Cys Trp Leu Ser Lys Leu Glu Val Leu Asn Leu Tyr Tyr Ser Tyr 625 630 635 640 Ala Gly Trp Glu Leu Gin Ser Phe Gly Glu Asp Glu Ala Glu Glu Leu 645 650 655 Gly Phe Ala Asp Leu Glu Tyr Leu Glu Asn Leu Thr Thr Leu Gly He 660 665 670 Thr Val Leu Ser Leu Glu Thr Leu Lys Thr Leu Phe Glu Phe Gly Ala 675 680 685 Leu His Lys His He Gin His Leu His Val Glu Glu Cys Asn Glu Leu 690 695 700 Leu Tyr Phe Asn Leu Pro Ser Leu Thr Asn His Gly Arg Asn Leu Arg 705 710 715 720 Arg Leu Ser He Lys Ser Cys His Asp Leu Glu Tyr Leu Val Thr Pro 725 730 735 Ala Asp Phe Glu Asn Asp Trp Leu Pro Ser Leu Glu Val Leu Thr Leu 740 745 750 His Ser Leu His Asn Leu Thr Arg Val Trp Gly Asn Ser Val Ser Gin 755 760 765 Asp Cys Leu Arg Asn He Arg Cys He Asn He Ser His Cys Asn Lys 770 775 780 Leu Lys Asn Val Ser Trp Val Gin Lys Leu Pro Lys Leu Glu Val He 785 790 795 800 Glu Leu Phe Asp Cys Arg Glu He Glu Glu Leu He Ser Glu His Glu 805 810 815 Ser Pro Ser Val Glu Asp Pro Thr Leu Phe Pro Ser Leu Lys Thr Leu 820 825 830 Arg Thr Arg Asp Leu Pro Glu Leu Asn Ser He Leu Pro Ser Arg Phe 835 840 845 Ser Phe Gin Lys Val Glu Thr Leu Val He Thr Asn Cys Pro Arg Val 850 855 860 Lys Lys Leu Pro Phe Gin Glu Arg Arg Thr Gin Met Asn Leu Pro Thr 865 870 875 880 Val Tyr Cys Glu Glu Lys Trp Trp Lys Ala Leu Glu Lys Asp Gin Pro 885 890 895 Asn Glu Glu Leu Cys Tyr Leu Pro Arg Phe Val Pro Asn 900 905 (2) INFORMATION FOR SEQ ID NO:143: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:143: Pro Lys Ala Glu Asn Trp Arg Gin Ala Leu Val He Ser Leu Leu Asp 1 5 10 15 Asn Arg He Gin Thr Leu 20 (2) INFORMATION FOR SEQ ID NO:144: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:144: Pro Glu Lys Leu He Cys Pro Lys Leu Thr Thr Leu Met Leu Gin Gin 1 5 10 15 Asn Ser Ser Leu Lys Lys He 20 (2) INFORMATION FOR SEQ ID NO:145: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:145: Pro Thr Gly Phe Phe Met His Met Pro Val Leu Arg Val Leu Asp Leu 1 5 10 15 Ser Phe Thr Ser He Thr Glu He 20 (2) INFORMATION FOR SEQ ID NO:146: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:146: Pro Leu Ser He Lys Tyr Leu Val Glu Leu Tyr His Leu Ser Met Ser 1 5 10 15 Gly Thr Lys He Ser Val Leu 20 (2) INFORMATION FOR SEQ ID NO:147: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:147: Pro Gin Glu Leu Gly Asn Leu Arg Lys Leu Lys His Leu Asp Leu Gin 1 5 10 15 Arg Thr Gin Phe Leu Gin Thr He 20 (2) INFORMATION FOR SEQ ID NO:148: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 37 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:148: Pro Arg Asp Ala He Cys Trp Leu Ser Lys Leu Glu Val Leu Asn Leu 1 5 10 15 Tyr Tyr Ser Tyr Ala Gly Trp Glu Leu Gin Ser Phe Gly Glu Asp Glu 20 25 30 Ala Glu Glu Leu Gly 35 (2) INFORMATION FOR SEQ ID NO:149: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 25 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:149: Phe Ala Asp Leu Glu Tyr Leu Glu Asn Leu Thr Thr Leu Gly He Thr 1 5 10 15 Val Leu Ser Leu Glu Thr Leu Lys Thr 20 25 (2) INFORMATION FOR SEQ ID NO:150: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 amino acids (B) TYPE: amino acid (D) TOPOLOGY: 1inear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:150: Leu Phe Glu Phe Gly Ala Leu His Lys His He Gin His Leu His Val 1 5 10 15 Glu Glu Cys Asn Glu Leu Leu Tyr Phe Asn Leu 20 25 (2) INFORMATION FOR SEQ ID NO:151: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 26 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:151: Pro Ser Leu Thr Asn His Gly Arg Asn Leu Arg Arg Leu Ser He Lys 1 5 10 15 Ser Cys His Asp Leu Glu Tyr Leu Val Thr 20 25 (2) INFORMATION FOR SEQ ID NO:152: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 29 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:152: Pro Ala Asp Phe Glu Asn Asp Trp Leu Pro Ser Leu Glu Val Leu Thr 1 5 10 15 Leu His Ser Leu His Asn Leu Thr Arg Val Trp Gly Asn 20 25 (2) INFORMATION FOR SEQ ID NO:153: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:153: Ser Val Ser Gin Asp Cys Leu Arg Asn He Arg Cys He Asn He Ser 1 5 10 15 His Cys Asn Lys Leu Lys Asn Val Ser Trp Val Gin Lys Leu 20 25 30 (2) INFORMATION FOR SEQ ID NO:154: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 28 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:154: Pro Lys Leu Glu Val He Glu Leu Phe Asp Cys Arg Glu He Glu Glu 1 5 10 15 Leu He Ser Glu His Glu Ser Pro Ser Val Glu Asp 20 25 (2) INFORMATION FOR SEQ ID NO:155: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:155: Pro Thr Leu Phe Pro Ser Leu Lys Thr Leu Arg Thr Arg Asp Leu Pro 1 5 10 15 Glu Leu Asn Ser He Leu 20 (2) INFORMATION FOR SEQ ID NO:156: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein ( i) SEQUENCE DESCRIPTION: SEQ ID NO:156: Pro Ser Arg Phe Ser Phe Gin Lys Val Glu Thr Leu Val He Thr Asn 1 5 10 15 Cys Pro Arg Val Lys Lys Leu 20 (2) INFORMATION FOR SEQ ID NO:157: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 5134 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:157: AAGCTTTACA GATTGGATGA TCTCTTAATG CATGCTGAAG TGACTGCAAA AAGGTTAGCA 60 ATATTCAGTG GTTCTCGTTA TGAATATTTC ATGAACGGAA GCAGCACTGA GAAAATGAGG 120 CCCTTGTTAT CTGATTTTCT GCAAGAGATT GAGTCTGTCA AGGTAGAGTT CAGAAATGTT 180 TGCTTGCAAG TTCTGGATAT ATCACCTTTT TCCCTGACAG ATGGAGAAGG CCTTGTTAAT 240 TTCTTATTAA AAAACCAGGC CAAGGTGCCG AATGATGATG CTGTTTCTTC TGATGGAAGT 300 TTAGAGGATG CAAGCAGCAC TGAGAAAATG GGACTTCCAT CTGATTTTCT CCGAGAGATT 360 GAGTCTGTTG AGATAAAGGA GGCCAGAAAA TTATATGATC AAGTTTTGGA TGCAACACAT 420 TGTGAGACGA GTAAGCACGA TGGAAAAAGC TTTATCAACA TTATGTTAAC CCAACAGGAC 480 AAGGTGCTGG ACTATGATGC TGGTTCAGTG TCTTATCTTC TTAACCAAAT CTCAGTAGTT 540 AAAGACAAAA TATTGCACAT TGGCTCTTTA CTTGTAGATA TTGTACAGTA CCGGAATATG 600 CATATAGAAC TTACAGATCT CGCTGAACGT GTTCAAGATA AAAACTACAT TCGTTTCTTC 660 TCTGTCAAGG GTTATATTCC TGCTTGGTAT TACACACTAT ATCTCTCTGA TGTCAAGCAA 720 TTGCTTAAGT TTGTTGAGGC AGAGGTAAAG ATTATTTGTC TGAAAGTACC AGATTCTTCA 780 AGTTATAGCT TCCCTAAGAC AAATGGATTA GGATATCTCA ATTGCTTTTT AGGCAAATTG 840 GAGGAGCTTT TACGTTCTAA GCTCGATTTG ATAATCGACT TAAAACATCA GATTGAATCA 900 GTCAAGGAGG GCTTATTGTG CCTAAGATCA TTCATTGATC ATTTTTCAGA AAGCTATGTT 960 GAGCATGATG AAGCTTGTGG TCTTATAGCA AGAGTTTCTG TAATGGCATA CAAGGCTGAG 1020 TATGTCATTG ACTCATGCTT GGCCTATTCT CATCCACTCT GGTACAAAGT TCTTTGGATT 1080 TCTGAAGTTC TTGAGAATAT TAAGCTTGTA AATAAAGTTG TTGGGGAGAC ATGTGAAAGA 1140 AGGAACACTG AAGTTACTGT GCATGAAGTT GCAAAGACTA CCACTAATGT AGCACCATCT 1200 TTTTCAGCTT ATACTCAAAG AGCAAACGAA GAAATGGAGG GTTTTCAGGA TACAATAGAT 1260 GAATTAAAGG ATAAACTACT TGGAGGATCA CCTGAGCTTG ATGTCATCTC AATCGTTGGC 1320 ATGCCAGGAT TGGGCAAGAC TACACTAGCA AAGAAGATTT ACAATGATCC AGAAGTCACC ' 1380 TCTCGCTTCG ATGTCCATGC TCAATGTGTT GTGACTCAAT TATATTCATG GAGAGAGTTG 1440 TTGCTCACCA TTTTGAATGA TGTGCTTGAG CCTTCTGATC GCAATGAAAA AGAAGATGGA 1500 GAAATAGCTG ATGATCTACG CCGATTTTTG TTGACCAAGA GATTCTTGAT TCTCATTGAT 1560 GATGTGTGGG ACTATAAAGT GTGGGACAAT CTATGTATGT GCTTCAGTGA TGTTTCAAAT 1620 AGGAGTAGAA TTATCCTAAC AACCCGCTTG AATGATGTCG CCGAATATGT CAAATGTGAA 1680 AGTGATCCCC ATCATCTTCG TTTATTCAGA GATGACGAGA GTTGGACATT ATTACAGAAA 1740 GAAGTCTTTC AAGGAGAGAG CTGTCCACCT GAACTTGAAG ATGTGGGATT TGAAATATCA 1800 AAAAGTTGTA GAGGGTTGCC TCTCTCAGTT GTGTTAGTAG CTGGTGTTCT GAAACAGAAA 1860 AAGAAGACAC TAGATTCATG GAAAGTAGTA GAACAAAGTC TAAGTTCCCA GAGGATTGGC 1920 AGCTTGGAAG AGAGCATATC TATAATTGGA TTCAGTTACA AGAATTTACC ACACTATCTT 1980 AAGCCTTGTT TTCTCTATTT TGGAGGATTT TTGCAGGGAA AGGATATTCA TGACTCAAAA 2040 ATGACCAAGT TGTGGGTAGC TGAAGAGTTT GTACAAGCAA ACAACGAAAA AGGACAAGAA 2100 GATACCCGCA CAAGGTTTCT TGGACGATCT TATTGGTAGG AATCTGGTGA TGGCCATGGA 2160 GAAGAGACCT AATGCCAAGG TGAAAACGTG CCGCATTCAT GATTTGTTGC ATAAATTCTG 2220 CATGGAAAAG GCCAAACAAG AGGATTTCCT TCTCCAGATC AATAGGTAAA AAAAACTGTA 2280 TTAATTTTAC ATTACAAAAA AAAAGAACTG TATTAATTTT ACTGTATTAT GTTTATGCCA 2340 ACTCTCATTT CCATGTGTTC TCTTTTATTC AATTCAGTGG AGAAGGTGTA TTTCCTGAAC 2400 GATTGGAAGA ATACCGATTG TTCGTTCATT CTTACCAAGA TGAAATTGAT CTGTGGCGCC 2460 CATCTCGCTC TAATGTCCGC TCTTTACTAT TCAATGCAAT TGATCCAGAT AACTTGTTAT 2520 GGCCGCGTGA TATCTCCTTC ATTTTTGAGA GCTTCAAGCT TGTTAAAGTG TTGGATTTGG 2580 AATCATTCAA CATTGGTGGT ACTTTTCCCA TTGAAACACA ATATCTAATT CAGATGAAGT 2640 ACTTTGCGGC CCAAACTGAT GCAAATTCAA TTCCTTCATC TATAGCTAAG CTTGAAAATC 2700 TTGAGACTTT TGTCGTAAGA GGATTGGGAG GAGAGATGAT ATTACCTTGT TCACTTCTGA 2760 AGATGGTGAA ATTGAGGCAT ATACATGTAA ATGATCGGGT TTCTTTTGGT TTGCGTGAGA 2820 ACATGGATGT TTTAACTGGT AACTCACAAT AACCTAATTT GGAAACCTTT TCTACTCCGC 2880 GTCTCTTTTA TGGTAAAGAC GCAGAGAAGA TTTTGAGGAA GATGCCAAAA TTGAGAAAAT 2940 TGAGTTGCAT ATTTTCAGGG ACATTTGGTT ATTCAAGGAA ATTGAAGGGT AGGTGTGTTC 3000 GTTTTCCCAG ATTAGATTTT CTAAGTCACC TTGAGTCCCT CAAGCTGGTT TCGAACAGCT 3060 ATCCAGCCAA ACTTCCTCAC AAGTTCAATT TCCCCTCGCA ACTAAGGGAA CTGACTTTAT 3120 CAAAGTTCCG TCTACCTTGG ACCCAAATTT CGATCATTGC AGAACTGCCC AACTTGGTGA 3180 TTCTTAAGTT ATTGCTCAGA GCCTTTGAAG GGGATCACTG GGAAGTGAAA GATTCAGAGT 3240 TCCTAGAACT CAAATACTTA AAACTGGACA ACCTCAAAGT TGTACAATGG TCCATCTCTG ' 3300 ATGATGCTTT TCCTAAGCTT GAACATTTGG TTTTAACGAA ATGTAAGCAT CTTGAGAAAA 3360 TCCCTTCTCG TTTTGAAGAT GCTGTTTGTC TAAATAGAGT TGAGGTGAAC TGGTGCAACT 3420 GGAATGTTGC CAATTCAGCC CAAGATATTC AAACTATGCA ACATGAAGTT ATAGCAAATG 3480 ATTCATTCAC AGTTACTATA CAGCCTCCAG ATTGGTCTAA AGAACAGCCC CTTGACTCTT 3540 AGCAAAGGTT TGTTCTTGCT GTGTTCATCC AAGTGCATTT AACATTTATT CATTTTGTTT 3600 TACACCAGAA CATGTTTATT TTGCTAGTAT TACTTGATAC ATTAAAAGAA ATCGAACTCA 3660 TATTTCTGCT ACAGTCTTAA CTTTTCTTGG GCTTACTTGA GGTCTAGATT AGATCAATGG 3720 TTCATGTAAT TTTTAATTCA CTGTTTCATT CAACTGTCTT ATGATAGTTG TGAAATGACA 3780 ATATTGTTAT CCCTAGCCAA ATTTATTATG TTCAAATGAA AACTGATGTC ACAACTACTT 3840 TTTTGTGAAA TGTTTTTGAA TTTTTTGCTA TAAAATTGAC GAATTGACAG CTTCTATATT 3900 TGTCAGCTAA ACTCTTTGTC ACCAGAAGTG TATTTAGAAT TACTGTGGTT TTATGAAAGA 3960 GTTCTGTAGA ATTTTATGCT TTTGCAGAAT ATAGTTTAAA ACAACAACAC TTCTCTGTTT 4020 CAGAGATAGC AGAAGCTAAA GTTCAAGGCA TTTTGTTTAT TTCTAGAACA AGTGGAGTTC 4080 TTATGTTGAA TTCTTGAAAA GAAGAAGAAT CAGGAGCAGG TAAAGTTATC TCTTTTTATG 4140 TTTTTCTTCT TTTAGATGTT ATTTCTTCAT CTTGAACGTG AACACCGCTG AAAGCATTTT 4200 AATAAAACCG GAGAGAAAAA TAAGATCTTT TTATATAAAG CATTATCATG TAAATATGCC 4260 TAAATCCATA TGGTACAACT GTTTGACAAA ATGATAGAGA GGGGAGTTTT ATAGTATAAG 4320 TAAAACAGGA TTGAGAAAAA AATCCTTGCA CGATTTTCAA TTTCTGGCCA CATCACAATG 4380 TGTGTCAAAG TTCCCCTCTT TAAGTGGAAC AAGCAATCAG AAAAGCTCAT TCTTATCGGT 4440 GACATACCAA TACCAGCTGA CTGTCTCATC TTGGTTAACT TAGCCTTGCT TACTTAGACT 4500 ATTAGATTAG TTACTAATGA ACTGGTAAAT TGGAACCAAA TGTAGTTAGC TTGATGAGCT 4560 GGTAGACATG TATATATGAA GATACACGCG TAACTTTAGT CGATGGTTAA TTTTTCATTT 4620 TTGATTTTTT TTCTTCACAG AGTATATATG AACTTGGCCT AAAAGTTTTG CTTCACTAAT 4680 TTAACTATTA CCGTGGATGA AACAAGCATG GCAACATTTT CAACAACTAT CACTCAAGCA 4740 ATGTAAAAAA TGGAGGTTCT ACGAGCGGTA CATGTAAGAG TTTTGTGCAC ACAAGAGGTT 4800 CTGAGACTTG AACCATCCAT GTCCAAGGCA GTTGAGATGC TAGTAAAGAA AGAAGAAGAT 4860 GAGCCTGCAC TAATTAATCT CCCTGTATGA ATGAGAGAAT GAGAAAAAGA TGGAGCTTCA 4920 TGAACCAAAA GTTACCTTTT TTTTTTCTTC TTAATGGCAT TACTTTGAAG CACATGTTTG 4980 TTAGTTGTAA ATTGTAATGG TGAAGTGTTT GTAAATATAG GGAGTGATAT TTGAAAGAAT 5040 GGTTGTGTTA TCTTTACAAA CCGGAATCAT TTCTGTATAA TTTTCTTCTG TAATTTTTGG 5100 TTTCGGTTTA TTCATTACTC ATTTCAGTAA GCTT 5134 (2) INFORMATION FOR SEQ ID NO:158: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:158: GGNATGGGNG GNNTNGGNAA RACNAC 26 (2) INFORMATION FOR SEQ ID NO:159: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:159: NCGNGWNGTN AKDAWNCGNA 20 (2) INFORMATION FOR SEQ ID NO:160: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 17 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:160: GGWNTBGGWA ARACHAC 17 (2) INFORMATION FOR SEQ ID NO:161: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 33 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:161: NRYNRDNGTN GTYTTNCCNA NNCCNNSNRK NCC 33 (2) INFORMATION FOR SEQ ID NO:162: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:162: GGNMYNSSNG GNNTNGGNAA RACNAC 26 (2) INFORMATION FOR SEQ ID NO:163: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 13 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:163: TYGAYGAYRT BRA 13 (2) INFORMATION FOR SEQ ID NO:164: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 16 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:164: TYCCAVAYRT CRTCNA 16 (2) INFORMATION FOR SEQ ID NO:165: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 26 base pairs (B) TYPE: nucleic acid - 137 - (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:165: VYMNAYRTCR TCNADNAVNA NNARNA 26 (2) INFORMATION FOR SEQ ID NO:166: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:166: WWNMRRDTNY TNNTNBTNHT NNARNA 26 (2) INFORMATION FOR SEQ ID NO:167: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:167: NCGNGWNGTN AKDWNCGNGA 20 (2) INFORMATION FOR SEQ ID NO:168: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:168: NCKNSWNGTN ADDATDAATN G 21 - 138 - (2) INFORMATION FOR SEQ ID NO:169: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 12 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:169: NARNGGNARN CC 12 (2) INFORMATION FOR SEQ ID NO:170: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 17 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: 1inear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:170: GGWYTBCCWY TBGCHYT 17 (2) INFORMATION FOR SEQ ID NO:171: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 17 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:171: ARDGCVARWG GVARNCC 17 (2) INFORMATION FOR SEQ ID NO:172: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:172: NRNNWYNAVN SHNARNGGNA RNCC ' 24 (2) INFORMATION FOR SEQ ID NO:173: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 17 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:173: GGNYTNCCNY TNDSNBT 17 (2) INFORMATION FOR SEQ ID NO:174: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:174: ARRTTRTCRT ADSWRAWYTT 20 (2) INFORMATION FOR SEQ ID NO:175: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:175: ARNYYNTYRT ANSRNANNYY 20 (2) INFORMATION FOR SEQ ID NO:176: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:176: RRNWTHWSNT AYRANRVNY 19 (2) INFORMATION FOR SEQ ID NO:177: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:177: GTNTTYYTNW SNTTYMGRGG 20 (2) INFORMATION FOR SEQ ID NO:178: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:178: CCNATHTTYT AYRWBGTNGA YCC 23 (2) INFORMATION FOR SEQ ID NO:179: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 17 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:179: GTNGGNATHG AYRMNCA 17 (2) INFORMATION FOR SEQ ID NO:180: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:180: RAARCANGCD ATRTCNARRA A 21 (2) INFORMATION FOR SEQ ID NO:181: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:181: TTYYTNGAYA THGCNTGYTT 20 (2) INFORMATION FOR SEQ ID NO:182: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:182: CCCARTCYYK NADNWRRTCR TGCAT 25 (2) INFORMATION FOR SEQ ID NO:183: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:183: ATGCAYGAYY WNHTNMRRGA YATGGG 26 (2) INFORMATION FOR SEQ ID NO:184: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 15 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:184: NARNSWYTYN ARYTT 15 (2) INFORMATION FOR SEQ ID NO:185: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 17 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:185: WSNAARYTNR ARWSNYT 17 (2) INFORMATION FOR SEQ ID NO:186: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:186: DWWYTCNARN SWNYKNARNC C 21 (2) INFORMATION FOR SEQ ID NO:187: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 17 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:187: GGNYTNMRNW NNYTNGA 17 (2) INFORMATION FOR SEQ ID NO:188 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 13 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:188: Leu Lys Phe Ser Tyr Asp Asn Leu Glu Ser Asp Leu Leu 1 5 10 (2) INFORMATION FOR SEQ ID NO:189: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 16 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:189: Gly Val Tyr Gly Pro Gly Gly Val Gly Lys Thr Thr Leu Met Gin Ser 1 5 10 15 (2) INFORMATION FOR SEQ ID NO:190: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:190: Gly Gly Leu Pro Leu Ala Leu He Thr Leu Gly Gly Ala Met (2) INFORMATION FOR SEQ ID NO:191: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 11 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 2 (D) OTHER INFORMATION: /note= "Xaa is Met or Pro" (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 3 (D) OTHER INFORMATION: /note= "Xaa is Gly or Pro" (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 5 (D) OTHER INFORMATION: /note= "Xaa is He, Leu or Val" (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 10 (D) OTHER INFORMATION: /note= "Xaa is He, Leu or Thr" (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 11 (D) OTHER INFORMATION: /note= "Xaa is Ala or Met" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:191: Gly Xaa Xaa Gly Xaa Gly Lys Thr Thr Xaa Xaa 1 5 10 (2) INFORMATION FOR SEQ ID NO:192: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 11 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 1 (D) OTHER INFORMATION: /note= "Xaa is Phe or Lys" (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 2 (D) OTHER INFORMATION: /note= "Xaa is Arg or Lys" (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 3 (D) OTHER INFORMATION: /note= "Xaa is He, Val or Phe' ( ix ) FEATURE : (A) NAME/KEY: Modified-site (B) LOCATION: 5 (D) OTHER INFORMATION: /note= "Xaa is He, Leu or Val" (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 6 (D) OTHER INFORMATION: /note= "Xaa is He or Leu" (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 7 (D) OTHER INFORMATION: /note= "Xaa is He or Val" (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 10 (D) OTHER INFORMATION: /note= "Xaa is He, Leu or Val" (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 11 (D) OTHER INFORMATION: /note= "Xaa is Asp or Trp" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:192: Xaa Xaa Xaa Leu Xaa Xaa Xaa Asp Asp Xaa Xaa 1 5 10 (2) INFORMATION FOR SEQ ID NO:193: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 1 (D) OTHER INFORMATION: /note= "Xaa is Ser or Cys" ■ (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 2 (D) OTHER INFORMATION: /note= "Xaa is Arg or Lys" (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 3 (D) OTHER INFORMATION: /note= "Xaa is Phe, He or Val" (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 4 (D) OTHER INFORMATION: /note= "Xaa is He or Met" (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 5 (D) OTHER INFORMATION: /note= "Xaa is He, Leu or Phe" (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 7 (D) OTHER INFORMATION: /note= "Xaa is Ser, Cys or Thr" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:193: Xaa Xaa Xaa Xaa Xaa Thr Xaa Arg 1 5 (2) INFORMATION FOR SEQ ID NO:194: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 5 (D) OTHER INFORMATION: /note= "Xaa is Thr, Ala or Thr" (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 6 (D) OTHER INFORMATION: /note= "Xaa is Leu or Val" (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 7 (D) OTHER INFORMATION: /note= "Xaa is He, Val or Lys" (i ) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 8 (D) OTHER INFORMATION: /note= "Xaa is Val or Thr" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:194: Gly Leu Pro Leu Xaa Xaa Xaa Xaa 1 5 (2) INFORMATION FOR SEQ ID NO:195: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein ( ix ) FEATURE : (A) NAME/KEY: Modified-site (B) LOCATION: 1 (D) OTHER INFORMATION: /note= "Xaa is Lys or Gly" (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 2 (D) OTHER INFORMATION: /note= "Xaa is He or Phe" (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 5 (D) OTHER INFORMATION: /note= "Xaa is Asp or Lys" (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 6 (D) OTHER INFORMATION: /note= "Xaa is Ala, Gly or Asn" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:195: Xaa Xaa Ser Tyr Xaa Xaa Leu 1 5 (2) INFORMATION FOR SEQ ID NO:196: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:196: Asn Ser His Arg 1 (2) INFORMATION FOR SEQ ID NO:197: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 9 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:197: Arg Asp Arg Arg Arg Val Asp Pro Cys 1 5 (2) INFORMATION FOR SEQ ID NO:198: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH:- 4 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:198: Thr Gly Asp Leu 1 (2) INFORMATION FOR SEQ ID NO:199: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:199: His Gly Thr Tyr 1 (2) INFORMATION FOR SEQ ID NO:200: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 11 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein ■ (xi) SEQUENCE DESCRIPTION: SEQ ID NO:200: Arg Met Ser His Gly Phe Arg Asn Ser Gin Ser 1 5 10 (2) INFORMATION FOR SEQ ID NO:201: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:201: Gly Glu Met Val Glu Ser Thr Gly Lys Arg Ser Thr Lys Arg Arg Ala 1 5 10 15 Leu Leu Phe Thr Ala Leu Cys Ser Lys Leu He 20 25

Claims: Claims 1. A substantially pure oligonucleotide comprising the seguence: 5' GGNATGGGNGGNNTNGGNAARACNAC 3 ' , [SEQ. ID NO:158] wherein N is A, T, G, or C; and R is A or G. 2. A substantially pure oligonucleotide comprising the sequence: 5' NARNGGNARNCC 3', [SEQ. ID NO: 169] wherein N is A, T, G or C; and R is A or G. 3. A substantially pure oligonucleotide comprising the sequence: 5'NCGNGWNGTNAKDAWNCGNGA 3', [SEQ. ID NO: 159] wherein N is A, T, G or C; W is A or T; D is A, G, or T; and K is G or T. 4. A substantially pure oligonucleotide comprising the sequence: 5' GGWNTBGGWAARACHAC 3', [SEQ ID NO: 160] wherein N is A, T, G or C; R is G or A; B is C, G, or T; H is A, C, or T; and W is A or T. 5. A substantially pure oligonucleotide comprising the sequence: 5' TYGAYGAYRTBKRBRA 3', [SEQ. ID NO: 163] wherein R is G or A; B is C, G, or T; D is A, G, or T; Y is T or C; and K is G or T. 6. A substantially pure oligonucleotide comprising the sequence: 5' TYCCAVAYRTCRTCNA 3', [SEQ ID NO: 164] wherein N is A, T, G or C; R is G or A; V is G or C or A; and Y is T or C. 7. A substantially pure oligonucleotide comprising the sequence: 5' GGWYTBCC YTBGCHYT 3 ' , [SEQ ID NO.: 170] wherein B is C, G, or T; H is A, C, or T; W is A or T; and Y is T or C. 8. A substantially pure oligonucleotide comprising the sequence: 5' ARDGCVAR GGVARNCC 3 ' , [SEQ ID NO: 171] wherein N is A, T, G or C; R is G or A; is A or T; D is A, G, or T; and V is G, C, or A. 9. A substantially pure oligonucleotide comprising the sequence: 5' ARRTTRTCRTADSWRAWYTT 3' , [SEQ ID NO: 174] wherein R is G or A; is A or T; D is A, G, or T; S is G or C; and Y is C or T. 10. A recombinant plant gene comprising the DNA sequence: 5' GGNATGGGNGGNNTNGGNAARACNAC 3', [SEQ ID NO: 158] wherein N is A, T, G or C; and R is A or G. 11. The gene of claim 10, further comprising the sequence: 5' NARNGGNARNCC 3', [SEQ ID NO: 169] wherein N is A, T, G or C; and R is A or G. 12. The gene of claim 11, further comprising the sequence: 5' NCGNG NGTNAKDA NCGNGA 3 ' , [SEQ ID NO: 167] wherein N is A, T, G or C; W is A or T; D is A, G or T; and K is G or T. 13. A recombinant plant gene comprising a combination of any two or more sequences of claims lO, 11 and 12. 14. A substantially pure plant polypeptide comprising the amino acid sequence: Gly Xaa 2 Xaa 2 Gly Xaa 3 Gly Lys Thr Thr Xaa 4 Xaa 5 , [SEQ ID NO: 191], wherein Xaa 2 is Met or Pro; Xaa 2 is Gly or Pro; Xaa 3 is lie, Leu, or Val; Xaa 4 is lie, Leu, or Thr; and Xaa 5 is Ala or Met. 15. A substantially pure plant polypeptide comprising the amino acid sequence: Xaa- L Xaa 2 Xaa 3 Leu Xaa 4 Xaa 5 Xaa 6 Asp Asp Xaa 7 Xaa 8 , [SEQ ID NO: 192], wherein Xaa 2 is Phe or Lys; Xaa 2 is Arg or Lys; Xaa 3 is lie, Val, or Phe; Xaa 4 is lie, Leu, or Val; Xaa 5 is lie or Leu; Xaa 6 is lie or Val; Xaa 7 is lie, Leu, or Val; and Xaa 8 is Asp or Trp. 16. A substantially pure plant polypeptide comprising the amino acid sequence: Xaa χ Xaa 2 Xaa 3 Xaa 4 Xaa 5 Thr Xaa 6 Arg, [SEQ ID NO: 193] wherein Xaa χ is Ser or Cys; Xaa 2 is Arg or Lys; Xaa 3 is Phe, lie, or Val; Xaa 4 is lie, or Met; Xaa 5 is lie, Leu, or Phe; Xaa 6 is Ser, Cys, or Thr. 17. A substantially pure plant polypeptide comprising the amino acid sequence: Gly Leu Pro Leu Xaa 2 Xaa 2 Xaa 3 Xaa 4 , [SEQ ID NO: 194], wherein Xaa 2 is Thr, Ala, or Ser; Xaa 2 is Leu or Val; Xaa 3 is lie, Val, or Lys; and Xaa 4 is Val or Thr. 18. A substantially pure plant polypeptide comprising the amino acid sequence: Xaa- L Xaa 2 Ser Tyr Xaa 3 Xaa 4 Leu, {SEQ ID NO: 195], wherein Xaa- ^ is Lys or Gly; Xaa 2 is lie or Phe; Xaa 3 is Asp or Lys; and Xaa 4 is Ala, Gly, or Asn. 19. A method of isolating a disease-resistance gene or fragment thereof from a plant cell, comprising: (a) providing a sample of plant cell DNA; (b) providing a pair of oligonucleotides having sequence homology to a conserved region of an RPS disease-resistance gene; (c) combining said pair of oligonucleotides with said plant cell DNA sample under conditions suitable for polymerase chain reaction-mediated DNA amplification; and (d) isolating said amplified disease- resistance gene or fragment thereof. 20. The method of claim 19, wherein said amplification is carried out using a reverse- transcription polymerase chain reaction. 21. The method of claim 19, wherein said reverse- transcription polymerase chain reaction is RACE. 22. A method of identifying a plant disease- resistance gene in a plant cell, comprising: (a) providing a preparation of plant cell DNA; (b) providing a detectably-labelled DNA sequence having homology to a -conserved region of an RPS gene; (c) contacting said preparation of plant cell DNA with said detectablly-labelled DNA sequence under hybridization conditions providing detection of genes having 50% or greater sequence identity; and (d) identifying a disease-resistance gene by its association with said detectable label. 23. The method of claim 22, wherein said DNA sequence is produced according to the method of claim 19. 24. The method of claim 22, wherein said preparation of plant cell DNA is isolated from a plant genome. 25. A method of isolating a disease-resistance gene from a recombinant plant cell library, comprising: (a) providing a recombinant plant cell library; (b) contacting said recombinant plant cell library with a detectably-labelled gene fragment produced according to the method of claim 19 under hybridization conditions providing detection of genes having 50% or greater sequence identity; and (c) isolating a member of a disease-resistance gene by its association with said detectable label. 26. A method of isolating a disease-resistance gene from a recombinant plant cell library, comprising: (a) providing a recombinant plant cell library; (b) contacting said recombinant plant cell library with a detectably-labelled oligonucleotide of any of claims 1-9 under hybridization conditions providing detection of genes having 50% or greater sequence identity; and (c) isolating a disease-resistance gene by its association with said detectable label. 27. A recombinant plant polypeptide capable of conferring disease-resistance wherein said plant polypeptide comprises a P-loop domain or nucleotide binding site domain. 28. The recombinant plant polypeptide of claim 27, wherein said polypeptide further comprises a leucine- rich repeating domain. 29. A recombinant plant polypeptide capable of conferring disease-resistance wherein said plant polypeptide contains a leucine-rich repeating domain. 30. A plant disease-resistance gene isolated according to the method comprising: (a) providing a sample of plant cell DNA; (b) providing a pair of oligonucleotides having sequence homology to a conserved region of an RPS disease-resistance gene; (c) combining said pair of oligonucleotides with said plant cell DNA sample under conditions suitable for polymerase chain reaction-mediated DNA amplification; and (d) isolating said amplified disease-resistance gene or fragment thereof. 31. A plant disease-resistance gene isolated according to the method comprising: (a) providing a preparation of plant cell DNA; (b) providing a detectably-labelled DNA sequence having homology to a conserved region of an RPS gene; (c) contacting said preparation of plant cell DNA with said detectably-labelled DNA sequence under hybridization conditions providing detection of genes having 50% or greater sequence identity; and (d) identifying a disease-resistance gene by its association with said detectable label. 32. A plant disease-resistance gene according to the method comprising: (a) providing a recombinant plant cell library; (b) contacting said recombinant plant cell library with a detectably-labelled gene fragment produced according to the method of claims 1-4 under hybridization conditions providing detection of genes having 50% or greater sequence identity; and (c) isolating a disease-resistance gene by its association with said detectable label. 33. A method of identifying a plant disease- resistance gene comprising: (a) providing a plant tissue sample; (b) introducing by biolistic transformation into said plant tissue sample a candidate plant disease- resistance gene; (c) expressing said candidate plant disease- resistance gene within said plant tissue sample; and (d) determining whether said plant tissue sample exhibits a disease-resistance response, whereby a response identifies a plant disease-resistance gene. 34. The method of claim 33, wherein said plant tissue sample comprises leaf, root, flower, fruit, or stem tissue. 35. The method of claim 33, wherein said candidate plant disease-resistance gene is obtained from a cDNA expression library. 36. The method of claim 33, wherein said disease- resistance response is the hypersensitive response. 37. A plant disease-resistance gene isolated according to the method comprising: (a) providing a plant tissue sample; (b) introducing by biolistic transformation into said plant tissue sample a candidate plant disease- resistance gene; (c) expressing said candidate plant disease- resistance gene within said plant tissue sample; and (d) determining whether said plant tissue sample exhibits a disease-resistance response, whereby a response identifies a plant disease-resistance gene. 38. A purified antibody which binds specifically to an rps family protein. 39. A DNA sequence substantially identical to the DNA sequence shown in Figure 12. 40. A substantially pure polypeptide having a sequence substantially identical to a Prf amino acid sequence shown in Figure 5 (A or B) .

Inventors: AUSUBEL FREDERICK M, BAKER BARBARA, BENT ANDREW F, DAHLBECK DOUGLAS, ELLIS JEFFREY, KATAGIRI FUMIAKI, KUNKEL BARBARA N, MINDRINOS MICHAEL N, SALMERON JOHN, STASKAWICZ BRIAN J, YU GUO-LIANG, AUSUBEL, FREDERICK, M., BAKER, BARBARA, BENT, ANDREW, F., DAHLBECK, DOUGLAS, ELLIS, JEFFREY, KATAGIRI, FUMIAKI, KUNKEL, BARBARA, N., MINDRINOS, MICHAEL, N., SALMERON, JOHN, STASKAWICZ, BRIAN, J., YU, GUO-LIANG
Applicants: COMMW SCIENT IND RES ORG, GEN HOSPITAL CORP, UNIV CALIFORNIA, US AGRICULTURE, COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH OR, THE GENERAL HOSPITAL CORPORATION, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE UNITED STATES OF AMERICA, REPRESENTED BY THE S
Application year: 1995
Main classification: C07K14
IPC codes: A01H1, C07K14, C07K16, C12N5, C12N15, C12Q1